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Abstract
The critical first step in the host infection by influenza A virus is the binding of the viral
surface glycoprotein hemagglutinin (HA) to the sialylated glycan receptors terminated
by N-acetyineuraminic acid (Neu5Ac) expressed on the host cell surface. Glycans
terminating in Neu5Ac that is a2-6 and a2-3 linked to the penultimate galactose serve
as receptors for human- and avian- adapted influenza A virus respectively. This thesis
focuses on studying HA, glycan receptors and their interactions both in a biochemical
and physiological context to understand the role of these interactions in influenza A
virus pathogenesis.
The first Specific Aim of this thesis deals with understanding the molecular
determinants of glycan receptor-binding specificity and affinity of HA (or avidity in the
context of the whole virus) and how these properties govern antigenic drift and
efficiency of airborne transmission. This approach contributed to uncovering the
relationship between receptor-binding affinity and efficiency of transmission of the
2009 H1N1 pandemic influenza A virus and also predicting the evolution of this virus
into a more transmissible strain.
The second Specific Aim of this thesis focuses on understanding the distribution
of the glycan receptors for human-adapted HA (going beyond a2-3/aX2-6 linkages), in
ferret (animal model for influenza research) and in human respiratory tracts. Based on
this understanding, this part of the thesis contributed to developing new anti-viral
strategies based on targeting the host glycan receptors (instead of the common
strategies that directly target the viral proteins)
Overall, this thesis has provided functional insights into the role of HA-glycan
interaction in viral pathogenesis. As part of this research, various tools and methods
were developed. Further, such an approach paves way for elucidating the functional
significance of important protein-glycan interactions in other disease models.
Thesis Supervisor: Ram Sasisekharan
Title: Director & Edward Hood Taplin Professor of Harvard Health Science & Technology
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Technical Summary
Mammalian branched glycans that are present in the unique interface of cell
surface and extracellular matrix (ECM) impinge on a variety of biological processes. One
of the functions is to serve as receptors for recognition by glycan binding proteins on
the surface of the pathogen. This is well exemplified in the case of human influenza A
virus hemagglutinin (HA) that recognizes sialylated glycan receptors on the surface of
tracheal epithelium. This HA-glycan interaction also determines the host restriction of
influenza A viruses by virtue of the linkage specificity (between terminal sialic acid and
the subterminal galactose) of HA to the glycan receptors.
In order to investigate the role of the HA-glycan interaction in viral
pathogenicity, a multifaceted approach was used. This enabled gaining insights into
both the molecular components viz, the glycan and the HA which further led to the
understanding of its biological implication such as in transmissibility of the virus in
human host.
1. Understanding the viral hemagglutinin (HA) in the context of its interaction with the
host glycan receptors
Influenza A virus HA is the target of the host neutralizing antibody response. In
order to escape the antibody response, the viral HA acquires antigenic drift mutation in
and around the antigenic epitopes that prevents binding of the antibody. A careful
analysis of these mutations, shed light into a new mechanism for viral escape of the host
antibody response. A dose-dependent glycan array analysis of the escape mutants
showed that mutants had increased binding avidity to the host glycan receptors as
compared to the wild-type virus. Hence although the virus was able to bind the
neutralizing antibody but due to an increased binding avidity to glycan receptors, the
virus escaped the antibody response. This study hence provided a role for the receptor
binding avidity in driving antigenic drift in influenza A virus.
Yet another mechanism by which the virus escapes the antibody response is by
acquisition of new N-glycan sequons around the antigenic epitopes. The N-glycans
would then sterically block the binding of the antibodies to the epitope. While analyzing
such N-glycan sequons, conserved N-glycosylation sites were identified. One such site
(at 91-93) was identified in H1 HA subtype. This site is located closer to the receptor
binding domain (220-loop) of HA. Hence a potential role of the glycosylation site at 91
was analyzed using representative HAs from the 1918 pandemic. Recombinant HA
lacking this glycosylation site was expressed and purified from insect cells. We found
that lack of this glycosylation site led to a reduction or a complete loss of human
receptor binding avidity and that there was no change in the binding of the glycan
receptor by avian HA. This study provided a yet another role for site specific
glycosylation (apart from antibody escape) on the receptor binding property of HA.
Given that receptor binding property of HA governs host restriction and species
barrier, we next wanted to analyze its role in viral transmissibility using the 2009 HIN1
influenza A virus as a model system. We studied the transmissibility of the virus in
ferrets in collaboration with Dr. Terrence M Tumpey at the Centers for Disease Control.
This study showed that the virus was inefficiently transmissible in ferrets as compared
to seasonal and pandemic influenza A viruses. This was further corroborated by other
epidemiological studies. We then analyzed the recombinant HA from a representative
2009 H1NI virus (A/California/04/09 or CA04/09) on the glycan array platform. The HA
showed a strict binding specificity to human receptor similar to the 1918 pandemic HA
but had a reduced binding affinity as compared to the 1918 pandemic. This lower
binding affinity could have resulted in a lower transmissibility of the virus. A closer
examination of the HA showed a mismatched interaction network in the receptor
binding site. Fixing the mismatch (by introducing a single or a triple mutation) in the RBS
of the HA led to an increased binding affinity to the human receptors. The single mutant
was tested for its transmissibility in ferrets (in collaboration with CDC). The single
mutant had indeed acquired improved transmission efficiency in ferrets comparable to
that of the seasonal and pandemic strains. This study provided a direct correlation
between the receptor binding affinity of the HA to the transmissibility of the virus
further emphasizing the functional significance of HA in viral pathogenicity.
2. Understanding glycan receptors in the context of its interaction with HA
Ferrets are widely used as animal models for studying influenza A viral
pathogenesis and transmissibility. Though ferrets exhibit similar clinical symptoms of
influenza A infection as that observed in humans, the viral tropism is different between
ferrets and humans. Human-adapted influenza A viruses primarily target the upper
respiratory tract in humans, while in ferrets, both upper and lower respiratory tract are
targets. Viral tropism is governed by the distribution of host sialylated glycan receptors,
which are recognized by influenza A virus hemagglutinin (HA). Although detailed
structural characterization of glycan receptors in human upper respiratory tract was
done previously, much less is known about the distribution of glycan receptors in the
ferret respiratory tract. Hence we used a panel of plant lectins and recombinant HAs to
stain ferret trachea (which represents the upper respiratory tract) and lung hilar region
(which represents the lower respiratory tract). This lectin staining was further
multiplexed with enzymes such as Sialidase A to identify specific glycan motif
distribution in ferret respiratory tract. This study showed that the sialylated glycan
receptors recognized by human-adapted HAs are predominantly distributed in
submucosal gland of lung hilar region as a part of O-linked glycans. This is in contrast to
human trachea where these glycan receptors are predominantly distributed in goblet
cells as a part of O-linked glycans. Our study has implications in understanding influenza
A viral pathogenesis in ferrets and also in employing ferrets as animal models for
developing therapeutic strategies against influenza.
Based on the understanding of the glycan receptors for influenza A viruses, we
have identified a plant lectin (PSL) from the mushroom Polyporus squamosus, which also
binds to the receptors targeted by human influenza A viruses. We found that the N-
terminal domain of PSL by itself (rPSL-N) inhibits infection of human influenza A viruses
of H1 and H3 subtypes in MDCK cells. Hence we provide an alternate viable therapeutic
strategy to combat influenza A infection.
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Chapter 1. Introduction
1.1 Motivation
Annual influenza A epidemics results in about three to five million cases of severe
illness, and about 250,000 to 500,000 deaths
[http://www.who.int/mediacentre/factsheets/fs21/en/index.html]. Illnesses result in
hospitalizations and deaths among high-risk groups (the very young, elderly or
chronically ill). Epidemic viruses are derived from pandemic viruses by antigenic drift,
gradual minor antigenic changes caused by point mutations in the viral coat proteins
(hemagglutinin or HA and Neuraminidase or NA). Influenza epidemics are caused by A
and B viruses, whereas pandemics are only caused by influenza A viruses. It has been
estimated that there have been at least 13 pandemics in the last 500 years [1] including
3 scientifically well-documented ones in the 2 0 th century; the Spanish flu of 1918
(H1N1), the Asian flu of 1957 (H2N2), and the Hong Kong flu of 1968 (caused by H3N2)
and the first pandemic of the 21s century; swine flu pandemic of 2009 (caused by
H1N1). There has been a significant reduction in the number of deaths caused due to
pandemic and seasonal outbreaks. This has been possible due to the availability of
better vaccine and anti-therapeutic strategies against influenza A viruses. But the "big"
question that has to be answered is as follows: Is it possible to predict the emergence of
future pandemic outbreaks? In this context it is important to understand the key
molecular determinants of influenza A viral pathogenesis.
The critical first step in the host infection by influenza A virus is the binding of the
viral surface glycoprotein hemagglutinin (HA) to sialylated glycan receptors, complex
glycans terminated by N-acetyineuraminic acid (Neu5Ac) expressed on the host cell
surface [2]. Glycans terminating in Neu5Ac that is a2->6-linked to the penultimate
galactose are predominantly expressed in human upper respiratory epithelia and serve
as receptors for human-adapted influenza A viruses (henceforth referred to as human
receptors). On the other hand, glycans terminating in Neu5Ac that is a2-.3 -linked to
the penultimate galactose, serve as receptors for the avian-adapted influenza viruses
(henceforth referred to as avian receptors). The HA-glycan receptor interaction is crucial
for the human adaptation of influenza A viruses. Essentially a switch in the glycan
receptor binding preference of the avian influenza A HA from a2->3 to aX2->6 is known
to be crucial in the human adaptation of the virus.
Currently, much of the influenza A research has taken a simplified view of the
HA-glycan receptor interaction. HA-glycan interaction is a multivalent interaction,
involving multiple HA molecules interacting with multiple glycan receptors. The current
framework does not capture this multivalency associated with HA-glycan interaction
and defines this interaction in a more qualitative way just based on the linkage
specificity of the glycan receptor. Defining receptor specificity just based on terminal
linkage undermines structural complexity of physiological glycan receptors. Hence it is
challenging to correlate glycan-receptor specificity with molecular HA-glycan
interactions as well as biological functions such as virulence and transmissibility of
influenza A virus.
Motivated by the aforementioned challenges, this thesis work is aimed to further
understand the subtle nuances associated with the HA-glycan interaction given its
crucial role in influenza A pathogenesis. Given the complexities associated with the HA-
glycan interaction, this thesis aims at teasing out this multivalent interaction by using a
combination of three dimensional structural modeling and bioinformatics tools,
biochemical analysis of the interaction followed by validation using in vitro and in vivo
assays. Such an approach would not only enable understanding this critical interaction
but can also pave way to the development of alternate antiviral strategies to combat
influenza A infection.
The overall goal of this thesis is to
Elucidate the multifaceted role of influenza A virus hemagglutinin -
host glycan receptor interaction to gain insight into its role in viral
pathogenesis and for the development of alternate anti-viral
strategies against influenza A infection
The remainder of this chapter provides insight into the current framework to
understand influenza A hemagglutinin - host glycan receptor interaction and highlights
the challenges that has to be addressed with the current framework. Building on this is
the motivation of my research work, which paves way to the Specific Aims of this thesis.
Section 1.2 describes the biology and life cycle of Influenza A virus. Section 1.3
and 1.4 describes the two molecular components namely the viral hemagglutinin (HA)
and the glycan receptors respectively. Following on Sections 1.3 and 1.4, Section 1.5
describes the currently available tools to analyze HA-glycan interaction. Building on this
Section 1.6 provides an overview of the challenges associated with the current approach
to study HA-glycan interaction. Section 1.7 provides an emphasis on taking a
multifaceted approach to really correlate this critical molecular protein-glycan
interaction to the viral pathogenesis. Towards this end this section also describes the
tools that were developed in our lab and in this thesis to address the challenges
mentioned in Section 1.6. Based on the motivation provided in Section 1.1 and the tools
described in Section 1.7, Section 1.8 provides an overview of the Specific Aims and
outline of this thesis.
1.2 Influenza A virus
1.2.1 Influenza A virus: Biology and Pathogenesis
Influenza A virus belongs to the family of Orthomyxoviridae. The structure of
influenza A virus is somewhat variable, but the virion particles are usually spherical or
ovoid in shape and 80 to 120nm in diameter. The genome consists of eight negative
sense single stranded RNA segments encoding at least for 10 proteins (Figure 1.1). The
influenza virion is an enveloped virus that derives its lipid bilayer from the plasma
membrane of a host cells that it infects. There are three different proteins that are
embedded in the lipid envelop of the virion: two glycoproteins (neuraminidase and
hemagglutinin) and a transmembrane ion channel protein (M2). Underneath the lipid
bilayer lies the matrix protein (Ml), a major structural protein. Within the virus shell are
eight viral ribonucleoprotein complexes (vRNP), each composed of viral RNA (vRNA)
associated with the nucleoprotein NP and the three components of the viral RNA
polymerase complex (polymerase basic protein 1 or PB1, Polymerase basic protein 2 or
PB2 and polymerase acidic protein or PA). The NS1 protein, which counteracts the
cellular interferon response, is synthesized from an unspliced mRNA, and a spliced
mRNA yields the NS2, or NEP protein that mediates nuclear export of the vRNP
complexes [3]. In addition, the recently identified PB1-F2 protein, which is encoded by
the PB1 segment, is thought to play a role in viral pathogenicity [4-7].
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Figure 1.1 Schematic representation of influenza A viruses. The viral coat consists of three major
proteins: hemagglutinin (HA), neuraminidase (NA) and matrix protein 2 (M2). The genome consists of
eight negative sense single stranded RNA that interact with the components of the polymerase complex
(PA, PBl and PB2)
Human influenza infection is highly contagious that is transmitted by airborne
route via respiratory droplet. Infection is usually confined to the respiratory tract.
Replication occurs in the epithelia of the respiratory tract and normally reaches its peak
2-3 days after infection. The period of virus shedding is 5-7 days and may last with
infants and children as long as 2 weeks. After an incubation time of 1-5 days, patients
suffer from acute respiratory disease symptoms with headache, high fever, myalgia,
nausea and malaise. Severe cases develop typically primary influenza pneumonia or
combined viral-bacterial pneumonia. Persons usually at risk for complications during a
seasonal epidemic are the elderly and patients with cardiovascular diseases, metabolic
disorders or immunosuppression. Less frequent complications are myositis, myocarditis
and Reye's syndrome, a severe disease with brain and liver involvement and usually
lethal outcome.
Avian influenza A virus infection is different from that of the infection caused by
human adapted influenza A virus. Low Pathogenic influenza A virus (LPAI) virus
. ... .........
replication is confined to the intestinal and respiratory tract resulting in mild disease or
asymptomatic infection. Virus is shed in the faeces and hence the dissemination of the
virus among aquatic birds occurs through contaminated water. High pathogenic
influenza A viruses (HPAI) are also shed in faeces with high concentrations. However,
these viruses are more readily transmitted among birds in densely populated flocks by
the nasal and oral routes through contact with virus-contaminated materials. In contrast
to the local LPAI infection of the intestinal or respiratory tract, HPAI viruses cause
systemic infection affecting many organs. Large hemorrhages distributed all over the
body, edema and cutaneous ischemia are major symptoms of the disease. The final
stage of the infection can be characterized by the emergence of neurological signs, such
as photophobia and dullness [8].
HPAI viruses have been found to specifically target lymphocytes and lymphoid
tissues [9, 10], myocytes in the heart muscle [11] and endothelial cells [12]. Tropism to
these cells may play an important pathogenic role in systemic virus dissemination and in
the vascular leakage underlying hemorrhages and edema.
The role of various influenza A viral proteins and their role in viral pathogenesis
is discussed in the following section.
1.2.2 Viral proteins and their role in pathogenesis
Viral glycoproteins:
The HA protein mediates virus binding to sialic acid receptor on the host cell surface and
membrane fusion events in the life cycle of the virus (explained in detail in Section 1.4).
The efficient release of new virions from the infected cells requires the removal of sialic
acid by neuraminidase, another glycoprotein found in the lipid envelope of the virus.
The receptor binding and receptor destroying properties of HA and NA, respectively,
must be balanced [13, 14]. The NA stalk, which separates the head region with the
enzymatic center from the transmembrane and cytoplasmic domains, varies in
sequence and length, depending on the virus [15]. Typically, shortened stalks result in
less efficient virus release since the active site in the head region cannot efficiently
access its substrates [16]. Compared to viruses with a long-stalk NA, viruses with a short
stalk showed a decreased capacity to elute from RBCs and an increased virulence in
mice [16]. Moreover, most recent highly pathogenic H5N1 viruses isolated from
terrestrial poultry possess short NA stalks [17]. Influenza A virus HA and NA are the
targets of the host antibody response (explained in detail in Chapter 2). In order to
escape the neutralizing antibody response, the virus acquires mutations in its HA and NA
and this further contributes to the antigenic drift mediated evolution of the virus.
Internal proteins:
There are seven internal proteins in influenza A virus: RNA polymerase (PB1, PB2 and
PA), nucleoprotein (NP), matrix protein (Ml and M2), and non-structural proteins (NS1,
NS2/NEP).
Viral RNA polymerase complex:
The polymerase proteins (PB1, PB2 and PA) form a heterotrimer bound to a short
hairpin structure formed by the partially complementary terminal 5' and 3' untranslated
regions (UTRs) of each segment. P1 the central scaffold for trimer assembly, serves as
RNA - dependent RNA polymerase. Short amino terminal (aa 1-15) and carboxy terminal
(aa 685-757) sequences interacting with PA and PB2, respectively, are the only parts of
PB1 currently known at atomic resolution [18]. PB2 functions in mRNA synthesis by
binding host mRNA caps. The PB2 domains with known structure include an amino-
terminal peptide (aa 1-35) that interacts with the carboxy-terminal end of PB1, the cap-
binding domain (aa 320-483), a domain involved in host interaction carrying the
adaptive mutation 627 (aa 538-678), followed by the carboxy terminal NLS domain (aa
678-759) the contains the classical bipartite nuclear localization sequence 736-
RKRX12KRIR-755 [18].
While PA is necessary for a functional polymerase complex, including cap-
snatching endonucleolytic cleavage of host RNAs, the biology of which is poorly
understood [19]. The amino terminal domain of PA has been identified to have the
endonuclease activity. PA may have additional proteolytic activity and may also act as an
elongation factor during RNA synthesis. A recent study suggested that the replication
complex, particularly the PB1 protein, contributes to the virulence of the 1918 pandemic
virus in ferrets [20].
Reverse genetics studies have shown that lysine at position 627 of PB2 (found in
all highly pathogenic influenza A virus strains such as H5N1) determines high
pathogenicity in mice, while glutamate at this position determines low pathogenicity
[21]. However, the nature of the amino acid at position 627 of PB2 does not affect the
cell tropism but its replicative ability in mice and probably in humans. PB2-Lys 627 is
suggested to allow efficient replication not only in the lower but also in the upper tract
of mammals, a feature that may facilitate transmission. PB2-Lys 627 mutation is know to
facilitate the virus to adjust to physiological constraints such as differences in body
temperature [22]. In fact, replacement of PB2-Lys 627 with Glu reduced the
transmissibility if human influenza viruses in guinea pig model [23]. The amino acid at
position 701 of PB2 has also emerged as a determinant of virulence [24, 25], a role
probably related to its facilitation of binding of PB2 to importin a (a cellular nuclear
import factor) in mammalian cells [26].
Recently, PB2 and HA proteins of the Spanish influenza virus were show to be
critical for droplet transmission [27].
Viral nucleoprotein (NP):
NP acts primarily as a single-strand RNA-binding protein and serves as a structural
protein in the ribonucleoproteins (RNPs). In addition it plays an important role in
transcription and in the trafficking of RNPs between the cytoplasm and nucleus.
Influenza A virus RNA transcription and replication occur in the host cell nucleus, since
this process is dependent on host cell RNA processing machinery. The process of being
imported into the nucleus, exported back out to the cytoplasm, and then prevented
from re-entering the nucleus also all appear to depend on the interaction of NP with
host proteins.
Viral nonstructural (NS) protein:
The nonstructural 1 (NS1) protein has multiple functional domains, including N-terminal
dsRNA binding (1-73) containing a nuclear localization signal (NLS), a central effector
domain (73-207) containing a nuclear export signal, and a C-terminal region (207-230)
containing a PDZ domain [28]. NS1 has pleiotropic functions, including dsRNA binding,
enhancement of viral mRNA translation, inhibition of host mRNA processing and type I
interferon antagonism [29]. As demonstrated by reverse genetics, the resistance to the
antiviral effects of IFN and TNF-a is associated with glutamic acid at position 92 of NS1
protein. Also pigs infected with a virus containing Glu-92 in NS1 protein experience
higher virus titers and body temperatures than those infected with a control virus [30,
31].
The NS2 protein (also referred to as nuclear export protein, NEP) is found in
virions and facilitates nuclear export of viral RNP complexes.
PB1-F2 protein:
PB1-F2 is a small viral protein, which is encoded by PB1 gene by an alternative reading
frame. PB1-F2 targets the mitochondrial inner membrane, and may play a role in
apoptosis during influenza A virus infection. Recently, a single Asn66Ser mutation in the
PB1-F2 protein was shown to increase virulence in mice by inhibiting early interferon
response [32, 331.
M protein:
Segment 7 of influenza A viruses encodes the M1 matrix and the M2 ion channel
proteins. M1 protein, one of the several late viral proteins, is involved in the export of
viral ribonucleoproteins (vRNPs) from the nucleus into the cytosol for translation. Why
M1 is essential for export of vRNPs from the nucleus to the cytosol is not clear. It may
escort the vRNPs from the nucleus and through the nuclear pores, or it may be needed
to release the bound vRNPs from the nuclear matrix. Another possibility is that, by
associating with vRNPs in the cytosol, M1 may prevent their reimport into the nucleus
[34].
M2 possesses proton channel activity that allows virion acidification for efficient
uncoating after fusion in endosomes. Recently, M2 protein has been speculated to be
involved in regulating cell death by inhibiting antiapoptotic macroautophagy [35].
1.2.3 Life Cycle of influenza A viruses
The life cycle of influenza virus is depicted schematically in (Figure 1.2) and comprises of
the following key events.
1. Binding: The virus particle initially associates with a host cell surface by binding
to sialic acid-containing glycan receptors
2. Endocytosis: The bound virus is endocytosed by one of four distinct mechanisms.
Most internalization appears to be mediated by clathrin-coated pits, but
internalization via caveolae, macropinocytosis, and by non-clathrin, non-
caveolae pathways has also been described for influenza viruses [36].
3. Fusion and Release of viral ribonucleoprotein: Acidification of the endosome by
the M2 ion channel matrix protein, promotes fusion of the viral and endosomal
membranes mediated by the viral hemagglutinin (HA) protein, and the eventual
release of the uncoated viral ribonucleoprotein complex into the cytosol of the
host cell.
4. Transport into the nucleus: The ribonucleoprotein complex is transported
through the nuclear pore into the nucleus.
5. Replication: Once in the nucleus, the incoming negative-sense viral RNA (vRNA)
is transcribed into messenger RNA (mRNA) by a primer-dependent mechanism.
Replication occurs via a two-step process. A full-length complementary RNA
(cRNA), a positive-sense copy of the vRNA, is first made and this in turn is used as
a template to produce more vRNA.
6. Translation: The newly synthesized vRNAs are exported into the cytoplasm by
NEP or NS2 proteins, for translation, to make viral proteins.
7. Release of the viral particles: The viral proteins are expressed and processed
and eventually assemble with vRNAs at budding sites within the host cell
membrane. The viral protein complexes and ribonucleoproteins are assembled
into viral particles and bud from the host cell, enveloped in the host cell's
membrane. The viral neuraminidase cleaves the sialic acid receptors on the
surface of the host cell to prevent re-infection of the host cell and hence
mediates the release of the newly formed virions.
The main focus of this thesis is to understand the first critical step in the viral life cycle,
i.e., binding of the viral HA to the host cell surface glycan receptors and understand the
factors governing this critical protein-glycan interaction. This thesis further investigates
the structural and functional roles of viral HA and the host glycan receptors in the host
adaptation of the virus and its implication in the transmissibility of the virus in human
host. Building on the understanding of the host glycan receptors, this thesis also
investigates an alternate strategy to target the glycan receptors to combat influenza A
infection.
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Figure 1.2 Schematic representation of influenza A viral life cycle. Influenza A virus hemagglutinin binds
to the cell surface glycan receptors (shown in the inset) and mediates entry into the host cell by receptor
mediated endocytosis. Due to the acidic pH of the endosomes, the virus undergoes uncoating and the
viral ribonucleoprotein (vRNP) complexes are released into the cytoplasm and subsequently transported
to the nucleus, where replication and transcription takes place. mRNAs are transported back to the
cytoplasm for translation. Early viral proteins, which are required for replication and transcription, are
transported back to the nucleus. Late proteins on the other hand, facilitate nuclear export of the newly
synthesized vRNPs. The assembly and budding of the progeny virus occurs at the plasma membrane.
1.3 Host Cell Surface Glycans as receptors for Influenza A virus infection
Glycosylation is one of the key post-translational modification of proteins. Most
well characterized pathways for the biosynthesis of major classes of glycans are
confined within the ER and Golgi compartments. Thus, for example, newly synthesized
proteins originating from the ER are either co-transitionally or post-translationally
modified with sugar chains at various stages in their itinerary toward their final
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destinations. The glycosylation reactions usually use activated forms of
monosaccharides (nucleotide sugars Figure 1.3), as donors for reactions that are
catalyzed by glycosyltransferases. In proteins, glycosylation can be N- or 0- linked
depending on whether the glycan chain is added to the asparagine amine group or
serine/threonine hydroxyl groups respectively. Glycosylation takes place in the
endoplasmic reticulum and in the Golgi mediated by various enzymes.
Figure 1.3 A schematic representation of N-glycosylation in endoplasmic reticulum (ER). The nascent
polypeptide chain synthesized emerging from the ribosomes on the ER migrate into the ER and are
processed by a series of enzymes. Figure adapted from http://openlearn.open.ac.uk
Glycans on proteins play an important role in proper folding of newly
synthesized polypeptides in the endoplasmic reticulum (ER) and/or subsequent
maintenance of protein solubility and conformation. Indeed if proteins are incorrectly
glycosylated, they will fail to fold properly and/or exit the ER, being consigned instead to
degradation in proteasomes. When present on cell surface, glycans also shield the
underlying polypeptide from recognition by proteases and antibodies.
Since glycans on the glycoproteins are present in the unique interface of cell
surface and extracellular matrix (ECM), apart from the aforementioned roles, they also
serve as recognition sites (or receptors) for proteins on the surface of bacteria and
viruses [37] (Figure 1.4). The specific binding of bacteria and virus particles to these
glycan receptors on the host cell surface is a pre-requisite for evasion of host epithelium
in order to gain entry into the host cell.
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Figure 1.4 Glycans as recognition sites for pathogens. Glycans are present in the interface of cell surface-
ECM (extracellular matrix) and hence serve as recognition sites for bacteria, virus and some toxins. This is
responsible for tissue tropism of any disease pathogenesis.
One of the well-studied systems of host-pathogen interaction is that of influenza
A virus. One of predominant viral coat proteins, hemagglutinin (HA) [explained in detail
in Section 1.4.) is a glycan binding protein (or a lectin) which recognizes specific glycan
receptors on the surface of host cell and mediates attachment, viral entry and
membrane fusion events. The specificity of influenza A HA to specific host glycan
receptor, determines the viral host adaptation and tissue tropism.
Influenza A viruses exist as commensals in the gut of waterfowl. The gut and
respiratory tract of birds are known to predominantly express glycan receptors
terminated by a2-3 linked sialic acids (referred to as avian receptors) as shown in Figure
1.5 [38-43]. Most avian viruses cause no or only mild disease symptoms. These low
pathogenic avian influenza (LPAI) viruses comprising all subtypes are different from
highly pathogenic avian influenza (HPAI) viruses such as H5 and H7, which have a
polybasic HA cleavage site. HPAI viruses arise by introduction and circulation of H5 and
H7 LPAI viruses in domestic poultry with subsequent mutations in the HA cleavage site
[44, 45].
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Figure 1.5 Glycan receptors for influenza A HA in various hosts. Sialic acid linked to galactose in either
a2-3 or a2-6 linkages are the receptors for influenza A HA. Host restriction of the virus is determined by
the glycan receptor distribution. The gut and respiratory tract of birds predominantly express a2-3
glycans, which is in contrast to human respiratory tract, which express a2-6 glycans. A switch in the
receptor binding property of HA from a2-3 to a2-6 binding specificity is crucial for the human host
adaptation of the virus. This host adaptation is facilitated by pigs, which express both a2-3 and a2-6
glycans in their gut and respiratory tract and are hence called as "mixing vessels".
Since the host barrier is not an unsurmountable obstacle for LPAI viruses, they
can occasionally be transmitted from their natural reservoir to terrestrial birds and
mammals [46]. Most of these transmissions are transient and do not result in a stable
new lineage [18]. Occasionally however, the viruses adapt to the new species and give
rise to a new lineage. Adaptation requires multiple mutations and it may involve gene
reassortment after coinfection with another virus. Influenza A viruses can adapt to
human host and can cause infection in them.
The primary site of infection of influenza A viruses in humans is the upper
respiratory tissues. Therefore the glycan receptors in the upper respiratory epithelia
play a central role in mediating the host infection by the virus. It is known that these
glycan receptors are terminated by a2-6 linked sialic acids (referred to as human
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receptors). Using plant lectins such as SNA-l (binds specifically to Neu5Aca2-
6Gal/GaINAc motif [47]) and MAL-Il (binds specifically to a2-3 glycans), we and others
have shown that there is a predominant expression of a2-6 glycans in the human upper
respiratory tract whereas a2-3 glycans are predominantly expressed in the deep lung
region (Figure 1.5 and Figure 1.6) [41, 48, 49].
Further to assess the influenza A viral tropism and to understand the distribution
of the viral glycan receptors, Van Riel et al, determined the pattern of virus attachment
by virus histochemistry of three human and three avian influenza A viruses in human
nasal septum, conchae, nasopharynx, paranasal sinuses, and larynx. The human adapted
influenza A viruses attached abundantly to ciliated epithelial cells and goblet cells
throughout the upper respiratory tract. In contrast, the avian influenza A viruses,
including the highly pathogenic H5N1 attached only rarely to epithelial cells or goblet
cells. This was further corroborated by Chandrasekharan et al [48], using recombinant
hemagglutinin (HA) expressed in insect cells, to stain various regions of human
respiratory tract. HA from human adapted influenza A viruses showed predominant
staining of the non-ciliated goblet cells and the ciliated epithelial cells in the upper
respiratory tract indicating predominant distribution of a2-6 glycans in the upper
respiratory tract. In contrast HA from the avian influenza A viruses showed no staining
of the human upper respiratory tract. The avian HA showed predominant staining of the
deep lung alveolar tissue section indicating predominant expression of a2-3 glycans in
human deep lung or lower respiratory tract.
On the contrary, the epithelial cells of pig trachea contain both avian and
human receptors [50]. Hence pigs are highly susceptible to infection by both the avian
and human-adapted influenza A viruses [51]. Pigs may hence serve as "mixing vessel"
for reassortment between avian and human influenza A viruses that can occasionally
give rise to pandemic influenza A virus strains [52, 53].
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Figure 1.6 a2-6 and cz2-3 sialylated glycan receptor distribution in human respiratory tract. SNA-1, a
plant lectin, which binds to a2-6 glycans showed highly specific binding to human tracheal apical surface
ciliated and goblet cells (A). MAL-II, another plant lectin, which binds to a2-3 glycans, showed highly
specific binding to human alveolus (B). The nuclei were visualized by staining with propidium iodide (red).
The lectin staining is visualized by a green staining of the tissue sections. Trachea and alveolus represent
the upper and the lower respiratory tract in humans respectively.
1.4 Influenza A virus Hemagglutinin: Role in viral pathogenesis
The lipid envelope of influenza A virus consists of 2 major glycoproteins: Hemagglutinin
(HA) and Neuraminidase (NA), both of which bind sialic acid [14]. As mentioned in
Section 1.2, both these glycoproteins play an important role in the viral life cycle. Both
HA and NA are the targets of the host neutralizing antibodies which block the viral
infection [14]. As a result of this immune pressure, both HA and NA change their
antigenic properties by acquiring mutations during evolution to evade the host antibody
response. These antigenic differences are used to classify influenza A viruses into 16 HA
(H1 - H16) and 9 NA (N1 - N9) subtypes.
Of the two glycoproteins, HA play crucial roles in the early stage of virus
infection, including virus binding to host receptors, viral entry, and membrane fusion
... ......  . ...
[54]. The interaction of HA with the host glycan receptor plays a key role in the host
adaptation of the influenza A virus.
1.4.1 HA structure:
HA is a trimer of identical subunits (Figure 1.7). HA is initially synthesized as a
precursor, HAO, which trimerizes in the endoplasmic reticulum in association with
chaperones and is transferred to the cell surface through the golgi apparatus. HAO is
proteolytically cleaved into the functional HA1 and HA2 subunits linked by a single
disulfide bond. Cleavage of the precursor is essential for activation of membrane fusion
potential and hence infectivity. For HAs of most subtypes, the site of cleavage is a single
arginine residue, and cleavage occurs by an as yet unidentified enzyme. It has been
speculated that this cleavage may be mediated by the serine protease, tryptase Clara,
produced by Clara cells of bronchiolar epithelium [55, 56]. This enzyme shows
recognition specificity for the sequence Q/E-X-R found at the cleavage sites of these
HAs. HAT (human airway trypsin-like protease) and TMPRSS2 (transmembrane protease
serine S1 member 2, also known as epitheliasin) are present in human airway epithelial
cells and have been shown to be capable of cleaving HA having a monobasic cleavage
site [57]. In agreement with this, TMPRSS2 and the related protease TMPRSS4 have
been reported to cleave the HA of the 1918 HINI virus at a monobasic cleavage motif
[58]. However, for many cell types, the protease(s) responsible for HA cleavage remain
poorly defined.
In contrast, some members of the H5 and H7 subtypes (Highly Pathogenic Avian
Influenza A viruses or HPAI) however have acquired multiple basic residues at the site of
cleavage [59]. The HPAls have 75% or higher mortality after experimental infection of
chickens. Cleavage at these multibasic sites occur intracellularly and involves subtilisin-
like enzymes that are active in the post-translational processing of hormone and growth
factor precursors [60]. The furin recognition sequence R-X-R/K-R is a common feature of
the inserted polybasic sequences. The wide tissue distribution of furin-like enzymes and
the high efficiency of intracellular cleavage, compared with the extracellular cleavage,
appear to be related to the widespread systemic and virulent infections caused by the
H5 and H7 viruses in birds and the localized outbreak of H5N1 infection in humans in
Hong Kong in 1997 [61]. In all cases, enzymatic cleavage generates the N terminus of the
"fusion peptide (FP)", a conserved uncharged region of HA that plays an essential but
undefined role in membrane fusion.
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Figure 1.7 Molecular model of influenza A virus HA. Influenza A HA is a homotrimer consisting of a
globular head region that harbors the receptor-binding site and a stem region that harbors the protease
cleavage site. Each of the monomer is highlighted in red, blue and green respectively.
1.4.2 HA and its role in membrane fusion events in influenza A virus life cycle:
After binding to the host sialylated glycan receptor, influenza A virus is taken into
cells by endocytosis. Within the endosomal compartment, the virion is exposed to the
increasing acid pH 5-6, the HA protein undergoes irreversible conformational change
from its metastable prefusion conformation to a low-pH hairpin structure involving
extrusion of the "fusion peptide (FP)" from the interior of the HA2 at the neutral pH
structure toward the endosomal membrane, promoting fusion of the viral and
endosomal membranes (Figure 1.8) [62, 63]. X-ray crystallographic studies have
demonstrated the extensive rearrangement of residues in HA2 at low pH with respect to
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their relative orientation and coil-coil formation, loop-to-helix or helix-to-loop
transitions [64, 65].
The interaction between FP and the target membrane leads to an extended
intermediate the bridges the viral and cell membranes. Then the intermediate collapses
by zipping up of the C-terminal part of the ectodomain alongside the trimer-clustered N-
terminal part, which brings the two membranes into close proximity, resulting in
formation of a hemifusion stalk. A fusion pore opens up through which the genetic
material of influenza A virus is released into the host cell to generate new virions [62].
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Figure 1.8 Ribbon diagram of the neutral and low pH forms of the HA. HA monomer at neutral pH is
shown (A). Shown are HA1, HA2 and the central extended chain and the carboxy-terminal helix. At low pH
(B) HA undergoes a major conformational change leading to the formation of an extended helix. The
region of extended polypeptide chain between the N-terminal helix and the C-terminal helix is
incorporated into the extended helix following acidification and the fusion peptide is exposed. This fusion
peptide then interacts with the target membrane and enables membrane fusion.
Figure adapted from (http://www.hiv.lanl.gov/content/sequence/HIV/REVIEWS/gp4l.html)
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1.4.3 Molecular insights into HA-glycan interaction:
Each HA monomer contains a receptor - binding site (RBS) at its membrane
distal tip, which has at its base, a number of conserved amino acids, Tyr-98, Trp-153,
His-183 and Tyr-195, and at its edges, three conserved elements of secondary structure,
the 130- and 220- loops and the 190 a-helix (Figure 1.9). Sialic acid is bound similarly in
all HAs by hydrophobic interactions and by hydrogen bonds with the 130- and 220-
loops and conserved amino acid in the base of the site.
Human receptor
190 a-helix
5 loop
220-loop22~ ~10-loop ioop
Figure 1.9 Crystal structure of a representative H1NI HA in complex with human receptor. Shown is the
crystal structure of HA from the 1918 pandemic A/South Carolina/1/18 or SC18. The protein was co-
crystallized with LSTc (human receptor analog). Shown are the various loops (in various colors) and helix
in the receptor binding site of the HA that interact with the glycan receptor.
The binding affinity of a single HA molecule to a single glycan receptor is in the
mM range [66]. These estimates of low affinity imply that the tight binding of viruses to
the cells during infection is mediated by the simultaneous interactions of a number of
............
HA molecules. In other words, HA-glycan interaction is multivalent similar to other
protein-glycan interactions.
During antigenic variation, many amino acid sequence changes occur near the
RBS on HA. Some of these influence receptor binding affinity and specificity. Such amino
acid changes influence the specific interaction of HA with the sugars that are linked to
sialic acid. The changes observed are different in H1 HA compared with H2 and H3 HAs.
In H1 HA, mutations in residues 190 and 225 are important. An Asp190Glu and
Asp225Gly double mutation in a prototypic H1 HA from the 1918 pandemic, A/South
Carolina/1/18 or SC18, resulted in a complete switch from the human-like a2-6 receptor
binding preference to the avian-like a2-3 receptor binding specificity [67]. In both H2
and H3 HAs, Gin226Leu and Gly228Ser are the major differences between avian and
human viruses, with GIn226Leu observed in viruses isolated early in the pandemic.
X-ray crystal structures of several HA-ligand complexes have been determined in
which the sialylpentasaccharide a2-6 linked LSTc (the structure is shown below) was
used as a human receptor analog, and a2-3 linked LSTa (the structure is shown below)
was used as an avian receptor analog (structure of LSTa and LSTc is shown below). In the
complexes formed by all the human HAs with LSTc, the a2-6 linkage between sialic acid
and galactose adopts a cis-conformation in which the glycosidic oxygen faces out of the
site (Figure 1.9 and Figure 1.10). The galactose ring is oriented face on and together
with C-6 presents a non-polar surface towards the base of the site. The bound
oligosaccharide forms a folded-back structure and exits toward the right side of the site.
LSTa: Neu5Aci Galpl-3GcNAc1-3Gal@1-4Glc
LSTc: Neu5Aci Gal1-4GcNAc$1-3Gal 1-4Glc
In avian H1, H2, H3 and H5 complexes with LSTa, the first three sugars of the avian
receptor form a more extended chain in which galactose or Gal-2 (linked to sialic acid) is
projected upwards, and the oligosaccharide exits site over the 220-loop, roughly
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opposite to the direction taken by the folded human receptors. The a2-3 linkage is in a
trans-conformation, which exposes the glycosidic oxygen towards Gin-226 at the base of
the site, and the Gal-2 is oriented edge on. The trans-conformation allows the formation
of additional hydrogen bonds between the amine and carbonyl groups of Gln-226 and
the 4-OH of Gal-2 and the glycosidic linkage oxygen. These interactions do not occur
with human receptors, but this binding motif is common to all avian HAs.
In essence, the receptor binding pocket of the human adapted influenza A virus
HA is more open than the avian HA binding pocket (Figure 1.10B). Hence unlike the
human adapted HAs, the amino acids in avian HA that interact with the glycan receptor
are conserved across all the avian HAs.
A B
Figure 1.10 Molecular HA-Glycan receptor interactions. Shown are the HA-glycan receptor interactions
for avian HA-a2-3 glycan receptor (A) and human HA-a2-6 glycan receptor (B). As seen from the figure,
the avian HA receptor binding pocket is closed wherein the majority of the contacts are with the sialic acid
linked a2-3 to galactose. On the other hand, in case of the human HA, the receptor binding pocket is
more open than avian HA due to its contact with sugars beyond the terminal sialic acid linked a2-6 to the
subterminal galactose (as shown in B).
1.5 Current tools to study HA-glycan interaction
A variety of biochemical assays are traditionally used to characterize HA-glycan
interaction. This section highlights some of the pros and cons of these assays.
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1.5.1 RBC Agglutination Assay
One of the earliest methods that still is used extensively to probe the glycan
binding specificity of influenza A virus involves measuring the ability of the virus
(through its HA) to agglutinate red blood cells (RBCs) as shown in Figure 1.11. RBCs from
a variety of species such as chicken, turkey, horse, guinea pigs and humans are used for
the assay due to their differential expression of a2-3 and a2-6 glycan receptors [67-71].
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Figure 1.11 Schematic representation of RBC agglutination assay. The assay is a simple visual and a
qualitative analysis to test the receptor binding specificity of viruses or recombinant HA.
Equine RBCs predominantly express a2-3 glycans on their cell surface whereas
turkey and guinea pig predominantly express a2-6 glycans on their cell surface.
Interestingly, chicken RBCs express both a2-3 and a2-6 glycans on their cell surface. To
improve the specificity and the usefulness of the assay, the agglutination assay has been
modified to include a step of complete desialylation of RBCs from a particular species
followed by specific resialylation by either a2-3 or a2-6 sialyltransferase [72].
Agglutination assay is used extensively as it presents a simple approach for rapid
analysis of influenza A virus. The visual read out further contributes to the easiness of
the assay. Agglutination leads to a "matty" appearance of the RBCs as opposed to the
non-agglutinated RBCs, which settle to form a tight button (Figure 1.11).
Though the agglutination assay is widely used, there are several drawbacks with
the assay. Firstly, agglutination and other traditional hemagglutination assays define
virus specificity according to the sialic acid linkage. However no information is obtained
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on the virus specificity beyond the sialic acid linkage and hence probing the fine
specificity of HA binding is not possible. Secondly, there is possibly substantial variability
in the N- and 0- linked cell surface glycans between different batches of between
different batches of RBCs and related potential for variable response. This can skew
results and mask any important specificity differences among viral strains. Additionally,
the glycan structures on the cell surface of RBCs do not represent the glycan structures
found on surface of human upper airway cells and hence are not physiologically relevant
also this can undermine the diversity associated with the physiological glycan receptor
[48].
1.5.2 Fetuin Binding Assay
Fetuin is a blood glycoprotein that is heavily glycosylated with N-glycans. Fetuin
binding assay is based on competition for binding to solid phase immobilized virus
between a horse radish peroxidase (HRP) conjugated fetuin, and unlabeled a2-3 and a2-
6 sialyloligosaccharides [731. The a2-3 and a2-6 sialyloligosaccharides are coupled to
polyacrylamide, providing increased valency to compensate for the low HA affinity (mM
range) for receptor analogues [74, 75]. Assays like these have been used to understand
the diversity of receptor specificities of influenza A viruses from both birds and
mammals [76-79] including H5 influenza A viruses [80]. Like the agglutination assays,
fetuin binding assay also has several issues. First, measuring the binding of fixed viruses
to glycans in solution is opposite to the physiological event where glycans are less
mobile of the cell surface as compared with the virus. Finally, this assay is relatively a
low throughput, and has been optimized for screening with whole viruses, thereby
restricting the study of new pathogenic strains to specialized laboratories [81].
1.5.3 Solid Phase Fetuin Capture Assay
Subsequent development of fetuin binding assay has provided a wealth of
information on the glycan binding properties of influenza A viruses (Figure 1.12). In
these assays, viruses are immobilized on fetuin-coated surfaces and their binding to
various sialylated glycans (including polyvalent compounds) is evaluated [78, 79, 82, 83].
One of the major issues with the assay is the presentation of viruses, which is
heterogeneous because the amount of virus captured on the plate depends on the
binding of the viral HA to the sialylated glycans on fetuin. Moreover, similar to the fetuin
binding assay, the binding event is opposite of the physiological event where the viruses
in solution bind to the less mobile glycan receptors on the cell surface.
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Figure 1.12 Schematic representation of Fetuin Capture Assay. Viruses can be captured on the fetuin
coated plates through their interaction with the sialylated N-glycans on fetuin. Binding affinity constants
can be estimated by adding varying concentrations of soluble ligands. This assay can also be used to
estimate the potency of soluble sugar analogs that competitively inhibit binding of the virus to the glycan
receptors.
1.5.4 Glycan Array Analysis
The recent advent of chemical and chemoenzymatic synthesis of glycans has led
to the development of glycan array platform (Figure 1.13) [81, 84, 85]. Analogous to a
DNA microarray platform, the glycan microarray platform consists of hundreds of
synthetic glycan motifs (typically present on N- and 0- linked glycoproteins and
glycolipids) displayed on the surface of glass slide (sugars with amino terminal linkers
are immobilized on amino-reactive N-hydroxysuccinimide activated glass slides by a
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covalent amide bond). If the glycans are biotinylated, they can be immobilized on
streptavidin-coated surfaces. Multiple types of arrays have been developed depending
upon the source of glycans that are immobilized onto the surface. Recently a novel
strategy for creating naturally derived glycan microarrays have been developed [86].
Such an approach will enable imprinting natural glycans extracted from the cell surface
to be imprinted on a glycan array format thus allowing one to probe the glycan
repertoire of a biological system. Further to improve the presentation of glycan similar
to the physiological scenario, various strategies including the formation of
neoglycolipids [87] and neoglycoprotein [85, 88].
More recently, the glycan array platforms developed by Consortium for
Functional Glycomics (CFG) have been used to screen wild-type and mutant forms
(mutations in HA) of intact viruses and recombinant HAs belonging to the H1, H2, H3,
H5, H7 and H9 subtypes [89-921. These studies have increased our understanding of HA
binding to sialylated glycan receptors by mapping the effect of glycan modifications such
as sulfation and fucosylation on the HA-glycan interactions. Glycan array analysis with
whole viruses provides a quick snapshot of the various human and avian glycan
receptors that are bound by the viral HA. Viruses are quantified as hemagglutination
units (HAU) based on their ability to agglutinate RBCs. Since HAU is dependent on the
binding affinity of the viral HA to the receptors on the surface of RBCs, it varies between
different viruses. Hence it is challenging to compare the binding property of one virus
(analyzed on the array) with that of another virus. Also this makes it challenging to
quantify the affinity of HA for a specific glycan receptor.
1.5.5 Flow Cytometry to analyze HA-glycan interaction
Yet another technology that is being developed uses beads coated with specific
glycan motifs to probe binding of fluorescently labeled whole viruses or recombinant HA
(unpublished results). Binding can be analyzed by flow cytometry by measuring the
fluorescence emanating from the bound virus or HA. This assay mimics the multivalent
presentation of glycans on cell surface and hence is physiologically relevant.
1.5.6 Other Methods to analyze HA-glycan interaction
There are other (though not commonly used) methods to investigate HA-glycan
interactions such as isothermal titration calorimetry and surface plasmon resonance
(SPR), which have been used to determine equilibrium binding affinity constants and
thermodynamic parameters for glycan-protein interactions [93, 94].
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Figure 1.13 Schematic representation of the glycan array platform. Chemically synthesized enzymes can
be immobilized to glass slides by chemical modification. Binding of whole viruses and proteins to specific
glycans can be analyzed as shown above. Binding signals can be estimated by using a secondary antibody
tagged to an enzyme or other chemiluminescent molecules.
1.5.7 Staining of relevant tissue sections with whole viruses and recombinant HA
One of the factors determining the pathogenicity of influenza A viruses is their
tissue tropism. Human upper respiratory tract is the prime target of infection by human
adapted influenza A virus. The variation in pathogenicity of influenza A viruses is
speculated to be due to their differences in tropism to human upper respiratory tract.
Hence in order to understand the tissue tropism of influenza A viruses, various
strategies have been employed. Broadly, in order to understand the distribution of a2-3
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and a2-6 glycans, fluorescently labeled plant lectins have been used to stain paraffinized
human respiratory tract tissue section (Figure 1.6) [49]. Further, by looking at the
pattern of virus attachment (PVA) to various regions of the paraffinized tissue sections
from human upper respiratory tract, it was determined that the influenza A viruses that
transmitted efficiently among humans attach abundantly to human upper respiratory
tract, whereas inefficiently transmitted influenza A viruses attach rarely [38, 39, 41].
More recently, recombinant HA precomplexed with a primary antibody and a
fluorescently labeled secondary antibody has been used to stain paraffinized human
respiratory tract tissue sections [48]. This showed that the HA from human adapted
influenza A viruses showed predominant staining of the goblet cells and ciliated
epithelial cells of human trachea. On the contrary, recombinant HAs from avian
influenza A viruses showed predominant staining of the human alveolar region (deep
lung) [48, 95].
1.6 Challenges associated with bridging HA-glycan interaction with viral
pathogenesis
In 1989 Peter Palese and colleagues developed a method termed as "reverse
genetics" which allowed synthesis of whole influenza A virus from the cDNAs of
individual virus genes [96, 97]. In addition to the advent of reverse genetics to
understand influenza A virus biology, ferrets have emerged as a model system to study
influenza A virus pathogenesis and contact and respiratory droplet modes of
transmission [67, 98, 99]. Studies have shown that ferrets express similar glycan
receptors as that of humans and that they exhibit similar symptoms upon influenza A
viral infection [100].
Using reverse genetics, the pandemic 1918H1N1 viruses were reconstructed
[101] and its virulence was tested in ferret animal model. This further enabled
systematic exploration of the roles of various viral genes in the virulence and
transmissibility of influenza A virus strains [102, 103].
A systematic study was performed involving single gene reassortments of the
1918 pandemic human HIN1 influenza A virus (A/South Carolina/1/18 or SC18) with a
contemporary human H1N1 (A/Texas/36/91 or Tx9l) virus in ferrets (Table 1.1). It was
shown that the HA of SC18 had most profound effect on the virulence of the
reassortment viruses followed by NA and PB1 genes [1041. Further, a single (NY18) or
double (AV18) point mutation in the HA of SC18 resulted in a virus that was unable to
transmit efficiently via respiratory droplet in the ferret model (Table 1.1). This prompted
analyzing the glycan binding properties of these 1918 H1N1 HAs. RBC agglutination
assay (described in Section 1.5.1) was used to characterize SC18 and it was found to be a
strict a2-6 binder, NY18 was a mixed a2-3/c2-6 binder, and AV18 was a strict a2-3
binder. Given the predominant distribution of a2-3 glycans in the deep lung tissues of
the human respiratory tract, both NY18 and AV18 are more likely to infect deep lung
tissues. Since the NA of these a2-3 binders is same as that of SC18, it might be
inefficient at releasing the viral particles from the deep lung tissues, leading to lower
virulence of these mutant viruses.
Table 1.1 Glycan receptor binding specificity (identified by RBC agglutination assay) and respiratory
droplet transmissibility of H1NI influenza A viruses in ferrets
Virus Strain Binding specificity to Transmission efficiency
Sialic acid linkage in ferrets
A/South Carolina/1/18 or SC18 Only a2-6 Efficient
AV18 (SC18 + 2 mutations) Only a2-3 None
NY18 (SC18 + 1 mutation) c2-3 and a2-6 Inefficient
A/Texas/36/91 or TX91 a2-3 and a2-6 Efficient
By associating the inefficient virus transmissibility with the a2-3 binding
specificity of NY18 HA, it can be concluded that a loss of a2-3 binding is necessary of
efficient transmission but that the gain of (2-6 glycan receptor binding is insufficient. In
an apparent contradiction to this conclusion, TX91 also a mixed a2-3/a2-6 binding H1N1
virus is able to transmit efficiently [67] (Table 1.1). Also in other studies with H7 and H9
viruses [89, 92]. it was observed that although some of the wild-type or HA mutant
viruses showed substantial a2-6 binding, none transmitted via respiratory droplets in
the ferret model. However, in the same experimental system, the control human
adapted H3N2 viruses that showed similar a 2-6 binding specificity did transmit
efficiently. Studies like these show that defining the glycan receptor binding specificity
of HA only in term of a2-3 or a2-6 alone (based on RBC agglutination assay, glycan array
etc.) makes it challenging to correlate the glycan binding specificity to human
adaptation and viral virulence. Moreover, this also shows that there are additional
factors that govern the glycan receptor binding specificity of HA and determine its role
in influenza A virus infection and transmissibility in humans.
1.7 A multifaceted approach to study HA - glycan interaction and to decode its role
in viral pathogenesis
In order to address the aforementioned challenges, it is important to integrate
information from complementary set of approaches. Interfacing information obtained
from structural modeling of HA-glycan interaction to their biochemical characterization
and finally to correlate these with their biological significance in viral pathogenesis is the
essence of such a multifaceted approach (Figure 1.17). Such an endeavor starts with
understanding the properties of HA and the glycan receptors individually as two
molecular components involved in HA-glycan interaction.
To understand HA, it is important to look at the primary sequence of HA and
identify key amino acid sequences that play an important role in governing HA binding
properties. This would involve comparing and aligning HA sequences from influenza A
viruses infecting different hosts. This kind of an approach has enabled identifying
sequences that are common to the viruses isolated from a specific host and how a
change in the amino acid sequence at these regions can lead to new viral host
adaptation (explained in detail in Section 1.4.3.).
The second molecular component, the glycan receptors, can be characterized
using several approaches. At a high level, because human upper respiratory epithelia is
the primary target of human adapted influenza A virus, it is essential to characterize the
distribution of physiological sialylated glycan receptors on these tissues. It is well known
that the sialylated glycans on the epithelial cells of human upper respiratory tract are
the receptors for influenza A HA binding and endocytosis, epithelial cells themselves
possess a broad array of structurally diverse and complex glycans. Hence it is challenging
to access and elucidate the structures of glycan motifs, which are the receptors for
influenza A virus HA. One approach that has been employed to probe the distribution of
glycan receptors is to perform staining of relevant tissue sections with fluorescently
labeled plant lectins. Two plant lectins that are frequently used are Sambucus nigra
agglutinin or SNA-1 (binds specifically to Neu5Aca2-6Gal/GaINAc motif [47] and Maackia
amurensis lectin or MAL-II (binds specifically to a2-3 glycans) to identify the distribution
of a2-3 and a2-6 glycan [48, 49]. Co-staining of SNA-1 with another lectin, Jacalin, which
binds to the O-linked glycans (GaINAc-Ser/Thr), provides information on the distribution
of a2-6 glycans in the context of O-linked glycans. More recently, co-staining of Jacalin
with recombinant HA has shown that the HA from human adapted influenza A viruses
show significant co-staining with jacalin [48] indicating their preference for a2-6 0-
linked glycans. Studies like these using lectin matrix provide insight into the cellular
tropism of the virus and hence help specifically in identifying hallmarks of these human
adapted viruses.
Bridging the lectin staining of relevant tissue sections with glycan profiling of
representative cell lines enables deciphering the finer structural details of glycans.
Various analytical methods such as matrix-assisted laser desorption ionization (MALDI)
mass spectrometry (MS) and MS/MS (to fragment glycans) can be used for
characterizing glycans extracted from relevant cell lines [105, 106]. Other techniques
have also been employed, including capillary high-performance liquid chromatography,
liquid chromatography MS, and nuclear magnetic resonance [107, 108]. Recently lectin
staining of human respiratory tract tissue section (explained above) interfaced with
glycan profiling of representative human upper epithelial cells enable characterize the
glycan receptors for influenza A viruses [48].
The molecular and structural aspects of HA-glycan interaction can be identified
using conformational analysis of HA-glycan co-crystal structures. This provides a
meaningful sequence-to-structure correlation for HA and also enables identification of
distinct topologies adopted by c2-3 and a2-6 glycan receptors in the context of its
interaction with HA [48, 109]. Analysis of the various crystal structures indicated that a
highly conserved set of amino acids Tyr98, Ser/Thr136, Trp153, His183, Leu/Ile194
(numbered based on H3 HA) across different HA subtypes are involved in anchoring the
sialic acid. It was also established that the specificity of HA to either a2-3 or a2-6 is
governed by an extended range of interactions within the glycan-binding site - not only
with the sialic acid, but also with the glycosidic oxygen atom and monosaccharides
beyond sialic acid [48, 66]. The ensemble of conformations sampled by the a2-3 and a2-
6 glycan receptors upon their interaction with HA was given a shape-based topological
description. In the case of a2-3 glycans, the conformations sampled by Neu5Acc2-3Gal
linkage (keeping the Neu5Ac anchored) and the sugars beyond this linkage (at the
reducing end) span a region on the receptor-binding surface of HA that resembles a
"cone" (Figure 1.14). The assembly of these conformations is therefore described by the
term cone-like topology.
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Figure 1.14 Glycan topology influences HA-glycan interaction. Interactions of HA with cone-like topology
(A) is characteristic of avian HA binding to a2-3 and short a2-6 glycans (such as multiantennary N-linked
glycans with single lactosamine branches terminated with a2-6). In contrast to cone-like topology,
interactions of HA with umbrella-like topology (B) is characteristic of human HA binding to long a2-6
glycans (such as polylactosamine branch terminated with a2-6)
When contrasted with the Neu5Acc2-3Gal linkage, the presence of C6-C5 bond
within the Neu5Acc2-6Gal linkage provides additional conformational flexibility. The
different conformations sampled by Neu5Aca2-6Gal linkage (keeping Neu5Ac anchored)
and the sugars beyond this linkage (at the reducing end) this span a wider region on the
HA binding surface. One part of this wider region is similar to the cone-like surface and
the other part resembles a space that is readily described by the opening of an umbrella
from a fully folded to a fully open form. Hence in contrast to the cone-like topology, the
set of conformations sampled by a2-6 glycans is described using the term umbrella-like
topology (Figure 1.14). In this case, the stem of the umbrella is occupied by the
Neu5Aca2-6Gal motif and the spokes of the umbrella (the flexible part) are occupied by
the sugars at the reducing end of Gal.
In case of the glycans adopting cone-like topology, the majority of the
interactions with the HA are made by a trisaccharide a2-3 (Neu5Aca2-3Galp1-
3/4GIcNAc-) or a2-6 (Neu5Aca2-6GaP1-4GcNAc-) motif. However, the glycan
conformations that adopt umbrella-like topology are longer than a trisaccharide (at least
4 sugars and make substantial contacts with the receptor-binding site on HA. For
instance, umbrella-like topology is adopted by polylactosamine branches terminated by
a2-6 linked Neu5Ac (long a2-6). The cone-like topology can be adopted by both a2-6
and a2-3 glycans. In the case of a2-6 glycans those with a trisaccharide a2-6 motif such
as N-linked glycans having single lactosamine branches terminated by a2-6 linked
Neu5Ac (short a2-6), are more likely to adopt cone-like topology as compared with the
long a2-6 branch.
Hence by looking at several HA-glycan co-crystal structures and by applying a
topology-based description of glycan receptors, it was identified that the umbrella-like
topology was characteristic of long a2-6 motifs which interact with human adapted H1,
H2 and H3 HAs and the cone-like topology was characteristic of a2-3 glycans interacting
with avian HA [2, 48, 95]. Because the avian HA glycan binding pocket can accommodate
glycans which can adopt cone-like topology, it is highly likely that the short a2-6 glycans
can also bind to avian HA.
For biochemical characterization of HA-glycan interaction, it is important to have
an assay that can quantify relative binding affinity of HA for a particular glycan receptor,
while also capturing the multivalent HA-glycan interaction. As mentioned earlier, glycan
array platform has emerged as a very important tool for assessing HA-glycan interaction
(Section 1.5.4). In most of the earlier studies that focused on screening different HAs on
the glycan arrays, the binding of HA to specific glycan motif was designated as a single
point "on" or "off". This designation though potentially is useful to screen for HA binding
specificity to a particular glycan motif, the assay misses the context of the interaction
and relative biological importance of the interaction. Moreover, since these assays are
performed at a single saturating concentration of HA, it may overestimate the binding of
HA to the glycan motifs to which otherwise HA would show no or less binding at a lower
concentration. Taking into account these limitations, more recently biochemical assays
have been developed to screen HA-glycan interactions over a range of HA
concentrations [110]. Assays like these take into account the spacing of glycan motifs in
an array platform and the spatial arrangement of glycan binding sites. In this approach,
binding of HA to various glycan receptors is analyzed over a range of HA concentrations
to measure approach to saturation by taking into account avidity and cooperativity
effects. Further in order to specifically enhance the multivalency in the HA-glycan
interactions, the recombinant HA is precomplexed with the primary and secondary
antibody in a molar ratio of 4:2:1 [81]. The identical arrangement of 4 trimeric HA
protein in the precomplex fixes the avidity effects. In fact, Srinivasan et al showed that
incorporating the multivalency in HA-glycan interaction significantly enhances the glycan
binding signals. For instance, there was at least an 8-fold increase in binding of SC18 HA
to 6'SLNLN when HA was precomplexed with primary and secondary antibodies in a
molar ratio of 4:2:1 (Figure 1.15).
Moreover, because the affinity of HA for its glycan ligand is low (mM range) [74],
the use of such complexes has proved highly advantageous as increasing the valency by
precomplexing enable obtaining detectable binding signals and also would require only
small amount of protein. Using this assay, the HA-glycan receptor binding strength can
be quantified by estimating an apparent binding constant Kd', which can be calculated
by fitting the data (using the Hill equation) obtained by analyzing dose-dependent
binding of HA to representative avian and human receptors. The Hill equation is defined
as follows:
log(1  -) = n * log&HAb- log(Kd')
where "y" is the fractional saturation (average binding signal/maximum observed
binding signal) and "n" is the cooperativity associated with HA-glycan interaction.
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Figure 1.15 Glycan array assay to capture multivalent HA-glycan interactions. Shown is a comparison of
binding signals between sequential binding assay and precomplexation of HA units with primary and
secondary antibodies. Sequential assay favors the formation of HA:primary antibody:secondary antibody
in 1:1:1 molar ratio as compared to 4:2:1 when HA is precomplexed with primary and secondary
antibodies before adding to the glycans.
Figure adapted from Srinivasan et al (2008) PNAS
These assays have permitted quantification of the relative binding affinity of HA
to different glycan motifs. This biochemical assay also takes into account the
. ... . . .. ... ........................ . -- ------ - . .... . .....
multivalency associated with HA-glycan interaction. HA is pre-complexed with primary
and secondary antibody before adding to the glycans on the array. In fact it has been
established that the differences in the binding affinities of HA to glycan receptor is
amplified by precomplexing HA with the antibodies to increase multivalency [110].
Using such quantitative assays, it has been demonstrated that the human-
adapted HAs share a high binding affinity to a2-6 glycans (particularly those that have
multiple lactosamine repeats). Moreover, with the ability to express recombinant HA in
insect cells [110], it is possible to test the effect of amino acid substitution mutations on
the receptor binding property of HA. This can be used to monitor the evolution of the
virus into a more human-adapted virus. Also, the recombinant HA can be used as a
lectin to stain relevant respiratory tissue sections in order to understand the cellular and
tissue tropism of the HA.
Finally, it is important to correlate these biochemical, molecular and structural
aspects of HA-glycan interaction to their biological relevance in the viral pathogenesis.
Ferrets have been used as a reliable animal model to study flu pathogenesis as they
display symptoms similar to humans upon influenza A infection as mentioned in Section
1.6.
One of the important aspects defining the virulence of influenza A viral infection
is its ability to cause human-to-human airborne respiratory droplet transmission. Both
airborne respiratory droplet transmission and contact transmission of the virus can be
easily studied in ferrets. For studying respiratory droplet transmission in ferrets, the
infected ferret (inoculated with the virus) and the naive ferret are housed in separate
cages but share a common perforated wall (Figure 1.16). The onset of infection in the
naive ferret by respiratory droplet (due to sneezing by the inoculated ferret) is
monitored and efficiency of viral transmission is then scored. This also depends on the
number of contact ferrets that are infected by the inoculated ferret by airborne
transmission. Most of the human adapted influenza A viruses show efficient respiratory
droplet transmission in ferrets [67]. The 2009 H1N1 influenza A virus shows inefficient
transmission in both humans and in ferrets [98, 111, 112]. In order to monitor the
contact transmission, both the inoculated and the naive ferrets are housed together in
the same cage (without a perforated wall) and share common food and other
paraphernalia. Infection in the naive ferret is then monitored. The clinical signs that are
monitored to assess the pathogenicity of the virus (and the ensuing infection of the
naive ferret by the infected ferret) are sneezing, weight loss, virus shedding in the nasal
washes and histopathological examination of relevant tissues and organs to assess the
tropism (and systemic infection).
Recently, using the approach of interfacing various tools mentioned above, the
biochemical rationale for the inefficient transmissibility of NY18 (D225G mutant of
SC18) (Table 1) (a mixed a2-3/a2-6 binder) in contrast to efficient respiratory droplet
transmission of TX91 (which is also a mixed a2-3/a2-6 binder) was established [110].
These were compared to that of the HA from a prototypic 1918 H1N1 pandemic virus,
A/South Carolina/1/1918 or SC18, which has a strong a2-6 glycan receptor binding
preference and transmits efficiently in ferrets through airborne respiratory droplets.
Analysis of the molecular HA-glycan contacts showed subtle changes resulting from the
single amino acid variation between SC18 and NY18. The effect of these changes on
their glycan receptor binding was amplified by multivalency, resulting in quantitative
differences in their binding affinity to a2-6 glycan receptor which adopts umbrella-like
topology (or long a2-6) upon its binding with HA. Furthermore, these differences in their
binding affinities to the long a2-6 glycans was also reflected in the markedly distinct
binding pattern of recombinant SC18 and NY18 HA to the physiological glycan receptors
present in human upper respiratory tissues. Thus the dramatic lower binding affinity of
NY18 HA to long a2-6 glycan receptor, as against a mixed a2-3/a2-6 binding correlated
with its lower transmission efficiency in ferrets. Moreover, TX91 HA had an increased
binding affinity to long a2-6 glycan receptor (although it is also a mixed a2-3/a2-6
binder) in contrast to NY18, which correlated with its increased respiratory droplet
transmission in ferrets.
Similar approach was extended to understand the glycan receptor binding
property and transmissibility of the 2009 H1N1 swine origin influenza A virus [98, 99]
[Chapter 4]. It was demonstrated that the 2009 H1N1 influenza A virus HA has a lower
binding affinity to long a2-6 linked glycan (as compared to seasonal and pandemic
virus), which correlated with its inefficient transmissibility in ferrets and humans.
Further, by comparing the molecular HA-glycan interaction of 2009 H1N1 HA with that
of seasonal and pandemic H1N1 HA, it was shown that a mismatched amino acid
interaction network in the receptor-binding site (RBS) of 2009 HIN1 HA was responsible
for its lower binding affinity to long a2-6 glycan receptor. This was validated by fixing
this mismatched interaction (by introducing either a single or triple mutation) in the RBS
of 2009 H1N1 HA, which significantly improved its binding affinity to long a2-6 glycans
and hence its transmissibility (for the single mutant) in ferrets [99] [Chapter 4].
In summary, integration of information obtained from complementary set of
approaches is important to correlate an important molecular interaction to its relevant
biological function. Insight gained from aforementioned multifaceted approach for
understanding HA-glycan interaction can be extended to identifying alternative antiviral
strategies to combat influenza A infection as explained in Chapter 6. Such a multifaceted
approach can also be extended to gaining insights into other protein-glycan interactions
that impinge on other biological functions and whose functional significance is not yet
fully understood.
Inoculated
Perforated wall
B
Inoculated Direct Contact
Figure 1.16 Transmission experiments in ferrets. Shown are the (A) Respiratory droplet transmission and
(B) Direct contact transmission experiments. In (A) the naive ferret is placed in the cage adjacent to the
inoculated ferret but share a common perforated wall. In (B) the naive ferret is placed in the same cage as
that of the inoculated ferrets and share common water and food.
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Figure 1.17 A multifaceted approach to understanding HA-glycan interaction to correlate it with its biological
function. Understanding (A) HA and (B) glycans, the two molecular components involved in HA-glycan interaction,
the first critical step in influenza A virus infection. (A) Identifying signatures in HA protein sequences from different
host can enable identification of host-specific HA sequence to decipher its avian, human or swine origin. (B) Glycan
receptors for influenza A HA can be delineated using a combination of lectin staining of relevant tissue sections
and zooming in further using analytical tools for finer structural characterization of glycans extracted from
relevant cell lines (C) Understanding the molecular structural aspects of HA-glycan interactions by analyzing HA-
glycan crystal structures. Such an analysis can enable identification of distinct topologies adopted by glycans when
they interact with HA. Similarly the amino acid interaction network involved in making contacts with the glycan
receptor can also be identified. (D) The biochemical specificity of HA-glycan interaction can be characterized by
performing a dose-dependent glycan array analysis with either recombinant HA or whole viruses. The array
platform is designed to incorporate target glycan structures, which are predominantly expressed in upper
respiratory tract (this data is obtained from B). (E) Staining of relevant tissue sections from the human respiratory
tract with recombinant HA can enable probing the distribution of glycan receptors for influenza A HA. (F) The
comprehensive knowledge obtained on the key determinants of HA-glycan interactions from A-E provides a much
better handle to correlate it with its biological function in host adaptation and viral pathogenesis
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1.8 Thesis Outline and Specific Aims
With the aforementioned approaches and techniques, this thesis aims to
understand the multifaceted role of influenza A virus HA-glycan interaction going from
viral evolution to development of new antiviral strategies to combat the infection.
Overall the main objective of this thesis is to decode the role of HA-glycan
interaction in viral evolution. Towards this thesis is aimed at understanding three main
factors that contribute to host adaptation leading to viral evolution:
* Antigenic drift
* HA glycosylation and its role in glycan receptor binding
* Host adaptation
Also this thesis aims to understand distribution of physiological glycan receptors for HA
in ferrets and human respiratory tract. Based on this understanding, this thesis explores
the possibility of targeting the host glycan receptors instead of the viral components as
alternate anti-viral strategies.
SPECIFIC AIM 1: Understanding influenza A virus hemagglutinin (HA) in the
context of its interaction with its glycan receptors
a. Glycan receptor avidity of the virus and its effect on driving the
antigenic drift of the virus
b. Site-specific glycosylation of HA and its effect on glycan receptor binding
c. Correlating HA-glycan receptor binding affinity to evolution of human
host adaptation of 2009 swine origin influenza A virus
SPECIFIC AIM 2: Targeting glycan receptors of influenza A HA to combat viral
infection
a. Comparing distribution of glycan receptors in respiratory tract of model
organism (Ferret) and humans
b. Plant lectins as promising tools to specifically target glycan receptors of
influenza A virus
Chapter 2. Hemagglutinin Receptor Binding Avidity
Drives Influenza A Virus Antigenic Drift
Summary
In order to evade the host neutralizing antibody response, influenza A virus acquires
antigenic drift mutations on its hemagglutinin (HA). This chapter reports our analysis
understand this phenomenon, in order to gain insight into viral evolution. Based on this
analysis it was found that repeated passaging of a representative virus (A/Puerto
rico/8/34 or PR8) in immunized mice selected for mutants with single amino acid
changes on its HA. No changes were observed when the virus was passaged in non-
immune mice, indicating that the changes observed on HA were due to the neutralizing
antibody pressure. The point mutations observed on HA increased its binding avidity to
cell surface glycan receptors. Passaging these high binding avidity mutants in naive
mice, but not immune mice, selected for additional hemagglutinin mutations that
decreased cellular receptor binding avidity. Analyzing a panel of monoclonal antibody
hemagglutinin escape mutants revealed a positive correlation between binding avidity
and escape from polyclonal antibodies. Hence this study highlights a yet another
mechanism by which influenza A viruses evolve. In summary, in response to variation in
neutralizing antibody pressure between individuals, influenza A virus evolves by
adjusting binding avidity via amino acid substitutions throughout the hemagglutinin
globular domain, many of which simultaneously alter antigenicity.
2.1 Introduction
Currently licensed seasonal influenza vaccines are designed to protect humans
from the prevailing strains of human influenza A lineages H1N1 and H3N2 and of
influenza B virus. These vaccines' principal target is the most abundant viral surface
antigen, hemagglutinin (HA). Immunization against this sialic acid receptor-binding
glycoprotein typically elicits neutralizing antibodies, which may act by blocking the
attachment of the virus to host-cell receptors or by interfering with HA-mediated viral
fusion [113, 114]. The annually determined trivalent influenza vaccines are standardized
on the basis of the content of their HA components. Neuraminidase (NA), the other
major surface protein and determinant of serotype, is not standardized in current
vaccines, meaning that the amount is likely to vary from batch to batch. Antibodies
against NA do not block infection, but they can inhibit the enzymatic activity of NA
[115]. Therefore, immunization against NA can decrease viral replication in the lungs
and reduce disease severity upon subsequent challenge [115, 116]. Although HA and NA
are both highly immunogenic, intact influenza virions reportedly induce a humoral
response skewed toward HA because of antigenic competition [117]. However,
immunization with a commercial trivalent subvirion vaccine in which the HA and NA
components are dissociated increases NA-specific antibody titers in humans [118].
Approximately 20% of the world's population is infected by influenza A each
year, resulting in significant mortality and morbidity [119]. The high incidence of
influenza cases is attributable to the ability of the influenza virus to escape immunity
induced by prior infection or vaccination. This escape is potentiated by the accumulation
of mutations in the surface glycoproteins, hemagglutinin (HA), and to a lesser extent
neuraminidase (NA), which confer antigenic change to the virus. This happens due to the
acquisition of "antigenic drift" mutations specifically in the globular head domain of its
HA which serve as the antigenic epitopes for the neutralizing antibodies. Antigenic drift
mutations are also attributed to the error-prone reverse transcriptase encoded by the
viral genome. Hence one of the challenges with the vaccines against influenza A viruses
is that they need to be updated annually.
The survival of human influenza A viruses in nature in the presence of a relatively
high herd immunity due to prior infection or immunization has been attributed to the
immunological instability of these agents [1201. The partially immune hosts provide a
selective environment for the emergence of antigenic variants capable of resisting
neutralization by specific antibodies [120]. This hypothesis, first advanced by Taylor et al
(1949) [121], found support by the work of Archetti and Horsfall [122] who
demonstrated the occurrence of antigenic changes during serial passage of influenza A
viruses in fertile eggs in the presence of neutralizing antibodies to a related strain. This
has been further established in murine model by serial passage of a mouse-adapted
influenza A virus (A/Puerto rico/8/34 or PR8) in the lungs of mice previously vaccinated
with formalin-inactivated homologous virus [120]. In this model it was established that
antigenic variants evolve in this process only in vaccinated mice.
Previously, Yewdell et al (1986) have studied the effect of antibody response in
viral evolution [123]. They have shown that PR8 grown in allantois-on-shell cultures in
the presence of antibodies directed against antigenic epitopes on HA (Section 2.2) led to
the emergence of variants. Sequencing of vRNA from these variants revealed that each
of the variants differed from the parental virus by a single amino acid alteration in its
HA1 subunit. Moreover, two of these changes were close to the receptor-binding site
(RBS) on HA1 subunit and the third was near the trimer interface. It was hence proposed
that these mutations might alter the receptor binding by HA. Hence the main goal of
this study is to understand how influenza A viruses escape polyclonal antibodies given
that the frequency of variants with simultaneous multiple point mutations is
exceedingly low [124]. Also the effect of the single point mutations on HA1 subunit of
mouse-adapted PR8 (after serially passaging in an immune and non-immune murine
model) in glycan receptor binding by HA was investigated. We collaborated with
Professor Jonathan Yewdell who identified escape mutants when influenza A virus was
passaged in immune mice. We provided a structural and a biochemical rationale for
their ability to escape neutralizing antibody response providing an alternate new
mechanism for the emergence of escape mutants.
2.2 Antigenic structure of A/PR/8/34 or PR8 HA (HI subtype)
As explained in Chapter 1, hemagglutinin or HA is a trimeric glycoprotein which is
enzymatically cleaved into the amino-terminal HA1 (molecular weight 46kDa) and
carboxyl-terminal HA2 (m.wt. 27kDa) polypeptides. As elucidated from HA crystal
structures [125-127], HA monomer forms two distinct domains: a distal domain of
globular shape, which is made up exclusively by the major portion of the HA1
polypeptide, and a proximal fibrous stem-like structure, which anchors the HA into the
viral lipid envelope and is made up by the HA2 and part of the HA1 polypeptides.
Several different approaches have been employed to characterize the antigenic
structure of the HA molecule. One of the approaches was to generate a panel of
monoclonal anti-HA hybridoma antibodies and to use them to select mutants of the
influenza A/PR/8/34 or PR8 virus expressing antigenically altered HA molecules [128,
129]. These mutants, which escape neutralization by the monoclonal antibody can then
be expanded in a host system that supports virus replication. Based on this an
operational antigenic map of the HA molecule was constructed by comparative
antigenic analysis of the mutant viruses with the monoclonal antibodies. The
observation that individual mutations concomitantly modify certain epitopes provided
an operational basis for the construction of an epitope map. Thus an antigenic analysis
of 34 antigenically unique PR8 virus mutants with 58 monoclonal anti-HA antibodies
permitted assembling the mutant viruses into four antigenic groups viz. Sa, Sb, Ca and
Cb [128] (Figure 2.1) Several additional anti-HA monoclonal antibodies have been used
to map antigenic sites on HA [129]. Following section describes the 4 antigenic regions
on PR8 HA.
2.2.1 Antigenic sites Sa and Sb
These sites are defined by the residues in the upper part of the globular head of
the HA1 subunit (Figure 2.1). Antigenic analysis divides this region into two
operationally distinct areas, identified here as sites Sa and Sb, which are, however,
closely linked and cannot accommodate the simultaneous binding of antibodies to each
site [130]. Site Sa comprises the "front" of this region as viewed in Figure 2.1, including
residues 128 and 129 and residues 158, 160 and 162 to 167 (excluding 164). The Sa site
extends down through a region of P structure on the opposite side of the HA monomer
to the proposed receptor binding site (Wilson et al., 1981), and in the trimer comes
close to the monomer-monomer interface. The site occupies a position relatively near
the receptor-binding site of the adjacent monomer when the trimer is assembled
(Figure 2.1).
The antigenic site Sb occupies the "back" of the head region as viewed in Figure
2.1, comprising the external residues 192, 193 and 196 of a region of a helix, residue
198, and residues 156 and 159. These residues are along the upper edge of a pocket
containing the receptor-binding site. Residues 156 and 159 lie in the same region of
polypeptide chain as residues 158 and 160 of site Sa. Indeed, it is this polypeptide loop
(containing residues 156-160) that separates the operationally distinct antigenic sites Sa
and Sb, and residues which lie along this loop map, into one site or the other according
to whether they are front-facing (residues 158 and 160, site Sa) or back-facing (residues
156 and 159, site Sb.)
2.2.2 Antigenic sites Ca (Cal, Ca2) and Cb
Analysis of the location on the HA monomer of the residues that delineate
antigenic subsites Cai, and Ca2 shows two widely separated clusters of changed
residues. Subsite Cal, contains external residues 169, 173, 207 and 240. The location of
antigenic subsite Ca2 is indicated by mutations in two loops that contain residues 140,
143 and 145 and residues 224 and 225. These loops are close to each other in the three-
dimensional structure of the HA monomer, but lie on the opposite side of the monomer
to those mapped as belonging to the related subsite Cai. However, these two subsites
come into close proximity when the trimer is assembled, presenting a cleft which spans
the monomer-monomer boundary and which is operationally defined as the antigenic
site Ca (Figure 2.1).
The fourth antigenic site, Cb, defines a region near the bottom of the globular
head of HA1, distinct from the Ca cleft, as indicated by mutations at residues 78 to 83
(excluding residue 80) and residue 122. The location of this site is consistent with
previous analyses by competition binding of antibodies to sites Cb and Sa, which proved
these sites to be topologically distinct [130].
:128, 129, 158, 160 & 162 to
167 (excluding 164)
Sb: 192,193,196,198, 156 & 159
Ca:
Cal: 169, 173, 207 & 240
"E Ca2: 140, 143, 145, 224,225
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Figure 2.1 Antigenic sites on A/PR/8/34 (PR8) HA. PR8 has four non-overlapping antigenic sites. Each of
the sites are indicated in various colors. Indicated on the right are the amino acids that make up each of
the antigenic sites
Yellow - Sa; Red - Sb; Black - Ca; Pink - Cb; Green - Sialic acid
2.3 Receptor binding avidity and its role in driving antigenic drift
The next few sections provide proof-of-concept leading to identification of a new
mechanism by which antigenic drift in influenza A virus is driven by the receptor binding
avidity of its HA.
2.3.1 In vivo passaging of mouse-adapted A/PR/8/34 in immunized mice selects for
single mutants in HA
To better understand how antigenic drift occurs in human populations, classical
experiments modeling drift in outbred Swiss mice was revisited as explained in Section
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2.1 [1201. Three separate infectious stocks of the mouse-adapted strain A/Puerto
Rico/8/34 (H1N1) (PR8) were generated in MDCK cells using reverse genetics. Each
stock was serially passaged in naive mice or mice immunized with inactivated virus.
Mice were infected intranasally with virus prepared from lung homogenates (Figure
2.2).
Stock 1 or 2 or 3
Intranasal infection
Passage 1 Immunized or naive
Lungs homogenized
1 2 days p.i.
Passage 9
Sequence HA and NA genes from lung homogenates after each passage
Figure 2.2 Scheme for in vivo passaging of PR8 in mice. The virus was passaged upto 9 times in naive or in
immunized mice to identify escape mutants. The virus obtained from the lung homogenate was
subsequently used to inoculate (i.n.) the naive mice and so on.
After nine passages, HA gene sequencing revealed no detectable mutations in
viruses passaged in naive mice (Figure 2.3). By contrast, each lineage from vaccinated
mice contained a predominant population with a different single amino acid
substitution: residue 158 (E to K, lineage 1), 246 (E to G, lineage 11), or 156 (E to K, lineage
Ill). Residue 158 is located at the interface of the Sa/Sb antigenic sites, residue 156 is in
the Sb site, and residue 246 is located outside the defined epitopes [129] (Figure 2.4).
E158K, initially detected in lineage I following passage 2, predominated by passage 3. In
lineage 11, E246G abruptly emerged during passage 3. In lineage Ill, E158K and E156K co-
dominated from passage 2-7, with E156K predominating following passage 8. None the
lineages exhibited changes in the neuraminidase (NA) gene. Lack of any changes in NA
could be attributed to a poor neutralizing response against NA as compared to HA due
to low density of NA compared to HA.
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PR8 (stock 1) passaged 9x in vaccinated mice_ I1 NAP8 (soc ) E158K no change
PR8 (stock 1) passaged 9x in naive mice P no change no change
PR8 (stock 2) passaged 9x in vaccinated mice E246G no change
PR8 (stock 2) passaged 9x in naive mice no change no change
PR8 (stock 3) passaged 9x in vaccinated mice 4 E156K no change
PR8 (stock 3) passaged 9x in naive mice w no change no change
Figure 2.3 In vivo passaging of PR8 in vaccinated mice selects for single mutants in HA. HA and NA genes
were sequences in lung homogenates from three independent PR8 stocks serially passaged in vaccinated
and naive Swiss mice. Note that mutants were selected only in vaccinated mice. Also, no mutations were
identified in NA gene.
E1%K
E246G
E156K
sialic acid
Figure 2.4 Location of amino acid mutations in in vivo selected influenza A viruses
2.3.2 Single HA mutants escape antibody response
Next it was important to evaluate if the single HA mutants identified by serial passaging
in immunized mice were indeed escape mutants that have evolved to invade the
neutralizing antibody response in immunized mice. Hence the mutants' ability to escape
antibody responses was measured by hemagglutination inhibition (HAl) and virus
neutralization assays using immune serum pooled from 45 PR8-vaccinated mice. Each
mutant escaped antibody responses in these ternary (virus, antibody & cell) assays
(Figure 2.5A and B), despite demonstrating only minor (E156K, E158K) or no (E246G)
decreases in anti-HA antibody binding (Figure 2.5C). More precise antigenic analysis
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using ELISA confirmed that the amino acid substitutions had limited effects on individual
monoclonal antibody binding. E156K modified Sb antigenicity, but had no effect on the
other sites. E158K altered binding of a subset of Sa- and Sb- specific monoclonal
antibodies. Notably, just one of 16 monoclonal antibodies tested exhibited (slightly)
altered binding to E246G, consistent with the observation that the substitution resides
outside defined antigenic sites [129]. Hence it was clear that the single HA mutants
were indeed escape mutants with minimal changes in antigenicity.
2.3.3 Escape mutants acquire increased binding avidity to host glycan receptors
It was intriguing to identify escape mutants with minimal changes in their
antigenicity. This is a deviation from the popular mechanism of viral evasion of the host
antibody response wherein the viral acquires mutations on its surface proteins to
prevent antibody binding to its epitope. Hence the hypothesis whether the point
mutations on HA increase the binding avidity of HA to host glycan receptors and hence
enable evasion of the neutralizing antibody response (although the antibody can bind to
these mutants) was validated.
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Figure 2.5 Single HA mutants escape antibody response. PR8 and mutant viruses were tested for escape
from polyclonal antibodies to PR8 by (A) hemagglutination inhibition assay (HAl) with turkey RBCs or by
(8) virus neutralization assays with MDCK cells. Data are expressed as inverse concentration of serum and
are representative of three (HAl) or two (virus neutralization) experiments. Data are shown as mean ±
SEM (C) polyclonal antibody binding to HA was assessed by flow cytometry after addition of different
dilutions of polyclonal antibody to L929 cells infected with the indicated virus followed by the addition of
anti-mouse FITC. Shown is the mean fluorescent intensity (MFI) after normalizing HA expression based on
the binding of a mixture of Ca monoclonal antibodies or a NA specific monoclonal antibody. Negative
control used for the experiment is H3 HA/PR8 NA infected cells.
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2.3.3.1 Quantitative dose-dependent glycan array analysis of mutant viruses to
monitor changes in receptor binding avidity
With the advent of glycan array technology, it offers a handle to quantitatively
assess the receptor binding affinity and avidity of HA using either recombinant HA or
whole viruses. Glycan array platform, containing 5 different glycan motifs (Chapter 1)
was used to assess the glycan binding avidities of mutant viruses and compared it with
wild-type virus (Figure 2.6). In contrast to the wild-type virus, all the three mutants
displayed increased binding avidities to both the a2-3 and a2-6 sialylated glycan
receptors.
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Figure 2.6 Glycan binding avidities of escape mutants. Shown are the glycan binding avidities of the three
escape mutants (E156K, E158K and E246G) to the four glycan receptors (3'SLN, 3'SLNLN, 6'SLN, and
6'SLNLN). The binding avidities of the mutants were compared to that of the wild-type PR8 virus. Note the
increased binding avidities of the mutants to the glycan receptors as compared to the wild-type virus.
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2.3.4 Further passaging of mutants in immunized and non-immunized mice
Further passaging in vivo selected virus populations in mice (vaccinated with
homologous inactivated virus e.g., E156K virus passaged in E156K-vaccinated mice), with
novel amino acid substitutions distant from the receptor binding site, often distant from
defined neutralizing epitopes, were detected. Substitutions that enhanced receptor
binding enhanced polyclonal HAI antibody escape.
Optimizing viral fitness requires balancing host cell receptor binding of input
virus with release of progeny virus. Strikingly, in vivo passaging of mutants in naive mice
selected mutants with reduced cellular receptor binding avidity. Mutations selected by
naive mouse passage decreased polyclonal HAI antibody escape. E158K- and E246G-
derived mutants were inhibited at similar levels as wt PR8, demonstrating the central
role of cellular receptor binding in E158K and E246G single point mutants escape from
polyclonal antibodies (see also Figure 2.5C). E156K viruses with secondary mutations
acquired in naive mice, still escaped wt-specific polyclonal antibodies better than wt
virus, despite a return to wt binding avidity, demonstrating that E156K alteration of Sb
antigenicity contributes to immune escape.
Despite the absence of antibody selection, some secondary mutations selected
in naive mice modified HA antigenicity. A227T, located near the sialic acid-binding site,
reduced binding of the Sa-specific antibody, IC5-2A7. R220G reduced binding of the Sa-
specific antibody, H2-6A1. Thus, antigenic drift can be a by-product of Darwinian
selection for mutations that optimize host cell receptor binding during influenza virus
transmission between immune (increased receptor binding) and naive individuals
(decreased receptor binding).
To demonstrate an independent role for cellular receptor binding avidity in
polyclonal antibody mediated evolution, mice were co-infected with wt PR8 and AM6,
an absorptive mutant with a substitution (P186S) in the receptor binding site that does
not modify antigenicity [123, 131]. AM6 was rapidly selected in vaccinated but not naive
mice. Next, mice were co-infected with E246G virus (minor antigenic change/high
receptor binding) and E246G/A227T (greater antigenic change/low receptor binding).
Vaccinated mice selected E246G while naive mice selected E246G/A227T, confirming
the critical role of binding avidity in antibody-driven viral evolution.
To extend the drift model, E156K/R220G was passaged in mice given a high
vaccine dose to generate severe antibody selection pressure. This resulted in the
evolution of E156K/R220G/1244T (no selection occurred in naive mice). 1244T, located
in the Sa/Ca interface, increased cellular receptor binding, and as predicted, increased
polyclonal HAI antibody escape to levels exhibited by the E156K progenitor. Thus,
during these passages between nafve and immune individuals, influenza A virus
exhibited three cellular receptor binding avidity changes that were completely
concordant with immune pressure. All of these changes were accompanied by amino
acid substitutions that reduced the binding of different monoclonal antibodies.
2.4 Discussion and Significance of this study
The ramifications of this study are two-fold. First, this study leads to a new
hypothesis for antigenic drift (Figure 2.7). Immune individuals select single point
mutants with increased receptor binding avidity and under optimal circumstances (for
the virus), diminished antigenicity. This presents with an alternate new mechanism for
the emergence of escape mutants wherein influenza A virus evades neutralizing
antibody response by acquiring antigenic drift mutations which increase its binding
avidity to host glycan receptors. In this process there is no change in the antigenicity.
The antibody can bind to the mutant HAs but because of an increased binding avidity of
HA to glycan receptors than to the antibody, the virus escapes neutralization by the
antibody. Substitutions modifying receptor binding cover all four antigenic sites. Several
of these substitutions that enhance receptor binding, increase HA positive charge. Since
virions possess ~ 900 HA monomers [132], increased positive charge may enhance
cellular receptor binding by increasing charge attraction with negatively charged cell
surfaces [133]. Retrospective analysis supports a relationship between H3 HA charge
and receptor binding [134]. Using molecular modeling of HA with LSTc (a2-6 glycan), the
effect of these mutations at amino acid position 156, 158 and 246 on receptor binding
of HA was analyzed. Structural analysis showed that the distance between mutated
amino acid side chain (at 156, 158 and 246) and the terminal sialic acid in LSTc is
reduced indicating that the glycan receptor is more tightly held in the RBS of these
mutant HAs (Figure 2.8).
(A) PR8 wild-type HA (B) PR8 E156K HA
LSTc LSTc
Asn193 93Glu156 s 6
Figure 2.8 Structural modeling of wild-type and mutant (E156K) PR8 HA with LSTc. As seen from the
molecular model of PR8 wt HA (A), Glu156 interacts with Asn193, which in turn interacts with the glycan
receptor (LSTc). In the mutant GIu156Lys HA (B), this interaction between Lys and Asn193 is further
stabilized due to the longer side chain of Lys as compared to Glu at 156. This could potentially explain the
increased binding affinity of the mutant to the glycan receptors as compared to the wild-type.
Second, by our study also provides insight into the effect of passaging virus
between immune and naive population (Figure 2.9). Transmission to a non-immune
individual leads to selection of mutants with decreased receptor binding. Since binding
avidity altering-substitutions exist throughout the globular domain, they frequently
modify antigenicity, even when this is not a selecting factor. Repeating the cycle, results
in constant modulation of binding avidity along with steady alterations in antigenicity,
even in the absence of antibody selection. Our model posits that cellular receptor
binding alone exerts selection pressure for a substantial fraction of substitutions in
defined antigenic regions, explaining the fixation of 30% of mutations in the globular
domain outside defined antigenic regions [135].
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Figure 2.7 A new mechanism to evade host immune response by influenza A viruses. (a) In a naYve
individual in response to a viral infection, host neutralizing antibodies (usually against HA) clears the virus.
To evade this antibody response, the virus acquires antigenic drift mutations in HA, that prevents binding
of the antibody to HA (b) in a immunized individual, in response to neutralizing antibody response, the
virus acquires antigenic drift mutations on HA that does not change HA antigenicity but increases the
binding avidity of HA to host glycan receptors. Hence even if the antibody is able to bind HA, due to an
increase in the avidity effects between HA and host glycan receptors, the virus escapes antibody response
and hence active infection cycle of the virus still continues.
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Figure 2.9 New model of antigenic drift in influenza A virus. By modulating the binding avidity of HA to
host glycan receptors, influenza A virus escapes neutralizing antibody response when it transmits
between naive and immune individuals. In naive individuals, to escape the host immune response, the
virus acquires antigenic drift mutations on its HA such that there is not much change in the binding avidity
but there is a significant change in its antigenicity. On the contrary, in immune individuals, to evade the
neutralizing antibody response, the virus acquires mutations on its HA such that it has minimal change to
the antigenicity of HA and increases its binding avidity to host glycan receptors. Hence naive population
contributes to antigenic drift in influenza A viruses and hence it is important to reduce the proportion of
naive population by vaccination.
The properties of recent human isolates are consistent with this model.
A/Panama/2007/99, the 2003-2004 vaccine strain, did not match the circulating
A/Fujian/411/02 strain by HAI assays. This difference was attributed to two amino acid
substitutions [136]. Remarkably, one substitution is at residue 156, which in this study
was identified as playing a critical dual role in Sb antigenicity/receptor binding avidity,
while the other is at residue 155, which is immediately adjacent to the sialic acid binding
site, and also located in the Sb site. During the antigenic evolution of H3N2 viruses from
1968 to 2003, a limited number of amino acids (in one case, a single N to K substitution
increasing positive charge) dictate HAI escape from polyclonal sera [137].
This model complements recent work emphasizing the importance of HA
receptor specificity in influenza virus species and organ tropism [138]. Receptor
specificity and affinity are intimately related physiochemically, as demonstrated by our
observation that each of the first generation absorptive mutants (E156K, E158K, E246G)
demonstrates a unique avidity profile against the panel of sialylated oligosaccharides
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(Figure 2.6). Thus, alterations in the viral receptor avidity, which correlates with the
varied influenza virus phenotypes, can be exclusively attributed to changes in the HA-
glycan receptor binding specificity. In our model, antigenic drift is accelerated by
sequential passage of influenza A virus between immune and non-immune individuals,
which in the human population, are nearly all children. Therefore, decreasing the naive
population size by increasing pediatric influenza A virus vaccination rates will likely
retard antigenic drift and temporally extend the effectiveness of influenza vaccines. It
should be noted that change in binding avidity of HA could tip-off the balance between
viral binding and release from the host cell. Hence it was speculated that though the
virus escapes the neutralizing antibody response in immune population, a constant
increase in binding avidity may reduce viral fitness leading to a subsequent loss of the
virus circulation from the human population. Hence monitoring binding avidity of
circulating viral isolates may facilitate the accurate prediction of mutants with epidemic
potential.
2.5 Published manuscript
Scott E. Hensley, Suman R. Das, Adam L. Bailey, Loren M. Schmidt, Heather D. Hickman,
Akila Jayaraman, Karthik Viswanathan, Rahul Raman, Ram Sasisekharan, Jack R.
Bennink, Jonathan W. Yewdell "Hemagglutinin Receptor Binding Avidity Drives Influenza
A Virus Antigenic Drift" Science (2009); 326; 734-736
Specific contribution made by this thesis towards this publication: One of the critical
information needed for the study was to validate our hypothesis that receptor binding
avidity does drive antigenic drift of influenza A viruses. Hence the single HA mutants
were tested on our glycan array platform containing representative glycans of varying
lengths and terminal sialic acid linkages (Section 2.3.3 and Figure 2.6). This provided
quantitative comparison of binding avidities of mutants and wild-type PR8 viruses to
various glycan motifs. This hence helped validate our hypothesis linking receptor binding
avidity in driving antigenic drift. This study also provided a structural rationale for the
increased receptor binding avidities observed with the mutant viruses based on
understanding the local effects of the mutations at 156, 158 and 246 on the glycan
binding of HA.
Chapter 3. Site-specific N-glycosylation of influenza A
HA: Implication in Glycan Receptor Binding
Summary
Influenza A HA acquire new N-glycosylation sites (by antigenic drift mutations) on its HA
to evade the host neutralizing antibody response. Not much is known about the effect of
these N-glycans on the glycan receptor binding properties of HA. This chapter reports our
analysis of the role conserved N-glycosylation on HA and its influence on its glycan
receptor binding properties. Panel of HAs were analyzed to identify conserved N-
glycosylation sites on HA that could potentially impact the glycan receptor binding
properties owing to their location close to the RBS of HA. One such glycosylation site on
H1 HA is at the amino acid position 91. A series of deletion mutants (with the N-
glycosylation sequon deleted) were generated on representative 1918 influenza A HAs:
A/South Carolina/18 or SC18 (strict long a2-6 binder), A/New York/1/18 or NY18 (mixed
a2-3/a2-6 binder) and A/avian/i/18 or AV18 (strict a2-3 binder). These recombinant
mutant HAs were analyzed on glycan array platform. It was noticed that there was a
minimal change in the glycan receptor binding properties of mutant AV18 HA but a
substantial reduction in the binding affinity of SC18 to long a2-6 glycans. It was
interesting to note that there was a complete loss of glycan binding specificity and
affinity of mutant NY18 HA. Such an analysis brings into light yet another factor that can
affect the receptor binding of HA and hence the pathogenicity of the virus.
3.1 Introduction
As mentioned in Chapter 1, influenza A HA play a critical role in viral entry and
membrane fusion events in the viral life cycle. HA is a homotrimeric transmembrane
protein with an ectodomain consisting of a globular head and a stem region (Figure 1.7).
The globular head of HA comprises two domains: the RBD, an ~148 amino acid domain
that includes the sialic acid - binding site, and the vestigial esterase domain, a smaller
75-residue region just below the RBD. Like other cellular glycoproteins, HA is
synthesized on membrane-bound ribosomes and translocated into the lumen of the ER,
where signal peptide cleavage and core glycosylation occur. During its intracellular
transport, HA undergoes extensive posttranslational modifications, including
trimerization, fatty acid acylation, trimming and processing of the N-linked glycans, and
proteolytic cleavage into the disulfide-bound HAl and HA2 subunits [139].
N-glycans are added to the asparagine amine group in the glycosylation sequon:
Asn - Xaa - Ser/Thr. The amino acid sequence of the HA and hence the location of its N-
linked oligosaccharides are determined by the viral genome, which is replicated by an
RNA-dependent RNA polymerase encoded in the virus. This enzyme lacks editing
functions so mutations in all of the viral genes occur at a high frequency. The
composition and structure of the oligosaccharides put onto the HA at the various sites is
determined by their position on the protein and by the array of biosynthetic and
trimming enzymes provided by the cell. Thus, the plasticity of the viral genome and the
host specificity of the glycosylation machinery can, together, create virus populations
that are more heterogeneous in structure and function that those that would be
developed by wither process alone. This diversity is considered to be responsible for the
survival of these viruses in a variety of biological niches.
The HA appears to have regions that must be glycosylated, others that must be
free of oligosaccharides, and still others in which glycosylation may be either
advantageous or detrimental to survival of the virus. Glycosylation sites at certain
positions on the HA of influenza A viruses isolated from various animals and humans are
highly conserved and therefore appear to be essential for the formation or maintenance
(or both) [140]. Currently isolated human H1 and H3 strains have a total of 7-9
glycosylation sites per HA subunit (21-27/trimer) as shown in Figure 3.1. Based on
several studies, one can expect most of these sites to be glycosylated. The virus
circulating in the human population are therefore largely enclosed in carbohydrate, the
exact composition of which depends on the cells from which the virus has come and on
constraints generated by the secondary and tertiary structure of the HA.
Receptor Binding
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Figure 3.1 Functional roles of influenza A HA glycosylation. The glycosylation in the globular head domain
are implicated in immune evasion. The ones in the stem region are implicated in membrane fusion and
modulation of proteolytic cleavage of HA. The exact role of HA glycosylation in its receptor binding is not
fully understood. The N-glycosylations are represented in stick and ball representation in orange. The HA1
and HA2 in each monomer is represented in different colors.
Among different types of influenza A viruses, there is extensive variation in the
glycosylation sites of the head region, whereas the stem oligosaccharides are more
conserved. The glycans in both these regions impinge on the functional properties of
HA. The N-glycans in the stem region (Figure 3.1) maintain the HA protein in the
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metastable form and are required for the fusion activity [141, 142]. Also the conserved
N-glycans in the stem region are needed for replication of the virus and for the
formation of replication-competent influenza A viruses [141]. Loss of these conserved N-
glycans further decreased the pH stability of HA. Glycans in the globular head of HA,
which are the main targets of the neutralizing antibody have emerged to interfere with
the antibody recognition (Figure 3.1). These glycans block binding of antibodies by steric
hindrance. The glycans at the conserved positions on HA have been shown to promote
and stabilize a conformation compatible with the intracellular transport of HA and that
they enhance trimerization and/or folding rates of HA protein [139]. Apart from being
recognized by the antibodies, the glycans on the globular head also act as an important
target for recognition and destruction of virus by innate immune proteins of the
collectin family [143]. Loss of these glycans was shown to be associated with resistance
to collectins and increased virulence in mice. Apart from the functional significance of
HA glycosylation, the gross number and location of glycans on HA is known to be
important for HA folding and association with calnexin and calreticulin [144].
Little is known about the effect of conserved N-glycans on the glycan receptor
binding properties of HA. Effect of structure and composition of all the N-glycans on
HA's activity including its structure and receptor binding was studied by Wang et al
(2009) [145]. Wang et al showed that truncation of the N-glycan structures on HA had
effects on glycan binding specificities and affinities of HA. But if this effect is due to the
removal of a site-specific glycosylation or due to the removal of the entire N-glycan on
HA remains to be elucidated. Another study has also evaluated the overall effect of
host-dependent glycosylation (egg-adapted or MDCK propagated) of HA on its receptor
binding properties [146]. MDCK-grown viruses were shown to bind substantially more
weak than their egg-grown counterpart to the receptors of the avian origin (a2-3
glycans). More recently, the effect of glycosylation at 158 (not conserved in all H5) of H5
HA was known to play an important role in determining the glycan receptor binding
specificity of HA [147]. Wang et al [148] showed that truncation of the N-glycan
structures on a H5N1 HA increases a2,3 glycan receptor binding affinities, supporting
the notion that N-glycans of HA play a role in receptor binding. Moreover the loss of a
specific N-glycosylation site at position 158 in some of the H5N1 clade has been
associated with a potential to bind to human-like receptors [148].
Hence based on the aforementioned, this study is motivated by the need to fully
understand the structure, composition and functional significance of conserved N-
glycans in the globular head domain near the RBS of HA. Hence in this study, HAs from
H1, H2, and H3 subtypes were analyzed to identify conserved glycosylation sites near
the RBS of HA. In this study, deletion mutation analysis of the conserved N-glycosylation
sequon was performed and their influence on glycan receptor-binding of HA was
explored. Due to the challenges with the expression of H2, and H3 mutants, the data
presented here are for three representative Hi HAs from the 1918 pandemic. The
analyses presented here show that the conserved glycosylation site in H1 HA impinges
on the human receptor binding and minimal avian receptor binding of HA. Studies like
these could shed light on the plausible role of these conserved N-glycan sequons in
determining tissue tropism and species barrier of the influenza A virus through their
effects on the HA-glycan receptor interactions.
3.2 Identification of a new role for the N-glycan on the head domain HA
In this study we began our analyses by using a combination of structural
modeling and alignment tools to identify conserved glycosylation sites in H1, H2 and H3
HA subtypes. The role of the identified N-glycan in the receptor binding property of HA
was then biochemically validated.
3.2.1 Identification of conserved glycosylation site in H1 HA
A panel of H1 HAs (avian and human-adapted) were aligned by clustalW to identify
conserved N-glycan sequon that is glycosylated (Figure 3.2).
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Figure 3.2 HI HA ClustalW alignment. The N-glycosylation sites are marked . The N-glycosylation
site possibly involved in interaction with the receptor is marked E. The receptor binding subdomains are
marked grey. Conserved N-glycosylation sequons in the stem region are marked M.
The conserved N-glycosylation sequons in the stem region were identified by
aligning the HA sequences (Figure 3.2). The N-glycans in these conserved sequons are
known to play an important role in the membrane fusion activity of HA (Section 1.4.2).
The sequence alignment also revealed that the seasonal strains are heavily glycosylated
on the top of the HA head unlike the pandemic strains which are not glycosylated at this
region. Most of the seasonal strains have acquired multiple glycosylation sequons in the
head region to evade the host neutralizing response as shown in Table 3.1 [149].
Based on this analysis N-glycan sequon NGT at position 91-93, in the side of the
head domain, was hypothesized to affect the receptor binding property of HI HAs
(Figure 3.3). A/PR/8/34 or PR8 is different as it lacks this N-glycan sequon at 91. Most of
the H1 seasonal strains from 1933 till 1939 lacked this N-glycosylation sequon and later
the sequon re-emerged after 1939. This glycosylation sequon however has been
conserved in other seasonal and pandemic strains [149] as shown in Table 3.1.
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Time period Stem Side of head Top of head Side of head Stem
1918 28 40 104 304 498 557
1933 28 73 142' 179- 286 304 498 557
1934 1939 28 40 144' 286 304 498 557
1940 1948 28 40 104 144' 179' 286 304 498 557
1949 1957 28 40 90 104 144' 172' 177' 286 304 498 557
1977 1985 28 40 104 144' 177' 286 304 498 557
1986 2008 28 40 /1 104 142' 177~ 286 304 498 557
2009 present 28 40 104 304 498 557
'GlycsylIdons on the Lop of Lhe ieu, tGyLstiUons predicte in <o, of HA St!Uen ceS.
Table 3.1 Evolution of HINI glycosylations. The conserved glycosylation at 104 (SC18 numbering)
represent the N91, which was analyzed in the study. This site was lost in seasonal strains circulating
between 1933-1939 but re-emerged after this period. The glycans in the top of the head and in the stem
region are implicated in immune evasion and membrane fusion respectively.
The table was adapted from Wei et a/ (2010).
Based on the structural modeling of a representative HI HA (A/South
Carolina/1/18 or SC18), it was hypothesized that N-glycan at 91aa could potentially
stabilize the 220-loop (one of the 5 loops involved in glycan binding as explained in
chapter 5) that in turn would enable glycan receptor binding by HA. In order to validate
this hypothesis, a single mutant lacking the N-glycan sequon at 91 in the representative
H1N1 SC18 HA (a strict long a2-6 binder) was recombinantly expressed. To further
understand the role of this sequon in receptor binding, the mutants were also
generated in the avian HA (AV18) (Aspl90Glu/Asp225Gly mutant of SC18 and a strict
a2-3 binder) and in NY18 (Asp225Gly mutant of SC18 and a mixed a2-3/a2-6 binder).
These mutants were recombinantly expressed and biochemically analyzed to elucidate
the effect of N-glycan at position 91 in c2-3 and/or a2-6 glycan receptor binding of HA.
220-loop
130- o
Figure 3.3 Structure of 1918-Human H1 HA. The figure shows the loops and helix in the receptor-binding
site of HA. The critical N-glycosylation site on the NGT sequence is shown as red dotted circle. As seen in
the figure the N-glycosylation at the NGT site (91-93 amino acids) may play an important role in the 220-
loop (shown in blue) stabilization.
Only the HA monomer is shown in the figure.
3.2.2 Effect of removal of N-glycan at 91 on the receptor binding property of H1 H A
Addition of N-glycan at amino acid position 91 (Asn) was disrupted by
introducing Thr93Ala point mutation by site-directed mutagenesis. This disrupted the
sequon from NGT to NGA, thus preventing glycosylation at this site. The mutant HAs
were recombinantly expressed in insect cells. The glycan binding specificity and affinity
of the mutant HAs were characterized by performing a dose-dependent glycan array
analysis. The data obtained was compared with that of their wild-type HA counterpart.
Glycan array analysis of AV18T93A mutant HA indicated no change in its glycan
binding specificity and affinity. Similar to the wild-type HA, AV18T93A showed strict
binding preference to a2-3 glycans with minimal to no binding to a2-6 glycans. This
......... . .... ..   .
shows that the loss of N-glycan at 91 had no effect on the binding of avian glycan
receptor binding of HA (Figure 3.4A). Arg224 in the 220 loop makes ionic interactions
with the GlcNAc in the N-glycan at N91 (Figure 3.4B). This interaction is important for
stabilization of the 220-loop. Hence it can be assumed that knocking the glycosylation
could destabilize the 220-loop leading to the loss of glycan receptor binding by AV18 HA.
But a closer examination of the receptor-binding site (RBS) of AV18 indicates that the
binding pocket is tighter due to the presence of Gln226 and Glu190 (Figure 3.4B).
Moreover the interaction of the binding pocket in AV18 HA is only with the first two
sugars in the reducing end (terminal sialic acid and penultimate galactose). Hence no
change in the glycan receptor binding affinity and specificity of AV18T93A can be
explained by the "tightness" of the receptor-binding pocket of AV18 HA.
On the other hand the RBS of SC18 HA is more open (Figure 3.5B). This is due to
the presence of Asp190 and Asp225 (compared to avian), which makes critical contacts
with the human receptor. The short chain length at 190 (Asp instead of Glu) contributes
to the "openness" of the binding pocket. Hence it was predicted that the de-
stabilization of the 220-loop due to the loss of glycan at N91 (GlcNAc in N-glycan makes
contact with Are224 in the 220-loop) would have more pronounced effect on the
receptor binding property of SC18 HA. Consistent with the predictions, there was a
significant reduction in the binding affinity of SC18T93A (fold reduction to mention)
when compared to that of the wild-type SC18 HA (Figure 3.5A). There was no change in
the binding specificity of SC18 T93A (binding was seen only to 6'SLNLN).
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Figure 3.4 Effect of T93A mutation on AV18 receptor binding. Recombinant AV18 T93A HA was analyzed
on glycan array platform and its binding property was compared to that of the wild-type AV18 (A). There
was no change in the receptor binding property of AV18 T93A. This can be explained on the basis of the
receptor-binding pocket of AV18 HA (B). Arg224 in the 220-loop interact with GlcNAc of N-glycan at 91.
Destabilization of 220-loop due to loss of N-glycan at 91 has minimal effect of receptor binding property
of AV18 T93A due to the tightness of the binding pocket conferred by Glu 190 and GIn 226.
In case of NY18 T93A HA, it was interesting to see that there was a complete loss
of glycan receptor binding specificity and affinity as compared to that of NY18 wild-type
HA, a mixed a2-3/a2-6 binder (Figure 3.6A). This can be structurally explained on the
basis of its RBS, which is between an avian (e.g. AV18) and a human (e.g. SC18) influenza
A viruses (Figure 3.6B). Arg224 makes critical contacts with GlcNAc of the N-glycan at
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91. In the absence of 225Asp, the de-stabilization of the 220-loop due to the loss of N-
glycan at 91, has even more of a pronounced effect than that of SC18 T93A HA.
Loss of N-glycan is physiologically relevant given the emergence of Asn91Asp
mutants in response to cyanovirin resistance [150]. Cyanovirin (CVN) is a small peptide
(101 amino acid) that binds to high-mannose oligosaccharides on the viral HA (HA1)
subunit and neutralizes virus infectivity [151]. During virus (H1N1) adaptation to mice in
the absence of CVN treatment, the virus becomes resistant to CVN (CVN-MR) as did the
virus passaged in cell culture in the presence of CVN (CVN-R) [1501. The CVN-R viruses
possess a single amino acid mutation Asn9lAsp of HA1 leading to the abrogation of the
N-glycan sequon at 91-93. CVN-MR viruses on the other hand are double mutants
possessing either Asp225Gly/Asn9lAsp or Asp225Gly/Asn63Ser. Moreover the double
mutant was lethal and highly pathogenic in mice. Hence given the significance of Asn9l,
in CVN resistance and in mouse adaptation, Asn91Asp mutagenesis was carried out in
NY18 (Asp225Gly mutant of SC18) HA and the recombinant HA was characterized for its
glycan receptor binding property using the dose-dependent glycan array analysis. NY18
N91D mutant showed a complete loss of glycan binding specificity and affinity (Figure
3.7). This promiscuous receptor binding of the mutant perhaps would have contributed
to lethality in mice similar to the Asp225Gly mutant of A/California/04/09 (Chapter 4).
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Figure 3.5 Effect of T93A mutation on SC18 receptor binding. Recombinant SC18 T93A HA was analyzed
on glycan array platform and its binding property was compared to that of the wild-type SC18 (A). There
was significant reduction in the binding affinity to 6'SLNLN as compared to the wild-type SC18. There was
no change in the receptor-binding specificity of SC18 T93A. This can be explained on the basis of the
receptor-binding pocket of SC18 HA (B). Arg224 in the 220-loop interact with GlcNAc of N-glycan at 91.
Destabilization of N-glycan at 91 has a significant effect in the receptor binding
affinity of SC18 T93A due to the "open-ness" of the binding pocket conferred by Asp 190 unlike AV18,
which has Glu 190.
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Figure 3.6 Effect of T93A mutation on NY18 receptor binding. Recombinant NY18 T93A HA was analyzed
on glycan array platform and its binding property was compared to that of the wild-type NY18 (A). There
was a complete loss of receptor binding affinity and specificity of NY18 T93A as compared to the wild-type
NY18. This can be explained on the basis of the receptor-binding pocket of NY18 HA (B). Arg224 in the
220-loop interact with GlcNAc of N-glycan at 91. Destabilization of 220-loop due to loss of N-glycan at 91
has a significant effect in the receptor binding affinity of NY18 T93A due to the binding pocket being
between an avian and human HAs due to the presence of Asp225Gly and Glu190Asp.
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Figure 3.7 Effect of N91D mutation on AV18 receptor binding. Recombinant NY18 N91D HA was analyzed
on glycan array platform. There was a complete loss of receptor binding affinity and specificity of NY18
N91D as compared to the wild-type NY18 (Figure 3.16A). The loss of receptor binding combined with a
promiscuous binding by NY18N91D could have accounted for lethality in mouse similar to the D225G
mutants of 2009 H1N1 pandemic virus (Chapter 4). The binding signals presented in the figure are the
actual (and not the relative) binding signals to indicate the low non-specific binding of the HA (close to the
background).
3.2.3 Circular dichroism analysis of T93A mutant HI HAs
N-glycosylation is known to play an important role in folding and maintaining
the 3-dimensional structural stability of proteins. In order to make sure that knocking-
out of the glycosylation at position 91 did not affect the 3-dimensional structure of the
protein, circular dichroism (CD) analysis of the T93A mutant proteins was performed.
The spectra generated for the mutant proteins were compared with that of the wild-
type HAs. The CD spectra of all the mutant proteins were generated between 190nm
and 280nm to identify changes in the secondary structure of protein if any. All the
95
mutants had identical secondary structure as that of their wild-type counterparts as
indicated by their CD spectra (Figure 3.8).
SC18 NY18 AV18
Wildtype and deglycosylated Wildtype and deglycosylated Wildtype and deglycosylated
Figure 3.8 Circular Dichroism analysis of wild-type and mutant HAs. CD spectra were obtained between
190 and 280nm. The wild type (shown in color) and the mutant protein (shown in color) have similar
secondary structure indicating that the de-glycosylation did not affect the structure of the mutant
protein.
3.2.4 Glycosylation analysis of H2 and H3 HAs
H3 HAs have acquired several N-glycan sequon in the globular head domain by
antigenic drift mutations [152]. H2 on the other hand was lost from circulation in human
population and now currently circulates in birds. Hence there is not much change in the
N-glycosylation sequon in H2 HA [152]. In the course of viral evolution, some of the N-
glycan sequons were conserved.
Similar to the glycosylation analysis for H1 HA, identification of conserved N-
glycans was performed for H2 and H3 HAs. HA sequences from representative influenza
A viruses of H2 and H3 subtypes were aligned by ClustalW (Figure 3.9 and 3.10). In both
H2 (Asn169) and H3 (Asn165), the glycosylation in one monomer influences glycan
receptor binding of the adjacent monomer in HA trimer (Figure 3.11). In H2 HA the
glycosylation site is in the interface of trimerization. Hence expression of a
representative mutant H2 HA; A/Alb/6/58 or Alb58 lacking this conserved glycosylation
site, Alb58 T171A was challenging as trimerization of HA was affected though HA
monomers were seen to be expressed. Hence it was concluded that apart from our
speculated role of the glycosylation site at Asn169 in receptor binding property of H2
HA, it also plays an important role in maintaining the structural integrity of trimeric H2
HA.
Molecular dynamic simulations to understand HA-glycan interaction in a
representative H3 HA have shown that that the N-glycan at Asn165 in one monomer
directly with the sialic acid receptor bound by the adjacent monomer [153]. This
correlated with our molecular modeling analysis of a representative H3 HA, A/Aichi/68
(Figure 3.11). This is in contrast to H1 HAs, where the N-glycan at 91 interacts with the
220-loop (within the same monomer), which in turn interacts with the glycan receptor
(Section 3.2.2). Previously Srinivasan et al and Tumpey et al showed biochemically that
mutating residues in the 220-loop affects receptor-binding affinity of HA and hence its
transmissibility in ferrets [67, 110]. Given the importance of 220-loop in the receptor
binding property of HA, in this study in HI HA (in contrast to H2 and H3 HAs), one of the
other factors that could impinge on the stability of this 220-loop was identified.
Moreover the challenges associated with the expression of mutant H2 and H3 HAs
further prompted the analysis of H1 HAs and the role of its conserved N-glycan in its
receptor binding property.
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Figure 3.9 H2 HA ClustalW alignment. The N-glycosylation sites are marked . The N-glycosylation
site possibly involved in interaction with the receptor is marked M. The receptor binding subdomains are
marked grey.
HumanA/Moscow/10/99
HumanA/Wyoming/3/03
HumanA/Phillipines/2/82
HumanA/Aichi/2/68
AvianA/Dk/Ukraine/63
HumanA/Moscow/10/99
HumanA/Wyoming/3/03
HumanA/Phillipines/2/82
HumanA/Aichi/2/68
AvianA/Dk/Ukraine/63
HumanA/Moscow/10/99
HumanA/Wyoming/3/03
HumanA/Phillipines/2/82
HumanA/Aichi/2 /68
AvianA/Dk/Ukraine/63
MKTIIALSYILCLVFAQKLPGN TLCLGHHAVPLVKTITNDOI
MKTIIALSYILCLVFSKLPGN TLCLGHHAVPIVKTITNDQI
MKTIIALSYILCLVFAQNLPGN TLCLGHHAVPLVKTITNDQI
MKTIIALSYIFCLALGQDLPGN TLCLGHA VKTITDDQI
MKTVIALSYILCLTFGQDLPGN DTLCLGHHA IVKTITDDQI
***:******:**:.* **********************
EVLELVSSSTGRICDSPHQILDG IDALLGDPCDGFQNKEW
E[LVQSSSTGGICDSPHQILDGELIDALLGDPQCDGFQNKKW
EVELVSSSTGRICDSPHRILDGKL IDALLGDPHCDGFQNEKW
El t LVQSSSTGICNNPHRILDGIDCTLIDALLGDPHCDVFQW
EV LVSSSTGKICNNPHRILDGRACTLIDALLGDPHCDVF.Q
*************** **: ***.**** ***********.* **
130 1o
DLFVERSKAYSNCYPYDVPDYASLRSLVASSGTLEF WNAG
DLFVERSKAYSNCYPYDVPDYASLRSLVASSGTLE NAGVT
DLFVERSKAFSNCYPYDVPDYASLRSLVASSGTLEFINEGF VTQSG
DLFVERSKAFSNCYPYDVPDYASLRSLVASSG;TLTEGFWTVTNG
DLFVERSNAFSNCYPYDIPDYASLRSLVASSGTLEFITEGFTWTGVTQNG
*******:*:*******:****************** 
.***:**:*.*
183
50
50
50
50
50
100
100
100
100
100
150
150
150
150
150
HumanA/Moscow/10/99
HumanA/Wyoming/3/03
HumanA/Phillipines/2/82
HumanA/Aichi/2/68
AvianA/Dk/Ukraine/63
HumanA/Moscow/10/99
HumanA/Wyoming/3/03
HumanA/Phillipines/2/82
HumanA/Aichi/2/68
AvianA/Dk/Ukraine/63
HumanA/Moscow/10/99
HumanA/Wyoming/3/03
HumanA/Phillipines/2/82
HumanA/Aichi/2/68
AvianA/Dk/Ukraine/63
HumanA/Moscow/10/99
HumanA/Wyoming/3/03
HumanA/Phillipines/2/82
HumanA/Aichi/2 /68
AvianA/Dk/Ukraine/63
HumanA/Moscow/10/99
HumanA/Wyoming/3/03
HumanA/Phillipines/2/82
HumanA/Aichi/2 /68
AvianA/Dk/Ukraine/63
HumanA/Moscow/10/99
HumanA/Wyoming/3/03
HumanA/Phillipines/2/82
HumanA/Aichi/2/68
AvianA/Dk/Ukraine/63
HumanA/Moscow/10/99
HumanA/Wyoming/3/03
HumanA/Phillipines/2/82
HumanA/Aichi/2/68
AvianA/Dk/Ukraine/63
HumanA/Moscow/10/99
HumanA/Wyoming/3/03
HumanA/Phillipines/2/82
HumanA/Aichi/2/68
AvianA/Dk/Ukraine/63
HumanA/Moscow/10/99
HumanA/Wyoming/3/03
HumanA/Phillipines/2/82
HumanA/Aichi/2/68
AvianA/Dk/Ukraine/63
SSCKRRSIKSFFSRLNWLHQLKYRYP NNDKFDKLYIWG 200
SACKRRSFFSRLNWLTHLKYKYPALM NNEKFDKLYIWG 200
GSYTCKRGS FSRLNWLYESESKYP NNGKFDKLYIWGI 200
GSNACKRGPGSGFFSRLNWLTKSGSTYP NNDNFDKLYIWGIE 200
GSSACKRGPANGFFSRLNWLTKSESAYP NNDNFDKLYIWG 200
* :*** . . .******** . **.******** :******
190 helix 220 loop
TDSDQTSLYTQASGRVTVSTKRSQQTVIPNIGSRPWVRGISSRISIYW 250
TDSDQISLYAQASGRITVSTKRSQQTVIPNIGYRPRVRDISSRISIYW 250
TDKEQTNLYIRASGRVTVSTKRSQQTVIPNIGSRPWVRGLSSRISIYW 250
TNQEQTSLYVQASGRVTVSTRRSQQTIIPNIGSRPWVRGLSSRISIYW 250
TNQEQTNLYVQASGRVTVSTRRSQQTIIPNIGSRPWVRGQPGRISIYW 250
* *...* .** .****.****.*****.***** * .*****
TIVKPGDILLIGNLIAPRGYFKIRSGKSSIMRSDAPIGKCNSECITP
TIVKPGDILLIGNLIAPRGYFKIRSGKSSIMRSDAPIGKCNSECITP
TIVKPGDILLIGNLIAPRGYFKIRTGKSSIMRSDAPIGTCSSECITP
TIVKPGDVLVINSNGNLIAPRGYFKMRTGKSSIMRSDAPIDTCISECITP
TIVKPGDVLVINSNGNLIAPRGYFKMRTGKSSIMRSDAPIDTCISECITP
*******.*.***.***********.*************..* ******
IPNDKPFQNVNRITYGACPRYVKQNTLKLATGMRNVPEKQTRGIFGA
IPNDKPFQNVNRITYGACPRYVKQNTLKLATGMRNVPEKQTRGIFGA
IPNDKPFQNVNKITYGACPRYVKQNTLKLATGMRNVPEKQTRGIFGA
IPNDKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQTRGLFGA
IPNDKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQTRGLFGA
IAGFIENGWEGMDGWYGFRHQNSEGTGQAADLKSTQAAININGKLNRL
IAGFIENGWEGMMDGWYGFRHQNSEGTGQAADLKSTQAAINQINGKLNRL
IAGFIENGWEGMIDGWYGFRHQNSEGTGQAADLKSTQAAIDQINGKLNRV
IAGFIENGWEGMIDGWYGFRHQNSEGTGQAADLKSTQAAIDQINGKLNRV
IAGFIENGWEGMIDGWYGFRHQNSEGTGQAADLKSTQAAIDQINRKLNRV
************:***************************:*** 
****:
IEKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQ
IGKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQ
IEKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQ
IEKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQ
IEKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENOQ
* ************************************************
HTIDLTDSEMNKLFERTRKQLRENAEDMGNGCFKIYHKCDNACIGSI4
HTIDLTDSEMNKLFERTKKQLRENAEDMGNGCFKIYHKCDNACIESIU
HTIDLTDSEMNKLFEKTRKQLRENAEDMGNGCFKIYHKCDNACIGSIR
HTIDLTDSEMNKLFEKTRRQLRENAEEMGNGCFKIYHKCDNACIES I
HTIDLADSEMNKLFEKTRRQLRENAEDMGNGCFKIYHKCDNACIESI
DHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISCFLLCVVLLGF
DHDVYRDEALNNRFOIKGVELKSGYKDWILWISFAISCFLLCVALLGF
DHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISCFLLCVVLLGF
DHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISCFLLCVVLLGF
DHDIYRDEALNNRFQIKGVELKSGYKDWILWISFAISCLLLCVVLLGF
300
300
300
300
300
350
350
350
350
350
400
400
400
400
400
450
450
450
450
450
500
500
500
500
500
550
550
550
550
550
IMWACQKGNIRCNICI 566
IMWACQKGNIRCNICI 566
IMWACQKGNIRCNICI 566
IMWACQRGNIRCNICI 566
IMWACQRGNIRCNICI 566
Figure 3.10 H3 HA ClustalW alignment. The N-glycosylation sites are marked . The N-glycosylation
site possibly involved in interaction with the receptor is marked f. The receptor binding subdomains are
marked grey. Conserved N-glycosylation sequons in the stem region are marked 0.
Figure 3.11. Structure of a representative H3 HA (1963-Avian/Duck/Ukraine). Note: two monomers are
shown. The glycan ligand is shown as blue stick. The key glycosylation site on NVT (165 -167 amino acids)
is shown as magenta stick. It is quite interesting to note that the N-glycosylation site on one of the
receptor subdomain stabilizes the glycan binding on the other subdomain in the H1 trimer.
3.3 Discussion and Significance of this study
Glycosylation in influenza A virus hemagglutinin (HA) has evolved as part of the
antigenic drift mutations. Except for in H2, which is not in circulation in human
population, there has been an increase in the number of N-glycan sequons in the
globular head domain of HA. The globular head domain is the prime target of the host
antibody response. The glycans in the globular head domain have hence evolved to
block binding of neutralizing antibodies. There are a few N-glycan sequons that have
been preserved during the course of viral evolution. The ones in the stem region of HA
have been well studied and have been implicated in fusion activity of HA. The role of
gross glycosylations in the globular head domain has been implicated in replication of
virus. Moreover the global effect of HA glycosylation in HA receptor binding was studied
by Wang et al. However not much is know about the role of conserved N-glycan in the
receptor binding property of HA.
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In this study the effect of a conserved N-glycosylation sequon, Asn9l, in the
receptor binding property of H1 HA was systematically studied using a combination of
molecular modeling and biochemical assay. It was interesting to identify the role of the
N-glycan at N91 only in human glycan receptor binding but not in avian receptor
binding. This has been previously suggested by molecular dynamic simulation studies
[153]. Glycosylation site at Asn9l along with Asp225GIy mutation of HA has previously
been implicated in cyanovirin resistance and in mouse adaptation. Hence it was further
crucial to delineate the functional significance of Asn9l (and also in combination with
asp225gly) given its physiological relevance.
Such a systematic study is important for understanding molecular evolution of
influenza A viruses and also to identify factors that can potentially contribute to the
receptor binding property of the virus. This is crucial as glycan receptor binding impinges
on the host, tissue and cellular tropism of the virus that can contribute to viral
pathogenesis. Such an approach can also enable effective surveillance of evolution of a
virulent influenza A virus strains.
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Chapter 4. Correlating Glycan Receptor Binding of the
Pandemic 2009 HIN1 HA to Viral Transmissibility
Summary
This chapter reports our analysis of the transmissibility and pathogenicity of 2009
pandemic H1N1 virus. Our study showed that the virus has inefficient transmissibility in
ferrets as compared to seasonal and pandemic strains. Previously Srinivasan et al (2008)
had correlated the transmission efficiency of influenza A viruses to the human receptor
binding affinity of its HA. Hence the binding specificity and affinity of a representative
2009 pandemic H1N1 virus: A/California/04/09 or CA04/09 HA to human receptors was
characterized using the glycan array platform. This showed that the CA04/09 HA has
lower binding affinity to human receptor (6'SLNLN) as compared to the pandemic and
seasonal viruses and that this could potentially account for its lower transmission
efficiency. Further, to understand the lower human glycan receptor binding affinity, the
receptor binding site (RBS) of the HA was compared with that of the seasonal and
pandemic influenza A HA. It was hypothesized that the destabilization of interaction
network at 186, 189 and could account for its lower receptor binding affinity. In order to
validate this, the mismatched interaction was fixed by making it fully ionic
(CA04/09Mutl) or fully hydrophobic (CA04/09Mut2). Glycan array analysis of these two
mutants showed that fixing the mismatch indeed improved the human receptor binding
affinity. Next the transmission experiments with CA04/09Mutl in ferrets showed that it
had improved transmission efficiency compared to the wild type virus. This study
provides an alternate strategy for surveillance of influenza A viruses into a more
transmissible and pathogenic strain. This study has led to two publications in Science
(Maines T et al 2009) and Plos One (Jayaraman A et at, 2011)
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4.1 Introduction
The Year 2009 witnessed the first pandemic of the century due to the emergence
of the novel swine-origin H1N1 influenza A virus (Table 4.1). In response to the
emergence and the global spread, on June 11t , 2009, World Health Organization
declared it as a pandemic. Phylogenetic analysis of these viruses showed that these
viruses resulted from the reassortment of North American H3N2 and H1N2 swine
viruses (avian/human/swine "triple" reassortant viruses) with Eurasian avian-like swine
viruses (Figure 4.1) [154]. As a result these viruses possess PB2 and PA genes of North
American avian virus origin, a PB1 gene of human H3N2 virus origin, HA (Hi), NP and NS
genes of classical swine virus origin and NA (N1) and M genes of Eurasian avian-like
swine virus origin. Owing to a decline in the number of cases of 2009 HiN1 viral
infection in 2010, the WHO declared the end of the 2009 H1N1 pandemic in early
August 2010 [155]. As of August 2010, there are more than 600,000 laboratory
confirmed cases of 2009 H1N1 infection and over 18,449 deaths in more than 214
countries as reported by the WHO [1561. Although most confirmed cases have occurred
among individuals with uncomplicated, febrile, upper respiratory tract illnesses with
symptoms similar to seasonal influenza, there have been over 180 deaths and
approximately 40% of infected individuals have experienced symptoms that include
gastrointestinal distress and vomiting, which is higher than that reported for seasonal
influenza.
The factors that lead to the generation of pandemic viruses are complex and
poorly understood, however the ability of a novel influenza virus to transmit efficiently
through the air via respiratory droplets appears to be a critical property of pandemic
influenza strains [157]. Thus, knowing the inherent virulence and transmissibility of the
2009 A(H1N1) viruses, relative to seasonal influenza viruses, is important to inform
appropriate public health responses. We have therefore characterized the virulence and
transmissibility of influenza viruses of various subtypes in the ferret (Mustela putorius
furo) model, which appears to recapitulate not only human disease severity but also
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efficient transmission of seasonal (HINI and H3N2) influenza viruses and the poor
transmission of avian (H5 and H7) influenza viruses [89, 158-160]. Previously our group
has shown a strong correlation between the glycan receptor binding affinity of HA to the
transmissibility of influenza A virus [110]. Hence the glycan receptor binding specificity
and affinity of the viral HA to human receptors was characterized. Building on this
receptor-binding site (RBS) of a representative 2009 pandemic H1N1 virus:
A/California/04/09 or CA04/09 was compared to that of the seasonal and pandemic
H1N1 influenza A HA. The key differences in the RBS of CA04/09 HA were identified
which provided a structural rationale for the observed glycan receptor binding affinity
and transmissibility of the 2009 HIN1 virus in ferrets. Further, this hypothesis was
validated by engineering the RBS of 2009 H1N1 HA to make it similar to the RBS of
seasonal and pandemic HAs. The receptor binding property of these engineered HAs
were characterized and tested for their transmissibility in ferrets.
Classical swine North American Human (H3N2) Eurasian avian-
avian like swine
PB2 - North American
avian
P81 - Human H3N2
PA - North Ameican
avian
H1 - Classical swine
NP - Classical swine
N1 - Eurasian avian-
Influenza A H1N1) like swine
M - Eurasian avian-like
swine
NS - Classical swine
Figure adapted from Kawaoka et al (2009)
Figure 4.1 Genesis of 2009 H1N1 swine flu
virus. In the late 1990s, reassortment
between human H3N2, North American
avian, and classical swine viruses resulted in
triple reassortant H3N2 and H1N2 swine
viruses that have since circulated in North
American pig populations. A triple
reassortant swine virus reassorted with a
Eurasian avian-like swine virus, resulting in
the S-OlVs that are now circulating in
humans.
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Table 4.1 Timeline of Swine flu Outbreak
Date Event
Mid-February Outbreak if respiratory illness in La Gloria, Veracruz, Mexico
12 April 2009 Mexican public health authorities report outbreak in Veracruz
to the PAHO
15 April 2009 CDC identifies Swine-origin influenza A virus (H1N1) in the
specimen of a boy from San Diego, California
21 April 2009 CDC alerts doctors to a new strain of swine-origin influenza A
virus
24 April 2009 WHO issues disease outbreak notice
27 April 2009 WHO raises pandemic alert from phase 3 to 4 due to global
spread and human-to-human transmission
29 April 2009 WHO raises the pandemic alert from phase 4 to 5
21 May 2009 41 countries report infection and deaths due to the H1NI virus
June 2009 First case of tamiflu resistance
11 June 2009 WHO raises pandemic alert to Phase 6
October 2009 US declares national emergency and calls for more swine flu
vaccine production
November 2009 Emergence of Asp225 variants in Norway and Ukraine
December 2009 Reduction in flu related deaths and infection but above
epidemic threshold
January 2010 Reduction in flu related deaths and infection but below
epidemic threshold
April 2010 Isolated flu activity in various parts of the world
August 2010 WHO declares that the H1NI pandemic is over and it is declared
as a seasonal strain
4.2 Pathogenicity and Transmissibility of 2009 HINI influenza A viruses
We tested the pathogenesis and transmissibility of three 2009 A (H1N1) viruses (isolated
from nasopharyngeal swabs) and compared with a representative seasonal H1N1 virus,
A/Brisbane/59/2007 (Brisbane/07; H1N1) [160]. A/California/04/2009 (CA/04) virus was
isolated from a pediatric patient with uncomplicated, upper respiratory tract illness;
A/Mexico/4482/2009 (MX/4482) virus was isolated from a 29-year-old female patient
with severe respiratory disease; and Texas/15/2009 (TX/15) virus was isolated from a
pediatric patient with fatal respiratory illness. To date, 2009 A (HIN1) viruses exhibit
high genome sequence identity (99.9%) and lack previously identified molecular
markers of influenza A virus virulence or transmissibility [154]. Alignments of the
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deduced amino acid sequences between the three viruses revealed a few differences.
These were observed in the polymerase (PA), hemagglutinin (HA), nucleoprotein (NP),
and non-structural proteins NS1 and NS2 (Table 4.2). Viruses were propagated in
Madin-Darby canine kidney cells (MDCK) or embryonated hen's eggs (14). For
respiratory droplet transmission experiments, three animals were inoculated
intranasally (i.n.) with 106 PFU (plaque forming units) of virus (14). Approximately 24
hours later, inoculated-contact animal pairs were established by placing a naive ferret in
each of three adjacent cages with perforated side walls, allowing exchange of
respiratory droplets without direct or indirect contact (Figure 1.16) [158]. Direct contact
transmission experiments were performed similarly except naive ferrets were placed in
the same cage as each of the inoculated ferrets where they shared a common food and
water source. Transmission was assessed by titration of infectious virus in nasal washes
and detection of virus specific antibodies in convalescent sera [158]. Inoculated and
contact animals were monitored for clinical signs over a 14 day period using previously
described methods [158]. Three additional inoculated ferrets from each virus-infected
group were euthanized on day 3 post-inoculation (p.i.) for assessment of virologic
parameters [27].
4.2.1 Pathogenesis of 2009 H1N1 influenza A viruses in ferrets
Ferrets inoculated with CA/04 virus showed no overt clinical signs but displayed mild
signs of inactivity (relative inactivity index (RII = 1.0). TX/15 or MX/4482 virus infection
resulted in more pronounced clinical features including a slight increase in RII (1.2).
Significantly greater weight loss was observed with all of the 2009 A(H1N1) viruses than
that with the seasonal influenza virus, Brisbane/07 (P<0.05; Table 4.2). One ferret
infected by direct contact transmission from a TX/15-inoculated ferret was euthanatized
at 10 days p.i. due to excessive weight loss and three MX/4482-inoculated ferrets were
euthanatized before the end of the experimental period due to severe lethargy or
excessive weight loss (Table 4.2). Ferrets inoculated with either of the 2009 A(H1N1)
virus isolates had elevated body temperatures (peak mean change in body temperature
107
ranging from 2.0 to 3.2"C over baseline) and shed high peak mean titers of infectious
virus in nasal washes as early as day 1 p.i (107177 PFU/ml) (Supplementary Figures 1 &
2), that were sustained at titers of 2104-4 PFU/ml for 5 days p.i. The 2009 A(H1N1) virus
shedding showed similar kinetics to Brisbane/07 virus, which was also sustained for 5
days in ferrets at titers of 10 47 PFU/ml. In contrast to Brisbane/07, CA/04, TX/15 and
MX/4482 viruses were detected in the lower respiratory tract at high titers (105.8-6.0
PFU/g lung tissue) and the intestinal tract. For the latter, viral titers were detected in
rectal swabs or tissue samples collected throughout the intestinal tract (Table 4.2,
Figure 4.2). There was no evidence of viremia or infectious virus in the brain, kidney,
liver and spleen tissues with any of the viruses tested (Figure 4.3).
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Figure 4.2 Detection of H1N1 virus in ferret tissues. Three ferrets were intranasally inoculated with 106
PFU of virus and three days later tissues were collected and virus titers were determined. Bn-Ant,
anterior brain; Bn-Pos, posterior brain; Bn-OB, olfactory bulb; Sp, spleen; Kd, kidneys; Lv, liver; Bd, whole
blood; RS, rectal swab; ln(d), duodenum; In(j), jejuno-ileal loop; ln(dc), descending colon; NT, nasal
turbinates; Tr, trachea; Lg, lung. Mean virus titers are expressed as PFU/g for all tissues except Bd, RS and
NT which are expressed as PFU/mL. Mean virus titers of RS samples are based on the mean of positive
samples only. All isolation attempts without recovery of virus were given a value of 1.5 logio PFU/g or mL
for all tissues except those tested without dilution (Bd and RS) which were given a value of 0.5 log1o
PFU/mL.
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Table 4.2: Replication and transmission of novel 2009 and seasonal H1N1 viruses in ferrets.
Inoculated Animals
Virus Clinical Signs Virus Detection
DC Contact Animalsa RD Contact Animalsa
Virus ; Virus Qrnwmrc
Weight lt d Lung Intestinal Detection O' U ' H Detection
Loss (%)b Sneezingc Lethaty (peak titer)e Tract _
A/California/04/2009 6/6(10.3) 2/6 0/6 3/3 (5.8) 5/9(2.3) 3/3 3/3 2/3 2/3
A/Texas/15/2009 6/6 (9.1) 1/6 0/6 3/3(6.0) 1/9 (1.3) 3/3 3/3 2/3 2/3
A/Mexico/4482/2009 6/6 (17.5) 3/6 3/6 2/3 (4.1) 2/9 (2.7) h 3/3 h2/3
A/Brisbane/59/2007 6/6 (4.9) 6/6 0/6 0/3 0/9 3/3 3/3 3/3 3/3
a DC, direct contact; RD, respiratory droplet.
b The percentage mean maximum weight loss observed during the first 10 days post-inoculation.
'Number of animals in which sneezing was observed during the first 10 days post-inoculation.
d Number of animals euthanatized before the end of the 14 day experimental period due to reaching a clinical end point.
e Virus titers are expressed as mean logio peak PFU/mL or PFU/gram of tissue.
Virus titers in intestinal tissue or rectal swabs are expressed as the mean logio peak PFU/ml for the positive samples.
8 HI antibody titers ranged from 640 to 1280 and were determined using homologous virus and serum collected at least 17 days post contact.
h Virus was detected in intestinal tract as well as nasal wash for 1 of 3 DC and 2 of 3 RD contact animals.
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4.2.2 Transmission of 2009 H1N1 influenza A viruses in ferrets
To assess the transmission efficiency of the virus, viral shedding in nasal washes,
detection of neutralizing antibody in the convalescent sera and the onset of clinical
symptoms in the contact ferrets (housed in adjacent cage with perforated walls) are
monitored [67]. The number of contact ferrets infected by the inoculated ferrets also
determines the transmission efficiency of the virus. Previously, Tumpey et al., showed
that seasonal and pandemic influenza A viruses transmit efficiently via respiratory
droplets from inoculated to contact ferrets (all the 3 contact ferrets were infected by
the inoculated ferrets). A similar approach was used to test the transmission efficiency
of 2009 HIN1 influenza A viruses.
Consistent with the experimental transmission data obtained with contemporary
human H1N1 and H3N2 viruses [27, 67, 158, 161], the seasonal influenza H1NI
(Brisbane/07) virus efficiently transmitted via direct contact and respiratory droplets to
all of the contact ferrets which shed virus as early as day 1 post-contact (p.c.) (Figures
4.3 & 4.4). Direct contact transmission was observed between all animal pairs for CA/04,
TX/15 and MX/4482 viruses; infectious virus was recovered from nasal washes and
seroconversion was detected in all contact animals (Table 4.2 and Figure 4.4). However,
the 2009 A(H1N1) viruses did not spread by respiratory droplet to every contact ferret
and transmission was delayed by five or more days post exposure in two of six infected
ferret pairs (Figure 4.3). Respiratory droplet transmission of 2009 A(H1N1) viruses was
significantly reduced compared to respiratory droplet transmission of the seasonal
influenza virus (P:0.01; Table 4.2). Sneezing was frequently observed in Brisbane/07-
inoculated ferrets but was rarely observed in the CA/04-, TX/15- or MX4482-inoculated
ferrets during the study period, similar to the infrequent sneezing observed in ferrets
infected with avian influenza viruses [158]. Collectively, these findings demonstrate that
2009 A(H1N1) viruses elicited elevated respiratory disease relative to seasonal HIN1
viruses in ferrets, yet despite efficient direct contact transmission, the viruses exhibited
less efficient respiratory droplet transmission, compared with contemporary seasonal
human influenza viruses [27, 158].
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Figure 4.3. Respiratory droplet transmissibility of HINI influenza viruses. Three ferrets were
intranasally inoculated with 106 PFU of Brisbane/07 (A), CA/04 (B), TX/15 (C) or MX/4482 (D) virus. A
naive ferret was placed in an adjoining cage to each inoculated ferret and viral shedding in nasal washes
was assessed every other day for the inoculated (left and contact (right) ferrets. Results from individual
ferrets are presented. Solid and striped bars of the same color represent a ferret pair housed in adjoining
cages. Limit of detection is 1.5 logio PFU/mL.
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Figure 4.4. Direct contact transmissibility of H1N1 influenza viruses. Three ferrets were intranasally
inoculated with 106 PFU of Brisbane/07 (A), CA/04 (B), TX/15 (C) or MX/4482 (D) virus. A naive ferret was
housed in the same cage with each inoculated ferret and viral shedding in nasal washes was assessed
every other day for the inoculated (left) and contact (right) ferrets. Results from individual ferrets are
presented. Solid and striped bars of the same color represent a ferret pair housed together. Limit of
detection is 1.5 logio PFU/mL.
4.3 Glycan receptor binding property of 2009 HINI influenza A viruses
4.3.1 Biochemical characterization of glycan receptor binding property of 2009
H1N1 influenza A viruses
As mentioned earlier, one of the critical determinants of the viral transmission is
its HA (Chapter 1). HA mediates binding of the virus to their target cells by binding to
specific sialylated glycan receptors. Increased binding affinity and specificity of human-
adapted influenza A HA to human receptors (long a2-6 sialylated glycans which adopt
umbrella-like topology) was shown to correlate with increased transmission efficiency of
the virus in ferrets and humans [110]. Hence to understand the glycan receptor binding
property of 2009 H1N1 HA, glycan array analysis of the HA and whole viruses was
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performed using the glycan array platform (Chapter 1). Soluble HA from the
representative 2009 H1N1 virus A/California/04/09 or CA04/09 was recombinantly
expressed and purified in Sf9 insect cells. Whole viruses were generated using reverse
genetics by using eight-plasmid system 11011.
A quantitative dose-dependent glycan array analysis with HA (pre-complexed
with primary and secondary antibody) was performed. The array platform comprised of
5 glycans: 3'SLN, 6'SLN, 3'SLNLN, 6'SLNLN and 3'SLNLN (LN corresponds to lactosamine
(GalI1-4GlcNAc) and 3'SLN and 6'SLN respectively correspond to Neu5Aca2-3 and
Neu5Aca2-6 linked to LN). CA04/09 HA exhibited a dose-dependent binding to only a
single a2-6 glycan (6'SLNLN) and no observable binding to any a2-3 glycans (Figure
4.5A). While the binding specificity of CA04/09 HA is similar to that of HA from the 1918
pandemic influenza A virus (A/South Carolina/1/1918; or SC18 Figure 4.5B), the binding
affinity of CA/04 HA is however considerably lower than that of SC18 HA (Figures 4.6A).
We also performed glycan array analysis with CA04/09 whole virus (generated by
reverse genetics). CA04/09 virus showed a strict a2-6 binding specificity (although 6'SLN
binding was also seen in contrast to 6'SLNLN binding specificity of the HA) and no a2-3
binding was seen. The 6'SLN binding seen with the whole viruses can be attributed to
the increased multivalency of HA on viruses than the pre-complexed HA and hence an
amplification of binding signals can be seen with whole viruses (Figure 4.7).
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Inoculated Ferrets Respiratory Droplet Contact Ferrets
Number with characteristic/total number Number with characteristic /total Respiratory
Virus number droplet
Weight loss Nasal Virus Detection in nasal wash transmissionSneezing a b
_______ (%) Wash (Peak/dpc)
SC18 3/3 3/3 (11.7) 3/3 3/3 (7.5/1,1,1) Efficient
NY18 0/3 3/3 (18.9) 3/3 1/3 (3.8/3) Inefficient
CA/04 2/6 6/6 (9.1) 6/6 2/3 (6.7/2,8) Inefficient
Figure 4.6. Correlation between a2-6 binding affinity and respiratory droplet ferret transmission of H1N1. Shown on the top is the binding curve comparing
a2-6 binding (to 6'SLN-LN in the direct receptor binding assay) of SC18, NY18 (a single amino acid HA variant of SC18) and CA/04 HA. Shown in the bottom is a
table showing clinical symptoms, virus replication, transmissibility among ferrets inoculated with the H1N1 viruses. Note that the substantially lower aX2-6
binding affinity of NY18 and CA/04 HA as compared to SC18 HA correlates with their transmission efficiency.
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NY18 0/3 3/3 (18.9) 3/3 1/3 (3.8/3) Inefficient
CA/04 2/6 6/6 (9.1) 6/6 2/3 (6.7/2,8) Inefficient
Figure 4.6. Correlation between a2-6 binding affinity and respiratory droplet ferret transmission of H1N1. Shown on the top is the binding curve comparing
a2-6 binding (to 6'SLN-LN in the direct receptor binding assay) of SC18, NY18 (a single amino acid HA variant of SC18) and CA/04 HA. Shown in the bottom is a
table showing clinical symptoms, virus replication, transmissibility among ferrets inoculated with the H1N1 viruses. Note that the substantially lower a2-6
binding affinity of NY18 and CA/04 HA as compared to SC18 HA correlates with their transmission efficiency.
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Figure 4.7 Glycan array analysis with the wild-type CA04/09 virus (generated by reverse genetics). The
wild-type virus showed a strict binding preference to a2-6 glycans. In contrast to the HA (Figure 4.6), the
whole virus showed binding to 6'SLN glycans as well, this can be attributed to the increased multivalency
of the virus as compared to the recombinant HA.
Nevertheless, it can be concluded that one of the factors that contribute to the
lower transmission efficiency of the 2009 HINI influenza A viruses is their reduced
binding affinity to the human receptors. In order to corroborate this binding specificity
of CA04/09 on the glycan array to the binding of the HA to physiological glycan
receptors, the recombinant HA was used to stain human tracheal and alveolar tissue
sections. Previously, increased binding affinity to human receptors has been correlated
to extensive staining of goblet cells and in some cases to ciliated cells and apical surface
as well [41, 48, 162]. In accordance with that, CA04/09 HA showed less extensive
staining of the goblet cells and the apical surface of the tracheal epithelium (Figure
4.8A). Human deep lung comprising of the alveolus is known to predominantly express
a2-3 glycans. CA04/09 HA did not show any a2-3 binding on the glycan array, and hence
as expected there was minimal to no staining of the alveolus (Figure 4.8B). The sialic
acid binding specificity of CA04/09 HA was tested using Sialidase A treatment of tissues
prior to staining with HA (Figure 4.9).
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Figure 4.8 Human respiratory tract tissue binding of CA04/09 HA. Shown in (A) is the binding of CA04/09
HA at 20sig/ml concentration to apical surface (white arrow) of human tracheal tissue sections (green as
against propidium iodide staining in red). Note the binding of HA to the apical surface of tracheal tissue
which is known to predominantly express a2-6 sialylated glycans (Chandrasekharan et a/), Shown in (B) is
the minimal binding of HA at 20sgg/ml concentration to the alveolar tissue section. The binding of the
recombinantly expressed HA to the human tissues was carried out as described previously
(Chandrasekharan et aL) by precomplexing HA: primary antibody:secondary antibody in the molar ratio of
4:2:1 to enhance multivalent presentation of HA.
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Figure 4.9 Sialic acid specificity of CA04/09 HA The sialic acid specific binding of HA to the tracheal tissue
section was confirmed by the minimal binding of HA to the tissue section pre-treated with 0.2 U of
Sialidase A (recombinantly expressed in Arthrobacter ureafaciens). The binding of the recombinantly
expressed HA to the human tissues was carried out as described previously (Chandrasekharan et al.) by
precomplexing HA: primary antibody:secondary antibody in the molar ratio of 4:2:1 to enhance
multivalent presentation of HA.
4.3.2 Biochemical characterization of glycan binding properties of natural variants
of 2009 H1N1 virus
Since the emergence of CA/04 in March-April 2009, there has been an evolution of the
natural variants of the virus that have acquired mutations in the HA. Notably, Asp225
(H3 HA numbering) has mutated into Glu or Asn or Gly in the more recent 2009 H1N1
strains. The Asp225->Gly and Asp225->Asn variants were derived directly from clinical
specimens of patients with severe infection [1631. The Asp225Gly was isolated from the
deeper lung regions in three of the fatal cases in Ukraine [164]. Asp225 is a hallmark
residue of human-adapted H1N1 HAs and has been shown to play a critical role in the
a2-+6 glycan-binding specificity of these HAs [67] (Figure 4.10).
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Figure 4.10 Role of Asp225 in human receptor binding of HA. Shown is a molecular model of H1 HA with
human receptor. Aspartate at 225, is part of the 220-loop, and makes critical contacts with Gal-2 of the
human receptor. The recent isolates of 2009 H1N1 have mutated Asp225 to either Asn, Glu or Gly. Asp225
is highlighted in red dotted circle.
Hence in order to understand the effect of the D225 mutations, the natural
variants that acquired the Asp225->Glu (CA04M3), Asp225->Asn (CA04M4) and Asp225-
>Gly (CA04M5) mutations were also designed on CA/04 HA and a dose-dependent
glycan array analysis was performed (Figure 4.11). Our analysis showed that the binding
specificity to the representative human receptor (6'SLN-LN) was the same between the
Asp2254Glu (CA04M3) and Asp2254Asn (CA04M4) mutants, consistent with the
previous study [165]. However there were differences in their human receptor binding
strengths where CA04M4 (Kd'~ 0.7 nanomolar (nM)) > CA04 (Kd4' ~ 1 nM) >> CA04M3
(Kd' ~ 7 nM). The Asp2254Gly (CA04M5) mutant, on the other hand, showed
dramatically reduced dose-dependent binding to human receptors and bound to avian
receptors as well (Figure 4.11). The binding of CA04M5 mutant to representative avian
receptors is in agreement with the previous studies [165]. Taken together, none of the
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mutants with the natural amino acid substitutions at the 225 position show substantially
improved human receptor binding strength over the WT HA. More recently, the
Asp2254Gly mutation has been analyzed to understand its cellular tropism, as this
mutant is associated with causing a more severe and a fatal disease [166]. The 225Gly
mutant infected a higher proportion of ciliated cells in cultures of human airway
epithelium than did viruses with 225Asp or 225Glu, which mainly targeted non-ciliated
goblet cells. This converges with our glycan array data, where 225Asp and 225Glu
mutants showed highly specific binding to long a2-6 glycans (6'SLNLN). Hence a more
promiscuous a2-3 and a2-6 binding specificity of 225Gly (CA04M5) might contribute to
exacerbation of disease.
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Figure 4.11 Dose dependent glycan array analysis of natural variants of 2009 H1N1 virus. The three
natural variants: Asp225Glu or CAo4M3, Asp225Asn or CA04M4 and Asp225Gly or CA04M5 were
expressed in insect cells and analyzed on the glycan array. There was a complete loss of glycan binding
specificity and affinity for CA04M5 and this could account for its pathogenicity. Shown are the
promiscuous binding of CA04M5 to a2-3 and ax2-6 glycans. The binding signals seen for CA04M5 are
closer to the background binding signals. For comparison the binding data off CA04wt HA is also shown.
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Figure 4.12 6'SLNLN binding curves for the natural variants of the 2009 HIN1 virus. CA04M4
(Asp225Asn) had increased binding affinity to 6'SLNLN as compared to the wild-type. CA04M3
(Asp225Glu) had significantly reduced affinity to 6'SLNLN. This indicates that the amino acid chain length
at position 225 and not the charge governs the receptor binding property of the HA. Note that since
CA04M5 (Asp225Gly) displayed a complete loss of receptor binding affinity and specificity, its binding
curve is not shown.
4.3.3 Fixing the mismatched interaction in the RBS of CA04/09 HA
Two strategies were employed (based on the comparison of the RBS of
pandemic and a seasonal influenza A virus HA, Table 4.3, Figure 4.13) to correct the
mismatched combination of residues in the RBS of CA04/09 HA (Figure 4.14A) as
mentioned in Section 4.3.1. First strategy was to generate a single mutant; lle2194Lys
(CA04/09mutl) that would generate a stable ionic interaction between Lys219 and
Glu227. To confirm this analysis a homology-based structural of CA04/09mutl HA in
complex with human receptor was constructed (Figure 4.14B). Based on this model it
was observed that Lys219 and Glu227 are positioned to make ionic contacts that would
facilitate the stabilization of interaction network involving residues 186, 187, 189 and
190. The second strategy was to make this interaction network hydrophobic. This would
involve three amino acid changes, Ser186+Pro / Ala1894Thr / Glu2274Ala
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(CA04mut2) (Figure 4.14C) that would make the interactions hydrophobic similar to that
observed in the RBS of SC18 HA (Figure 4.14D). It was hypothesized that fixing this
mismatched interaction would improve the binding affinity of the HA and hence
improve its transmissibility in ferret model.
4.3.3.1 Biochemical characterization using glycan array analysis:
To test the aforementioned hypothesis, recombinant soluble CA04mutl and
CA04mut2 were expressed in insect cells and their respective glycan receptor binding
affinity and specificity was characterized by analyzing them (in their pre-complexed
state) using the dose-dependent glycan array analysis (Figure 4.15). A dose-dependent
binding of HA to representative human and avian receptors on a biotin-streptavidin
based glycan array platform permitted quantification of binding affinity using an
apparent binding constant Kd' [110]. The parameter Kd' was calculated by fitting the
binding data (over a range of HA concentrations) using the Hill equation for multivalent
binding [110].
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Table 4.3 Glycan binding residues of HiNi HAs
H1N1 Strains Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5
136 138 226 137 153 155 194 183 145 222 225 190 189 187 186 219 227 192 193 156 159 196
Solls_3_06 S S Q A W T L H S K D D G N P K E R A G G H
Bris_59_07 S S Q A W T L H S K D D G N P K E K A G G H
NewCal_20_99 S S Q A W T L H S K D N G N P K E R A G G H
TX_36_91 T S Q T W T I H S K D D R N S K E R A E G H
SC18 T A Q A W T L H S K D D T T P A A Q S K S Q
TX/1s T A Q A W V L H K K D D A T S I E Q S K N Q
Mex448209 T A Q A W V L H K K D D A T S I E Q S K N Q
CA/04 T A Q A W V L H K K D D A T S I E Q S K N Q
NeuSAc-1 Gal-2 GlcNAc-3 Gal-4, Glc-5,...
The residues are organized into network forming clusters. The sugar unit (numbered as shown in Figure 3), which makes contact
with the clusters, is shown in the last row. The unique amino acids in 2009 H1N1 HAs are highlighted in red. The key for the virus
strains SollS_3_06 (A/Solomon Islands/3/06); Bris_59_07 (A/Brisbane/59/07); NewCal_20_99 (A/New Caledonia/20/99);
Mex_4482_09 (A/Mexico/4482/09).
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CA04/09
A/SC/1/18
A/Brisbane/59/07
CA04/09
A/SC/1/18
A/Brisbane/59/07
CA04/09
A/SC/1/18
A/Brisbane/59/07
CA04/09
A/SC/1/18
A/Brisbane/59/07
CA04/09
A/SC/1/18
A/Brisbane/59/07
CA04/09
A/SC/1/18
A/Brisbane/59/07
MKAILVVLLYTFATANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCK
MEARLLVLLCAFAATNADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCK
MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENSHNGKLCL
*. *-*** -*... ***.*******************************. ******
LRGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETPSSDNGTCYPGDFIDYEELRE
LKGIAPLQLGKCNIAGNLLGNPECDLLLTASSWSYIVETSNSENGTCYPGDFIDYEELRE
LKGIAPLQLGNCSVAGWILGNPECELLISKESWSYIVEKPNPENGTCYPGHFADYEELRE
*.*.***.**.* .***-******. * .******* .******* * *******
QLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSK
QLSSVSSFEKFEIFPKTSSWPNHETTKGVTAACSYAGASSFYRNLLWLTKKGSSYPKLSK
QLSSVSSFERFEIFPKESSWPNHTVT-GVSASCSHNGESSFYRNLLWLTGKNGLYPNLSK
*********-****** ****** **-*.* .* ***.**.** * **.***
186 190 219 225
SYINDKGKEVLVLWGIHHPSTS SLYQNADTYVFVGSSRYSKKFKPEIAIRPKV4
SYVNNKGKEVLVLWGVHHPPT SLYQNADAYVSVGSSKYNRRFTPEI
SYANNKEKEVLVLWGVHHPPNIGUKALYHTENA SHYSRKFTPEIAKRP
** *-* ********-*** **. .**- - -** * **-* --. * **** *******
227
EGRMNYYNTLVEPGDKITFEATGNLVVPRYAFAENAGSGIIISDTPVHDCNTTCQTPK
AGRMNYYTLLEPGDTITFEATGNLIAPNYAFALNRGSGSGIITSDAPVHDCNTKCQTPH
EGRINYYWTLLEPGDTIIFEANGNLIAPRYAFALSRGFGSGIINSAPMDKCDAKCQTPQ
**.******.**** * *** ***. * ****. * ***** *-- - *--
GAINTSLPFQNIHPITIGKCPKYVKSTKLRLATGLRNIPSIQSR
GAINSSLPFQNIHPVTIGECPKYVRSTKLRMATGLRNIPSIQSR
GAINSSLPFQNVHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSR
****-******.**.***.*****.*.***. ************
Figure 4.13 ClustalW Sequence alignment of CA04109, SC18 and Bris07 HAs. Only the HA1 part of the HA
comprising of the RBS is shown. The hallmark Asp190 and Asp225 residues are highlighted in green.
Residue positions highlighted in gray represent the residues involved in positioning Asp190. Residue
positions 219 and 227 are highlighted in yellow to indicate the mismatched combination of residues in
CA04/09 H A.
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Thr189
Thri87
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Prol86
ALa227
LyS222 Asp225
Aia219
Prot86
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Lys222 Asp225 y
Figure 4.14 Fixing the mismatched interaction in RBS of CA04 HA. A, Structural complex of RBS of CA04 HA with human receptor (mismatched lle219 - Glu227
contacts highlighted in red circle). B, RBS of CA04M1 complexed with human receptor where Lys219 (highlighted in red) makes ionic contacts with Glu227. C,
RBS of CA04M2 complexed with the human receptor. D, RBS of SC18 HA complexed with human receptor. The hydrophobic interactions between lle219,
Pro186 and Ala227 and interactions between Ser187, Thr189 and Asp190 in RBS of CA04M2 HA are similar to that between analogous residues in SC18 HA. The
structural complexes are shown in stereo with RBS represented as a cartoon schematic with side chains of key amino acids. The substituted amino acids are
labeled red. Stick representation of human receptor is shown with carbon atoms in orange.
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CA04mutl and CA04mut2 showed specific binding to both the representative
human receptors (6'SLN and 6'SLN-LN) on the array (only minimal binding signals to
avian receptors were observed at the higher concentrations of 20-40 g/ml) (Figure
4.15). To compare the binding affinity of CA04/09, CA04/09mutl and CA04/09mut2 HAs
to a representative human receptor, the binding constant Kd' was calculated from the
6'SLN-LN binding curves (Figure 4.16). The binding strength of CA04/09mutl (Kd' ~ 50
picomolar (pM)) and CA04/09mut2 (Kd'~ 6 pM) to 6'SLN-LN is significantly higher than
that of CA04/09 HA (Kd' ~ 1.5 nM), and the natural variants at the 225 position. The
human receptor-binding affinities of CA04/09mutl and CA04/09mut2 HAs quantified
using Kd' is in the same range (picomolar) as that of SC18 HA (Kd' ~ 6 pM). Therefore
fixing the mismatched combination of residues in the RBS of 2009 H1NI HA substantially
increases its human receptor-binding affinity. We also verified that the dose-dependent
binding profile of recombinant CA04/09mutl HA was consistent with that of the whole
virus harboring the lle219->Lys HA mutation on our glycan array platform (Figure 4.18).
4.3.3.2 Binding of CA04/09mutl and CA04/09mut2 HAs to human tracheal tissue
sections
Human upper respiratory tissues are the primary targets for infection by human-
adapted influenza A viruses for efficient viral transmission by respiratory droplets [48,
110]. The tracheal tissue section, a representative human upper respiratory tissue, has
been shown to predominantly express a2-+6 sialylated glycan receptors in the ciliated
and non-ciliated (goblet) cells in the apical surface of the pseudostratified epithelium
[39, 41, 48, 49, 167]. In contrast, the human alveolus, a representative deep lung tissue,
has been shown to predominantly express ax2-+3 sialylated glycan receptors [38, 48,
138, 167]. The binding of CA04/09, CA04/09mutl and CA04/09mut2 HAs to
physiological glycan receptors was assessed by staining human tracheal and alveolar
tissue sections with these HAs. Consistent with their minimal C2-->3 glycan receptor-
binding on the array, no visible alveolar staining was observed with these HAs (data not
shown). On the other hand, CA04/09, CA04/09mutl and CA04/09mut2 HAs stained the
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apical surface of the human tracheal epithelium (Figure 4.15) consistent with their
human receptor-binding on the array. Furthermore, CA04/09mutl and CA04/09mut2
HAs showed more intense tracheal staining and goblet cell staining (Figure 4.17) in
comparison with CA04/09 HA, which correlated with the broader human receptor
specificity [binding to both 6'SLN and 6'SLN-LN] and increased human receptor affinity
of the mutant HA on the glycan array. The sialic acid specific binding of HAs to the
tracheal tissue sections was confirmed by loss of staining upon pre-treatment of the
tissue sections with Sialidase A (from Arthrobacter ureafaciens), an enzyme that cleaves
terminal sialic acid from both avian and human receptors.
127
CA/04 WT HA
Human Tracheal Tissue
HA concentration (Ig/mi)
40.00 20.00 10.00
IIe219Lys (CA04MI) mutant HA
'SLN
5 6'SLN
* 3SLN-LN
N 6'SLN-LN
*3'SLN-LN-LN
HA
PI
5.00 2.00 1.00 0.50 0.20 0.10 0.05
HA concentration (pglml)
Human Tracheal Tissue
Ser186Pro/AIa189ThrIGIu227AIa (CA04M2) mutant HA
3'mN Human Tracheal Tissue
* 6'SLN
S3'SLN-LN
I 6SLN-LN
I3'SLN-LN-LN
40.00 20.00 10.00
ti JI -'
5.00 2.00 1.00 0.50 0.20 0.10
HA concentration (p4g/ml)
Figure 4.15 Results from dose-dependent direct glycan-receptor binding assay (on the left) and human
tracheal tissue binding assay (on the right). LN: -+3Galp1-+4GlcNAcI1-+; 3'SLN and 6'SLN:
Neu5Aca2-+3 and Neu5Acax2->6 linked to LN respectively. Binding signals normalized to maximum
observed value. HA staining (green) of the apical surface (white arrow) is shown against propidium iodide
staining of cell nuclei (red). The images were captured at 25X magnification.
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Figure 4.16 Binding curves of mutant and wild-type HAs to 6'SLNLN. Binding curves of CA04, CA04M1,
CA04M2 and SC18 HAs to 6'SLN-LN. The experimental data (disconnected markers indicated using "Data")
is shown along with the theoretical binding curve (line indicated using "Model"). The Kd' of SC18 HA is
around 6pM (in the same range as that of CA04M2 HA) and hence is indicated using the same label.
CA/04 WT HA CA04mutl HA CA04mut2 HA
Figure 4.17 Human tracheal Goblet cell staining by wild-type and mutant HAs. The mutants
(CA04mutl and CA04mut2) show extensive staining of the apical surface and goblet cells in the
human tracheal epithelium. The images were captured at 63X magnification. The goblet cell staining
is marked with a star (*)
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Figure 4.18 Dose-dependent direct glycan array analysis of rgCA04/09 HA IIe219Lys mutant virus. The
binding profile of this virus is consistent with that of the recombinant CA04/09mutl HA shown in Figure
4.15.
4.3.3.3 Transmissibility of a reverse genetics wild-type and mutant CA04/09 virus in
ferrets.
The lle219Lys mutation (CA04/09mutl) lies in the mutational "hot-spot" of HA and
involves a single base pair change. Hence the probability of such a mutant to emerge is
quite high as compared to the triple mutant (CA04/09mut2). Since CA04/09mutl HA
showed increased binding affinity to human receptor, it was hypothesized that this
would have efficient air-borne transmissibility in case such a virus with this single
mutation were to evolve. Hence transmission studies were carried out in ferrets using
CA04/09 virus (generated by reverse genetics) harboring lle219Lys mutation in its HA.
For respiratory droplet transmission experiments, three ferrets were inoculated
intranasally (i.n.) with 106 PFU (plaque forming units) of virus. Approximately 24 hours
later, inoculated-contact animal pairs were established by placing a naive ferret in each
of three adjacent cages with perforated sidewalls, allowing exchange of respiratory
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droplets without direct or indirect contact [98]. Inoculated and contact animals were
monitored for clinical signs over a 16-day period and transmission was assessed by
titration of infectious virus in nasal washes and confirmed by the detection of virus
specific antibodies in convalescent sera. Ferrets inoculated with the CA04/09
(rgCA04/09) virus, created by reverse genetics, showed no substantial clinical signs and
only displayed transient weight loss during the first week of infection (Table 4.4). Ferrets
inoculated with rgCA04/09 virus shed high peak mean titers of infectious virus in nasal
washes as early as day 1 p.i. (106.1~6-9 PFU/ml), that were sustained at titers of 102.9
PFU/ml for 7 days p.i. The rgCA04/09 virus shedding showed similar kinetics to mutant
virus harboring the lle219->Lys amino acid mutation in HA, which was sustained for 5
days in ferrets at titers of 2104 PFU/ml. Consistent with the experimental transmission
data obtained with wild type CA04/09 H1N1 virus [98], rgCA04/09 virus did not spread
by respiratory droplet to every contact ferret and transmission was delayed by five days
post exposure in one of two contact ferrets (Figure 4.20). Seroconversion confirmed the
virus shedding data of 2/3 transmission events (Table 4.4). The reduced respiratory
droplet transmission suggests that additional virus adaptation in mammals may be
required to reach the high-transmissible phenotypes observed with seasonal H1N1 or
the 1918 pandemic virus [67, 98]. Mutation of the HA at amino acid position 219
(lle219->Lys) resulted in a virus (rgCA04/09 HA le219Lys) that efficiently transmitted via
respiratory droplets to all of the contact ferrets which shed virus by day 3 post-contact
(p.c.) (Figure 4.19). Despite the differences in transmissibility of the parental rgCA04/09
virus and the rgCA04/09 HA le219Lys mutant virus, similar virus replication kinetics, and
comparable levels of fever induction and weight loss in ferrets were observed with both
viruses (Table 4.4). This pattern of transmission suggests that a lysine at HA position 219
enhances transmission of the 2009 H1N1 virus through the air.
131
Table 4.4 Replication and transmission of CA04/09 Ile219->Lys HA mutant virus in ferrets
Inoculated Animals RD Contact Animalsa
Weight Weight
Loss Virus in Sero- Loss Virus in Sero-
Virus (%)C nasal washd Sneezinge conversionf (%)c nasal washd Sneezing" conversionf
rgCAO4/09 HA
ie29Lys b 13.1 3/3 (6.4) 1/3 3/3 (640-1280) 8.5 3/3 (6.9) 1/3 3/3 (640-1280)
rgCA04/09 8.0 3/3 (6.6) 2/3 3/3 (640-1280) 7.1 2/3 (5.5) 1/3 2/3 (80-160)
a RD, respiratory droplet
bThis experiment was performed using virus that was obtained from plaque purification and grown in MDCK cells.
c The percentage mean maximum weight loss observed during the first 10 days post-inoculation.
d Number of animals positive for infectious virus. Virus titers are expressed as mean logio peak PFU/mL
* Number of animals in which sneezing was observed during the first 10 days after inoculation (sneezing was infrequent for all
infected animals tested)
Hemagglutination inhibition (HI) assay was performed with homologous virus and turkey red blood cells. No. of positive animals
and HI range indicated.
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Figure 4.19 Respiratory droplet transmissibility of rgCA04/09 and rgCA04/09 HA Ile219Lys mutant virus.
Three ferrets were intranasally inoculated with 106 PFU of rgCA04/09 (A) or rgCA04/09 HA Ile219Lys
mutant virus (8). A naive ferret was placed in an adjoining cage to each inoculated ferret and viral
shedding in nasal washes was assessed every other day for the inoculated (left) and contact (right) ferrets.
Results from individual ferrets are presented. Limit of detection is 10 PFU/mL.
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4.4 Discussion and Significance of this study:
The emergence of the 2009 H1N1 virus created a global health concern given
that it was a novel strain of influenza A resulting from reassortment of gene segments
derived from avian, human and swine viruses. Although the 2009 H1N1 influenza A virus
was declared as a pandemic, the epidemiological studies [111, 112, 168] [combined with
our ferret transmission studies] showed that the virus had inefficient transmissibility as
compared to other pandemic and seasonal strains. Average secondary attack rates
amongst household contacts (comprising of 2-4 members) were ~13% in contrast to
pandemic and seasonal influenza A viruses, which is greater than 40% [112]. We have in
the current study, correlated this lower transmission efficiency of 2009 H1N1 virus to its
lower binding affinity to human receptors as compared to seasonal and pandemic
influenza A viruses. Currently the 2009 H1N1 virus circulates as a seasonal strain causing
dispersed infection worldwide. A representative 2009 H1N1 strain, A/California/04/09
(CA04/09), was chosen for trivalent seasonal flu vaccine in 2010.
In the study presented here the receptor-binding site (RBS) of CA04/09 HA was
also analyzed to gain insight into the amino acid interaction network that account for its
lower receptor binding affinity. Based on this analysis and after comparing with the RBS
of seasonal and pandemic influenza A HA, it was demonstrated that a single
(lle2194Lys or CA04/09mut2) amino acid change in the RBS of the HA, stabilizes the
ionic molecular interaction network involving residues 219, 227 and 186 in the RBS of
2009 HIN1 HA that in turn substantially increases its human receptor affinity in
comparison with wild-type HA. We also designed and tested another mutant form of
CA04/09 HA involving three mutations (Ser1864Pro / Ala189->Thr / Glu2274Ala) to
make this interaction network hydrophobic (similar to that in SC18 HA) and showed that
this mutant (CA04/09mut2) HA had substantially higher affinity than wild-type HA. The
findings presented here emphasize the importance of using a quantitative dose-
dependent binding assay with recombinant HA in order to correlate biochemical glycan-
binding affinity with molecular HA-glycan interactions. The increased human receptor
affinity of the mutant HA (CA04/09mutl) correlated with efficient airborne transmission
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of a virus that harbored this HA mutation in ferrets compared with inefficient
transmission of the wild-type rgCA04/09 virus. These results highlight two important
aspects of understanding evolution of 2009 H1N1 virus. First, the inter-amino acid
interaction network in the RBS plays a key role in governing human receptor binding
affinity of HA. Second, the ferret transmission results demonstrate that the quantitative
human receptor-binding affinity of HA is one of the key factors that govern human host
adaptation of the virus for efficient human-to-human transmission.
It has been estimated that around 59% of United States population has some
immunity to the 2009 H1N1 virus either due to pre-existing immunity, through
vaccination, or due to the infection with the pandemic virus [169]. Recent surveillance
data has shown that genetic variants of the 2009 H1N1 virus, carrying mutations in HA,
have already begun to dominate the later part of 2010 in Singapore, New Zealand and
Australia [170]. Although these mutations were found to be in the antigenic sites of HA,
the strains carrying these mutations were not antigenically different from CA04/09 (no
significant differences in hemagglutination inhibition titers using ferret anti-sera raised
to these viruses). Previous studies using another H1N1 strain (A/Puerto Rico/8/34) have
shown that in order to escape polyclonal neutralizing antibody challenge, this virus
acquires mutations in its HA that increased glycan receptor-binding affinity [171]. Given
that the 219 position is a part of the antigenic loop and that a single amino acid
mutation in 219 increases human receptor-binding affinity, this mutation may occur as a
part of antigenic drift in the currently circulating 2009 H1N1 strains. Moreover, the
lle219->Lys mutation requires a single nucleotide change, which also increases the
probability of such a mutation to occur. In summary, our study provides a systematic
approach to monitor the evolution of HA mutations in the currently circulating 2009
H1N1 viruses that would potentially result in strains with higher human receptor-
binding affinity and human-to-human transmissibility.
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Chapter 5. Decoding the Distribution of Glycan Receptors
for Human-Adapted Influenza A Viruses in Ferret
Respiratory Tract
Summary
Ferrets are widely used as animal models for studying influenza A viral
pathogenesis and transmissibility. Though ferrets exhibit similar clinical symptoms of
influenza A infection as that observed in humans, the viral tropism is different between
ferrets and humans. Human-adapted influenza A viruses primarily target the upper
respiratory tract in humans, while in ferrets, both upper and lower respiratory tract are
targets. Viral tropism is governed by the distribution of host sialylated glycan receptors,
which are recognized by influenza A virus hemagglutinin (HA). Although detailed
structural characterization of glycan receptors in human upper respiratory tract was
done previously, much less is known about the distribution of glycan receptors in the
ferret respiratory tract. In this study, a panel of plant lectins and recombinant HAs were
used to stain ferret trachea (which represents the upper respiratory tract) and lung hilar
region (which represents the lower respiratory tract. The sialylated glycan receptors
recognized by human-adapted HAs are predominantly distributed in submucosal gland
of lung hilar region as a part of O-linked glycans. Such a study has implications in
understanding influenza A viral pathogenesis in ferrets and also in employing ferrets as
animal models for developing therapeutic strategies against influenza.
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5.1 Introduction
An important determinant of influenza A virus pathogenesis is the tropism of
virus in terms of the specific tissues and cell types that it infects in different host
species. The host tissue or cell tropism of the virus was investigated previously using in
vitro pattern of viral adherence (PVA) to tissues from humans and other model animal
systems or staining of fixed ex vivo tissue sections with viruses [39]. These studies
demonstrated that human-adapted influenza viruses such as HIN1 and H3N2 subtypes
specifically bind to human upper respiratory tissues (tracheal/bronchial), whereas avian-
adapted viruses such as H5N1 bind to human deep-lung and gastrointestinal tract and
avian respiratory tissues [39, 40].
Ferrets are widely used as an animal model for understanding influenza A viral
pathogenesis and transmission. Unlike the mouse, human influenza A viruses infect the
ferret without the requirement for prior host adaptation. Ferrets exhibit clinical signs
(sneezing, fever and nasal discharge), pathogenesis, and immunity similar to humans
upon influenza A infection [100]. Furthermore, ferrets show respiratory droplet
transmission of viruses that have adapted to human host but not avian-adapted viruses
[67, 158]. However, the tissue and cellular tropism of human-adapted viruses is
different between ferrets and humans. In humans, viral binding and infection is
observed predominantly in the upper respiratory tract [167], whereas in ferrets, it is
observed in lower respiratory tract (specifically in the hilar regions and not as much in
the alveolar regions) [20, 172, 173].
One of the important factors governing the tissue or cellular tropism of the virus
is the specific binding of its surface glycoprotein hemagglutinin (or HA) to sialylated
glycan receptors (complex glycans terminated by sialic acid) on the host cell surface [2,
174]. Human-adapted influenza A viruses preferentially bind to a2-+6 sialylated glycan
receptors (or human receptors) wherein the terminal sialic acid is aX2->6-linked to the
penultimate galactose (Neu5Aca2->6Gal). On the other hand, avian-adapted viruses
bind preferentially to a2-->3 sialylated glycan receptors (or avian receptors) wherein the
terminal sialic acid is a2-+3-linked to the penultimate galactose (Neu5Aca2-+3Gal) [43,
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82, 175]. The distribution of sialylated glycan receptors in cells and tissues of different
species has been investigated by histological staining with plant lectins such as
Sambucus nigra agglutinin (SNA) and Maackia amurensis lectin (MAL) [49]. The glycan-
binding specificity of these plant lectins were defined traditionally based on their
binding to a specific terminal sialic acid linkage, for example, SNA bound to a12->6-
sialylated glycans and MAL bound to a2-+3-sialylated glycans.
The advancements in the chemical and chemoenzymatic synthesis of glycans
have led to development of microarray platforms comprising of hundreds of diverse
glycan structures and structural motifs displayed on various surfaces [81, 84]. Screening
the binding of plant lectins and HA on these glycan microarray platforms have permitted
the elaboration of their glycan binding specificities going beyond the terminal sugars
such as sialic acid linkage [84]. This expanded knowledge on glycan-binding specificities
improves the use of these lectins and/or HAs in tissue staining experiments to obtain
more detailed information on glycan structural motifs present on different tissues.
Given the importance of ferrets as widely used animal models for influenza infection, in
this study, the glycan structural motifs distributed in the trachea and hilar region
(primary sites of influenza A virus infection) of the ferret respiratory tract was
systematically characterized (Figure 5.1). This study has important implications in better
understanding the tropism of influenza A viruses in the established ferret animal model
that in turn provides a better understanding of the viral pathogenesis.
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Cranial
TRACHEA Figure 5.1 Regions of ferret respiratory tract
analyzed in the study. Ferret trachea can be
separated into a cranial region (upper trachea) andCauda--,
a caudal region (lower trachea). Hilar regionMAIN feresOsNdptdHoIt
represents the lower respiratory tract of ferret. The
respiratory system of ferrets is adapted to its
HILAR ZONE burrowing nature. The long trachea and the larger
diameter airways in ferrets result in a much lower
pulmonary and central airway resistance than other
lab animals
5.2 Lectins as tools to probe the distribution of glycan receptors in ferret
respiratory tract
The lectins used in this study and their glycan binding specificities are
summarized in Table 5.1. In order to characterize the a2--+6 sialylated glycan receptors,
SNA, and recombinant HAs of two prototypic human-adapted pandemic virus strains
from the 1918 H1N1 pandemic, A/South Carolina/1/1918 (or SC18), and from 1957-58
H2N2 pandemic, A/Albany/6/58 (or Alb58) were used in this study. MAL was used to
characterize c2-+3 sialylated glycan receptors. As observed earlier, human-adapted
viruses showed predominant binding to non-ciliated (including goblet cells) cells in the
upper respiratory tract [110]. Goblet cells are known to predominantly express 0-linked
glycans as a part of mucins [176, 177]. Jacalin, which has high specificity to Tn antigen
(GaINAc-0-Ser/Thr) predominantly found as part of 0-linked glycans in mucins, was
used to delineate the goblet cell regions in the tissue section. These lectins and
recombinant HAs were used individually or in a multiplexed fashion (co-staining) to stain
different regions of the ferret respiratory tract that are known to be infected by human-
adapted influenza A viruses. The extent of lectin staining of various cell types in the
different tissue sections was visually scored and is summarized in Table 5.2. Based on
this staining pattern, a detailed picture of the distribution of sialylated glycan structural
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motifs going beyond terminal sialic acid linkage was obtained. This glycan receptor
distribution observed in ferrets were further compared with that observed in the human
upper respiratory tract.
Table 5.1 Lectins and their glycan binding specificities
Lectins Glycan motifs recognized
SNA-I J iAsn inked
ia-O-linked
OR
a2-6
a-O-linked
MAL-Il -3 N- or O- linked
Jacalin LJ-O-Ser/Thr
SNA-I/Jacalin co-staining ia olinked
OR
ia 0 nked
SC18 HA (Hi) from the 1918 *-O-*0 N- or O-linked
pandemic 0 -linked
AIb58 HA (H2) from the 1958 N or linked
pandemic
Nomenclature for the cartoon representation of distinct glycan motifs recognized by the lectins used in
this study is as follows
: Galactose M: N-Acetyl Glucosamine *: N-Acetyl Neuraminic Acid 0: Mannose N-Acetyl
Galactosamine
5.2.1 Hematoxylin and Eosin staining of Ferret Respiratory Tract tissue sections
Paraffinized tissue sections (0.5u thickness) were stained with hematoxylin and
eosin to identify distinct cell types and compare it with that of human respiratory tract.
Tracheal tissue sections (cranial and caudal) and ferret lung hilar region were analyzed
(Figure 5.2). Both cililated and non-ciliated goblet cells (which store mucins that are
heavily 0-glycosylated) were identified in all the three regions. However, the regions
differed in the proportion of goblet cell distribution. The cranial region had very few
goblet cells (identified as unstained non-ciliated cells) as compared to the caudal region.
On the contrary, goblet cells formed a major fraction of the epithelium in the lung hilar
region. Human trachea has more goblet cells than ferret trachea.
A B C
IL W cka/glycocalyx
Goblet cell s
D
Apical Side of the tracheal
tissue epithelia
(mucus transport)"
Figure 5.2 H & E stained images of tissue sections. Ferret Cranial (A), Caudal (B), Hilar region (C) and
human Trachea (D) were stained with hematoxylin and eosin to identify major subcellular types and their
distribution. As seen from the images, the lung hilar region which represents the lower respiratory tract,
in ferret, seems to have more goblet cells than the ferret trachea (upper respiratory tract), a feature
distinct from human respiratory tract wherein abundant goblet cells are found in trachea (upper
respiratory tract) than in deep lung (lower respiratory tract). The apical surface is marked with a black
arrow.
5.2.2 0-linked glycans in ferret respiratory tract
Jacalin was used to probe the distribution of O-linked glycans in ferret
respiratory tract and in human trachea (Figure 5.3). All the goblet cells and submucosal
glands that express soluble and membrane-bound mucins showed staining with Jacalin
(Figure 5.3). All the goblet cells in the human trachea also showed intense staining with
Jacalin. As was shown in H & E staining of the tissue sections, the ferret trachea cranial
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region had goblet cells that were sparsely distributed as compared to the caudal region.
The ferret lung hilar region had abundant goblet cells as highlighted by jacalin staining.
Staining intensity in these cells was scored (Table 5.2).
Jacalin/PI
Ferret Cranial Ferret Caudal Ferret Lung hilum Human Trachea
25X 25X
Figure 5.3 0-linked glycan distribution in ferret respiratory tract. FITC-labeled Jacalin (green), a plant
lectin having specificity to Tn antigen was used to stain ferret cranial, caudal, lung hilar regions and
human trachea. Jacalin stained the goblet cells, and the submucosal glands in all the three regions of
ferret respiratory tract. In human trachea only the goblet cells were intensely stained with jacalin. The
nuclei were stained with PI (red). The images were captured at 25X magnification. The apical surface is
marked with a white arrow. The goblet cell staining is marked with a star (*).
5.2.3 0-linked a2-+-6 glycan receptor distribution in ferret respiratory tract
Fluorescently labeled SNA-1 was used to stain the tissue sections as mentioned
above (Figure 5.4) to probe the distribution of a2-6 glycans. Glycocalyx in the apical side
of both cranial and caudal regions and the submucosal gland in ferret trachea showed
significant staining with SNA-l. There was no staining of the goblet cells which suggests
minimal expression of a2->6 glycan motifs that are a part of mucin-type 0-linked
glycans typically found on goblet cells. In contrast to the ferret tracheal glycan receptor
distribution, ferret lung hilar region showed significant SNA-1 staining of goblet cells in
the bronchial epithelium and of submucosal glands. This is also in contrast to human
deep lung region that has predominant expression of a2-'3 glycans and not a2->6
glycans [48, 49] In order to probe distribution of a2->6 0-linked glycan in ferret
respiratory tract, a combination of Jacalin and SNA-1 was used to co-stain ferret trachea
and lung hilar region (Figure 5.5). There was minimal to no co-staining of goblet cells in
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ferret trachea (co-staining is identified by yellow staining pattern). There was significant
co-staining of submucosal glands in ferret trachea. On the contrary, in the ferret lung
hilar region, the submucosal glands and a fraction of goblets cells showed significant co-
staining. This staining pattern indicates predominant distribution of a2->6 sialylated
glycan motifs as a part of cell surface mucin-type 0-linked glycans in the hilar region as
compared to the tracheal region of the ferrets. The tracheal staining pattern in ferrets is
in contrast to human trachea wherein there is extensive co-staining of SNA-l and Jacalin
in goblet cell regions [48]. The staining pattern in human trachea indicates substantial
expression of a2->6 sialylated glycan motifs as a part of mucin-type 0-linked glycans in
the goblet cell regions [48].
SNA-l/PI
Ferret Cranial Ferret Caudal Ferret Lung hilum Human Trachea
25X 25X
Figure 5.4 a2-6 linked glycan distribution in ferret respiratory tract. FITC-labeled SNA-1 (green) was used
to stain ferret cranial, caudal, lung hilar region and human trachea. As seen from the images, SNA-1 did
not stain any of the goblet cells (in comparison to human trachea) in the ferret trachea although some of
the goblet cells in the lung hilar region were stained by SNA-l. Submucosal glands and glycocalyx in both
the trachea and lung hilar region showed significant staining with SNA-1. The nuclei were stained with PI
(red). The images were captured at 25X magnification. Goblet cells staining is marked with a star (*). The
apical surface is marked with a white arrow.
5.2.4 a2-3 glycan receptor distribution in ferret respiratory tract
Maackia amurensis agglutinin (MAL-II) was used to probe a2-3 glycan receptor
distribution in ferret respiratory tract (Figure 5.6). There was no staining of the ciliated
or non-ciliated cells in the tracheal cranial epithelium. Although there was staining of
the underlying connective tissue. In the caudal region, there were a very small
proportion of goblet cells (~1%) that showed faint staining with MAL 11, indicating some
expression of O-linked c2-3 glycans. The underlying connective tissue was also
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extensively stained with MAL-II. In contrast to the ferret trachea, there is no expression
of a2-3 linked glycans in the ferret lung hilar as indicated by a complete lack of staining
of both ciliated and non-ciliated cells in the epithelium and in the underlying connective
tissue and submucosal glands (Figure 5.6). The staining intensity was scored as shown in
Table 5.2.
Jacalin/SNA-1
Ferret Cranial Ferret Caudal Ferret Lun hilum Human Tr
Figure 5.5 O-linked a2-6 glycan distribution in ferret respiratory tract. Co-staining with FITC-labeled
Jacalin (green) and SNA-1 tagged to a 546nm fluorophore (red) was done to probe O-linked a2-6 glycans in
ferret cranial, caudal, lung hilar regions and in human trachea. Co-staining is seen as yellow color due to
the overlap of green (Jacalin) and red (SNA) fluorophores. As seen from the images, although some co-
staining was seen in the goblet cells in ferret lung hilar region, significant co-staining was seen in the
submucosal glands. Submucosal gland co-staining was also seen in ferret trachea. This co-staining pattern
is in contrast to human trachea wherein significant co-staining is seen in the goblet cells rather than in
submucosal glands. The nuclei were stained with P (red). The regions that show co-staining are marked
with a star (*). The apical surface is marked with a white arrow.
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MAL-li/PI (25X magnification)
Ferret Cranial Ferret Caudal Ferret Lung hilum
Figure 5.6 a2-3 linked glycan distribution in ferret respiratory tract. MAL-Il lectin (green) was used to
stain ferret cranial, caudal and lung hilar regions. As seen from the images, MAL-Il stained the submucosal
glands, the underlying mucosa and some goblet cells (in the caudal region marked with broken arrow) in
ferret trachea. There was no staining of the lung hilar region indicating an absence of a2-3 sialylated
glycans. The nuclei were stained with P1 (red). The images were captured at 25X magnification. The apical
surface is marked with a white arrow.
5.2.5 Tropism of human influenza A HA and distribution of their glycan receptors in
ferret respiratory tract
It has been shown that human-adapted HAs from the pandemic viruses such as
SC18 and Alb58 bind with high affinity to glycans having Neu5Aca2--6-linked to longer
oligosaccharide motifs (> trisaccharide) such as polylactosamine terminating in ct2->6-
linked sialic acid (6'SLN-LN) [95, 110]. Moreover, both these viruses from the 1918 and
the 1958 pandemic have been shown to transmit efficiently via respiratory droplet in
ferrets [67, 95]. SC18 HA shows highly specific binding to 6'SLN-LN and minimal binding
to a2->3 sialylated glycans. On the other hand, Alb58 HA has a broader binding
specificity to a2-+6 sialylated glycans including both short a2->6 oligosaccharide such
as 6'SLN and the longer 6'SLN-LN. In addition Alb58 HA also shows observable binding to
a2-+3 sialylated glycans albeit at a much lower affinity than that to a2->6 sialylated
glycans [95]. Recombinant HAs have been used to stain human tracheal and alveolar
tissue sections to probe the distribution of glycan receptors for human-adapted
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influenza A viruses [48, 95, 98]. Therefore using these recombinant HAs to stain the
ferret tracheal regions provides additional details on distribution of short and long
a2--+6 oligosaccharide motifs.
SC18 HA showed predominant staining of submucosal glands in both ferret
trachea and deep lung (Figure 5.8). It was interesting to note that SC18 HA did not stain
goblet cells (which were stained by SNA-1) in lung hilar region. This indicates that a2-+6
sialylated glycans comprising of longer oligosaccharide motifs are more extensively
distributed in the sub-mucosal glands in comparison with the goblet cells in the hilar
region. On the other hand, due to a broader glycan binding specificity of Alb58 HA, it
stained the glycocalyx and the underlying submucosal glands in ferret trachea (Figure
5.7). Alb58 HA also stained the goblet cells (similar to SNA-1) and the submucosal glands
in the lung hilar region.
Furthermore, a characteristic staining pattern of human-adapted HAs such as
SC18 and Alb58 is substantial binding to goblet cell regions of human tracheal tissue [95,
110] (Figure 5.7). Hence predominant binding to the a2-6 glycan motifs is seen in the
context of O-linked glycans. In order to correlate this in ferret respiratory tract, ferret
tracheal and lung hilar tissue sections were co-stained with a representative HA (Alb58)
and jacalin (Figure 5.9). Predominant co-staining was seen in the submucosal glands in
ferret trachea (Figure 5.11) and lung hilum. Some co-staining was seen in the goblet
cells in the tissue sections analyzed. This could also be due to the binding of 0-linked
c2-3 sialylated glycan motifs in the goblet cells by Alb58 HA. Further staining with MAL-
Il lectin also indicated some expression of a2-3 O-linked glycans (Figure 5.6). Hence it is
the co-staining pattern indicates a predominant distribution of O-linked a2-6 glycans
(recognized by human influenza HAs) in submucosal glands of ferret respiratory tract.
The restricted staining of submucosal glands by SC18 HA further corroborates this.
In order to verify the sialic acid binding specificity of lectins used in this study,
the tissue sections were treated with Sialidase A prior to staining with the lectins.
Sialidase A is an endonuclease that broadly cleaves terminal sialic acids (both a2-33 and
a2-+6). All the plant lectins and HAs used in this study showed a complete loss of
147
staining upon Sialidase A treatment of ferret tissue sections (Figure 5.10). However, in
case of human trachea, the goblet cell staining by SNA-1 is still retained upon Sialidase A
treatment although there is a complete loss of SNA-l staining of the glycocalyx and also
HA staining of both goblet cell region and glycocalyx on the apical surface. SNA-1 has a
broader a2--6 sialylated glycan-binding specificity in that it binds to both
Neu5Acc2->6Gal(or GalNAc)@1-+ terminal motif in N- and O-linked glycans and
Neu5Aca2->6Gal NAca1-+O-Ser/Thr (sialyl-Tn-antigen) motif in O-linked glycans. On the
other hand human-adapted HAs recognize at least a trisaccharide
Neu5Aca2->6Galp1->4GcNAc$1-+ motif. This could perhaps explain the differences in
loss of staining to human tracheal tissue by SNA-1 and HAs after sialidase treatment.
Alb58/PI(25X magnification)
Ferret Caudal Ferret Lung Hilum Human Trachea
Figure 5.7 Glycan receptor distribution for recombinant Alb58 (H2) HA. Recombinant Alb58 HA
(expressed in insect cells) was used to stain ferret trachea (shown is the caudal region), lung hilar and
human tracheal regions. As seen from the images, Alb58 HA stained the submucosal glands, the
underlying mucosa and some goblet cells in the caudal. This staining pattern is contrast to that in human
trachea wherein all the goblet cells, submucosal glands and the glycocalyx are stained extensively with
Alb58 HA. The nuclei were stained with PI (red). The significant goblet cell staining of Alb58 HA of human
trachea as compared to ferret respiratory tract is in accordance with predominant expression of 0-linked
a2-6 sialic acid in human tracheal goblet cells as compared to that in ferret respiratory tract (Figure 5.4).
The images were captured at 25X magnification. The apical surface is marked with a white arrow.
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Ferret Trachea
SC18/PI(25X magnification)
Ferret Lung Hilum
Figure 5.8 Glycan receptor distribution for recombinant SC18 (Hi) HA. Recombinant SC18 HA (expressed
in insect cells) was used to stain ferret trachea, lung hilar region and human trachea. As seen from the
images, SC18 HA stained only the submucosal glands in the ferret lung hilar region. This restricted binding
pattern of SC18 HA can be attributed to its stringent binding specificity to long a2-6 linked (6'SLNLN)
glycans. This restricted staining in human trachea is seen only in the goblet cells and not in submucosal
gland. The nuclei were stained with PI (red). The goblet cell and submucosal gland staining is marked with
a star (*). The images were captured in 25X magnification. The apical surface is marked with a white
arrow.
Jacalin/Alb58(25X magnification)
Ferret Cranial Ferret Caudal Ferret Lung hilum Human Trachea
Figure 5.9 Co-staining of recombinant Alb58 (H2) HA with Jacalin. Ferret cranial (A) caudal (B) lung hilar
region (C) were co-stained with 10tg/ml of Jacalin (FITC labeled) and 20tg/ml of recombinant Alb58 HA.
The intensity of co-staining (yellow) was scored as shown in the table above. As seen from the images, co-
staining was predominantly seen in the submucosal glands of ferret trachea and lung hilar region (A, B
and C). Some co-staining was also seen in the goblet cells of trachea and lung hilar region. This staining
pattern is in contrast to human trachea (D) wherein co-staining is predominantly seen in goblet cells. The
goblet cell and submucosal gland staining is marked with a star (*). The images were captured in 25X
magnification. The apical surface is marked with a white arrow.
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A (Ferret Lung Hilar region)
SNA/PI AIb58/PI cria/Pi
B Sialidase A + SNA-I/PI (human trachea)
Figure 5.10 Sialic acid binding specificity of lectins. Sialidase A from Arthrobacter ureafaciens was used to
cleave all the sialic acids from the relevant tissue sections (shown is that for the ferret lung hilar region)
prior to staining with (A) SNA-1, AlbS8 HA and SC18 HA (green). There was a complete loss of staining
upon Sialidase A treatment. This was compared with the staining pattern of (B) SNA-1 of human trachea,
where the goblet cell staining was retained upon Sialidase A treatment. There was a complete loss of
SC18 and Alb58 HA staining of human trachea upon Sialidase A treatment (data not shown). The goblet
cell staining in human trachea (after Sialidase A treatment) is marked with a star (*). The images were
captured in 25X magnification. The apical surface is marked with a white arrow.
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Jacalin/Alb58 HA
Figure 5.11 Submucosal gland co-staining with Jacalin and Alb58 HA. Submucosal glands in the ferret
trachea showed extensive co-staining with Jacalin and Alb58 HA. The co-staining is indicated by a yellow
staining pattern. The submucosal glands are marked by white dotted circle. The images were captured in
25X magnification. The apical surface is marked with a white arrow.
5.3 Discussion and significance of this study:
Ferrets are widely used as an animal model for understanding influenza A viral
pathogenesis and transmission. Although ferrets exhibit similar clinical manifestation as
that of humans upon influenza A infection, there seems to be a difference in viral
tropism between ferrets and humans. Upper respiratory tract is the primary site of
influenza A infection in humans. Apart from upper respiratory tract, involvement of
lower respiratory tract (lung hilar region) is also reported in ferrets. Viral tropism
impinges on the viral pathogenesis and hence understanding former is crucial. Viral
tropism is determined by distribution of influenza A glycan receptors, which are
recognized by the viral hemagglutinin (HA) to gain entry into the epithelial barrier. In
this study a panel of plant lectins and recombinant HAs were used to probe the
distribution of glycan receptors for influenza A HA (Figure 5.12). As can be seen from
this analysis, there are differences in the glycan receptor distribution between human
and ferret respiratory tract. SNA-1 lectin staining showed that a2-6 glycans are
predominantly found in the glycocalyx and submucosal glands in both ferret trachea and
lung hilar region. Some of the goblet cells in the lung hilar region also showed staining
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with SNA-1. Of these the long a2-6 glycans, which are the main receptors for human-
adapted influenza A HA are predominantly found in the submucosal glands in both
ferret trachea and lung hilar region (Figure 5.9). This correlates with earlier reports of
viral antigens being predominantly found in the submucosal glands in ferret trachea and
lung hilar region upon infection with human influenza A virus [178]. It is interesting to
note that though glycan receptors for human influenza A viruses are differentially
distributed in humans and ferret, they are predominantly expressed in the context of 0-
linked glycans in either goblet cells (in humans) or in submucosal glands (in ferrets).
Binding to these mucin secreting cells could potentially might promote respiratory
droplet mediated transmission of the virus and hence contribute to viral pathogenesis.
This further demands for studies evaluating the role of mucins in influenza A infection.
The recent findings on increased expression of this Tn antigen (in the context of mucin
secreting cells) upon virus infection due to goblet cell and/or acinar gland neoplasia was
shown [179]. This highlights yet another aspect of influenza A virus infection, though its
exact role in viral pathogenesis has to be elucidated.
MAL-Il lectin staining of ferret tissues showed that that there are no a2-3
sialylated glycans found in the ferret lung hilar region. This is in contrast to humans,
wherein a2-3 glycans are predominantly expressed in deep lung region. This warrants
the need to assess ferret as a model system especially to study avian influenza A virus
(e.g. H5N1) pathogenesis. This is because, the viral tropism (determined by glycan
receptor distribution), impinges on the route of transmission and pathogenesis. Hence
varying sites of infection (in humans and ferrets), can make it challenging to correlate
viral pathogenesis of avian influenza A viruses in ferrets to that in humans.
In summary, using a panel of lectins, the glycan receptor distribution for
influenza A HA in ferret respiratory tract was systematically characterized (Figure 5.9).
Also the staining intensity of lectins in specific cell types was visually scored (Table 5.2).
Such an approach is needed to understand viral pathogenesis in ferrets in order to truly
correlate it with that in humans. Moreover, it is important to have a thorough
understanding of glycan receptor distribution for improving anti-influenza drug delivery
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strategies for especially those drugs, which target glycan receptors such as DAS181, a
sialidase fusion protein that cleaves off the sialic acid and hence prevents viral entry
[180].
Table 5.2 Visual scoring of lectin staining intensity of various cell types in ferret upper (trachea) and
lower (lung hilar region) tract
Trachea Lung Hilar
Lectins used
Glycocalyx Goblet Submucosal Glycocalyx Goblet Submucosal
cells glands cells glands
SNA I ++ ++ + + ++
MAL 1i +/ ++
Jacalin ++ ++ ++ ++ ++
SNA/Jacalin ++ + ++
co staining
A/Albany/6/58 ++ ++ + ++
(Alb58) HA
A/South ++ ++
Carolina/1/18
(SC18) HA
Alb58 HA/ + ++
Jacalin co
staining
No staining
+ Moderate staining
+/- Only few cells stained (<10%)
++ Extensive staining
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N-linked
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Figure 5.12 Mapping of glycan receptor distribution in ferret respiratory tract. The figure shown above
highlights the glycan receptor distribution in ferret trachea (A) and in lung hilar region (B). Note that
predominant at2-6 glycan receptors recognized by human influenza A viruses are found in the submucosal
glands of trachea and lung hilum. Further, unlike human lower respiratory tract, there is minimal to no
at2-3 sialylated glycan receptor expression in the lung hilar region of ferret. Except for differences in the
number of goblet cells in ferret cranial and caudal region, there were no significant differences in the
glycan receptor expression. The apical surface is marked with a black arrow.
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Chapter 6. Targeting Glycan Receptors of Influenza A
virus: A Viable Alternative Strategy
Summary
One of the major challenges with the currently available anti-viral therapeutics is the
evolution of drug resistant strains. Also the vaccine against flu has to be updated
annually due to emergence of new strains of viruses by antigenic drift. In essence any
antiviral strategy targeting the viral components can lead to evolution of drug resistant
strains. This chapter reports our strategy of targeting the host glycan receptors instead
of the viral components. Two specific plant lectins; SNA-l and PSL, which have binding
specificity to a2-6 sialylated glycans (6'SLN and 6'SLNLN), which are predominantly
recognized by human influenza A viruses on the host cell surface, were chosen to target
glycan receptors. Unlike SNA-l, PSL was easily expressed in E.coli based expression
system and hence PSL was chosen for the study. The glycan-binding domain of PSL lectin
(designated as rPSL-N) was recombinantly expressed. This domain by itself displayed
stability and retained the glycan binding specificity as that of the native lectin which was
validated using a combination of homology-based structural modeling of rPSL-N -
trisaccharide motif complex and a dose-dependent glycan array binding assay. While
native PSL was highly cytotoxic, rPSL-N was not cytotoxic even at the highest
concentration tested. rPSL-N was able to effectively inhibit infection of MDCK cells by
representative H3N2 and H1N1 influenza A viruses. Here our study provides an alternate
viable strategy to combat influenza infection using rPSL-N that can block viral infection
by its high affinity binding to the sialylated glycan receptors of human-adapted influenza
A virus HA.
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6.1 Introduction
Annually the seasonal influenza epidemic results in about three to five million cases of
severe illness [181]. Illnesses result in hospitalizations and deaths mainly among high-
risk groups (the very young, elderly or chronically ill). The current anti-viral strategies
against influenza A virus includes an annual formulation of influenza A vaccine and other
small molecule anti-viral drugs. The following section describes these anti-viral
strategies in detail.
6.1.1 Vaccines to prevent influenza A infection
Vaccines against influenza have been around for 50 years. The results of
challenge studies indicated that immunity is induced by the host responses to the virus
hemagglutinin (HA) and to neuraminidase (NA). Antibody against HA is the most
important component in the protection against influenza viruses. Due to a lower density
of NA in comparison to HA, the host antibody response is more skewed towards HA
[182]. The annual trivalent influenza A vaccine comprises of a combination of A/H3N2,
A/H1N1 (seasonal) and influenza B viruses. Though vaccination has been successful in
reducing human cost of influenza virus infection, antigenic drift and complete genetic
reassortments periodically result in new viral strains, which require vaccines to be
constantly updated.
6.1.2 Therapeutic strategies to combat influenza A infection
There are currently two classes of therapeutic agents against influenza A viruses: the M2
channel blockers (admantanes) and neuraminidase inhibitors or NAls (oseltamivir and
zanamivir) [7]. Both of these are described in detail in the following section.
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6.1.2.1 M2 channel blockers (admantanes)
Amantidine and rimantidine are M2 channel blockers that are only effective
against influenza A, because only A strain of viruses have M2 ion channel proteins. Both
these adamantane class of drugs blocks M2 channel protein that is implicated in viral
uncoating.
Amantidine has been shown to have both therapeutic and prophylactic effects.
The compound confers 70% protection against influenza A when given prophylactically.
Amantidine can occasionally induce mild neurological symptoms such as insomnia, loss
of concentration and mental disorientation. The therapeutic and prophylactic activity of
amantidine is now generally accepted and numerous analogues of this compound have
been prepared. Prophylaxis with 200mg of amantidine per day for 5 to 6 weeks or for
the duration of the influenza A outbreak is not recommended for all persons. However,
elderly persons with chronic underlying disease, institutionalized persons, staff and
patients in hospital, close contacts of an index case, and patients who cannot receive
influenza A vaccine due to sensitivity to egg protein may benefit from prophylaxis.
Amantidine can also be used for therapy of uncomplicated influenza A infections. The
recommended dose is 200mg for 5 days.
Rimantadine may be used in place of amantadine for prophylaxis and the
treatment of uncomplicated influenza A infections. Rimantadine is similar to amantidine
but has fewer side effects. It is approved by the FDA for the treatment and prophylaxis
of influenza A infection in persons one year or older. It should be used for
uncomplicated influenza A infections only since it is thought to be less effective than
amantidine. Amantadine and rimantadine resistant viruses are readily generated in the
laboratory. Resistance has been linked to changes in the M2 protein. To date, the
emergence of resistant influenza A has been documented primarily in young children
undergoing therapy with rimantadine. The resistant viruses had been transmitted and
caused influenza. The universal susceptibility of all types of naturally occurring influenza
A isolated from man and animals suggests that resistance will be found only in
individuals treated with the drug.
157
6.1.2.2 Neuraminidase inhibitors (NAI)
The rational approach to drug design has led to the design of several potent
inhibitors of influenza neuraminidase. Zanamivir was the first neuraminidase inhibitor
available for clinical use and is effective against both influenza A and B. Because of its
poor bioavailability, zanamivir must be administered by inhalation. Zanamivir had been
shown to be effective and devoid of significant side effects in clinical trials. It is now
approved by the FDA for use as treatment for influenza A and B in persons 12 years or
older but not for prophylaxis.
Oseltamivir is another neuraminidase inhibitor but unlike zanamivir, it can be
given orally. Like zanamivir, it had been shown to be effective and devoid of significant
side effects in clinical trials. It is approved by the FDA for use as treatment for influenza
A and B in persons 18 years or older. It is also approved for prophylaxis in persons 13
years or older. Lack of side effects with neuraminidase inhibitors makes them
particularly an attractive drug against influenza.
Apart from the aforementioned therapeutic agents, there are drugs designed
against other viral components such as ribavirin, which inhibits viral RNA polymerase.
Ribavirin was found to have inherent cytotoxicity and hence is not used currently [183].
With the recent identification of host factors necessary for viral replication [184],
research is underway to target some of these host factors such as receptor tyrosine
kinase. Drug targets against these demand more analysis to evaluate their specificity
and hence cytotoxicity. Moreover any drug that targets viral components can potentially
lead to an emergence of drug resistant viral strains. Therefore the search continues for
effective broad-spectrum therapeutic agents for influenza A virus. Targeting the glycan
receptors of influenza A virus instead presents an attractive alternate therapeutic
strategy to counter viral infection. Moreover, such a strategy is less likely to induce drug
resistance given that a change in specificity to the target glycan receptors would alter
host tissue tropism of the virus or a loss of replicative efficiency of the virus in the
human upper respiratory tract.
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6.1.3 Plant lectins as tools to target host glycan receptor
As mentioned in chapter 1 of this thesis, the viral coat glycoprotein,
hemagglutinin (HA), is a lectin, which recognizes specific sialylated glycan receptors on
the surface of host cell and mediates attachment, viral entry and membrane fusion
events [14, 54]. Specifically the HA of human-adapted influenza A viruses recognize
a2->6 sialylated glycan receptors, i.e. glycans terminated by N-acetyl neuraminic acid
(Neu5Ac) linked a2->6 to galactose (Neu5Aca2-+3Gal), expressed on the human upper
respiratory epithelia [41]. On the other hand HA of avian influenza A viruses recognize
ax2->3 sialylated glycan receptors (Neu5Aca2->3Gal) expressed both on the gut and
respiratory epithelia of birds [40, 49].
Plant lectins that recognize human receptors for influenza A viruses. The data
mining method described by Srinivasan et al (2008) was used to determine binding
classifiers or rules in terms of glycan structural motifs that govern binding of each lectin
to the glycan array. Motifs that have a detrimental effect on binding are shown in red
dotted line with red X. Calsepa, Morniga and SalT show binding to a2->6 sialylated
glycans in the context of the trimannosyl-core and hence they also bind to several non-
sialylated N-linked glycans. On the other hand PSL and SNA-l bind exclusively to a2->6
sialylated glycans. While PSL recognition requires a trisaccharide motif (common feature
of glycan motifs recognized by human-adapted HA), SNA-l also recognizes
Neu5Aca2->6GalNAca1-+ motif in O-linked glycans. The glycan array data can be
accessed by inserting the CFG ID (shown in first column) at the end of the following URL:
http://www.functionaglycomics.org/glycomics/HServlet?operation=view&sideMenu=n
o&psld=. Based on this analysis, we hypothesized that the glycan-binding domain of
SNA-l and PSL could potentially be used to target host glycan receptors to combat
influenza A infection.
6.2 Sambucus nigra agglutinin I or SNA-I to target host glycan receptor
In 1984 SNA-l was isolated from the elder (Sambucus nigra) bark by affinity
chromatography on fetuin-agarose [185, 186]. The lectin was found to be rich in
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asparagine/aspartic acid, glutamine/glutamic acid, valine and leucine. SNA-l belongs to
the family of type 11 ribosome-inactivating protein (RIP) containing an A-chain or RNA N-
glycosylase domain which binds to one specific adenosine of the large ribosomal RNA
and catalyzes the endohydrolysis of the N-glycosidic bond, whereas the B-chain
comprises a typical glycan binding or a lectin domain [187].
Table 6.1 Rationale for Selection of SNA-I and PSL to target the glycan receptors of Influenza A virus
Protein Binding Classifiers
Calystedia sepium lectin (Calsepa)
CFG ID: primscreen 3428
Morus nigra lectin (Morniga) A ay N-isnked ,ncuding
CFG ID: primscreen 3431 those containing
Orystata satvia lectin (Sail m
CFG ID: primscreen_3424
Polyporus squamosus lectin (PSL)
CFG ID: primscreen_2825 O-O-0---
,O41nked--
nte-rnal GaNAc
Sambucus nigra agglutinin (SNA-1)
CFG ID: primscreen 2794 +
O-hinked
Internal GIcNAc
A/South Carolina/1/18 HA (Human HINI)
CFG ID: primscreenPA v1 262 12072005
AlMoscow/10/99 HA (Human H3N2)
CFG ID.primscreen PA v1 260 12072005
Galactose M: N-Acetyl Glucosamine *: N-Acetyl Neuraminic Acid 0: Mannose N-Acetyl
Galactosamine
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6.2.1 Molecular structure of SNA-l
SNA-l specifically binds to the disaccharide motif Neu5Aca2-6Gal/GaNAc [47,
186, 188]. SDS-PAGE of reduced and iodoacetylated SNA-I has demonstrated that it is
composed of two different polypeptides, namely an A chain of 33kDa and a B chain of
35kDa (Figure 6.1A). Molecular cloning and sequence analysis demonstrated that the B
chains consist of six randomly arrayed subdomains (1c, 1p, ly, 2C, 2P, 2y) of
approximately 40 amino acid residues. The domain 1 and 2 adopt a characteristic $-
trefoil fold reported for carbohydrate binding domains of toxins such as ricin which is a
type 2 ribosome inactivating protein (RIP) [186, 188]. Only subdomains 1c, and 2y
possess a functional carbohydrate-binding site where la is a low affinity glycan binding
site whereas 2y is a high affinity glycan binding site (Figure 6.1B) [189].
A B
ProSNAI M Wj L_0j 9
LS High affinitA chain LS8 chain  h onffnt
(pD of 2p glycan-binding site
(OklDa) 1-3-3 brmig faneinwt beteet teeW G c--. a m IQ 2a
(A-ss-B- -B-ss-AjLow affinity
glycan-binding site Lnke
High affinity
O (i2OkDa) N~a se-c.i t isot of two [A..i-B-.3S-i-
Low affinity
Mature SNAI [A-s-s-B-s-s-B-s"s.AJ2
4D 0(240koa)
Figure 6.1 (A) Molecular structure of SNA-l Schematic representation of molecular structure of the
mature lectin. Shown are the key steps involved in the generation of mature lectin from SNA-l precursor.
(B) Schematic representation of the f-trefoil structure of the B chain (generated by homology modeling).
Shown are the high affinity and a low affinity glycan binding sites. Shown in the top is the cartoon
representation of the molecular model of the B chain shown below.
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6.2.2 Homology modeling of SNA-l
Given that there are no X-ray crystal structures of SNA-l, homology based
structural model of its lectin domain was generated. The co-crystal structure of SNA-Il
(the lectin domain or B chain) in complex with lactose (PDB ID: 3CA4) [190] was chosen
as the template. The homology-based structural model was obtained using the SWISS-
MODEL web-based homology modeling tools (http://swissmodel.expasy.org/) (Figure
6.1B). The use of co-crystal structures as templates facilitated the identification of the
glycan-binding sites and docking of a2-6 oligosaccharide motifs into the putative glycan
binding sites helped in analyzing the molecular contacts between the lectin and the
glycan motif.
Based on the homology modeling, details on various aspects of structural
features of the lectin domain were obtained. First, the lectin domain of SNA-I adopts a
ricin-B chain like fold comprising of two p-trefoil scaffolds connected by a linker. Second,
each scaffold has three antiparallel 0 sheets (1a, 10, 1y, 2a, 20, 2y) and each sheet has 4
1-strands (A, B, C and D) connected by loop regions (Figure 6.1B). The co-crystal
structure of lectin domain of SNA-Il with lactose shows the presence of two glycan
binding sites, one in the la sheet and the other in the 2y sheet. Both the binding sites
are constituted by two antiparallel 0 strands and the loop regions between them, -1CC-
loop-laD-loop- and 2yC-loop-2yD-loop-. The analogous regions in the homology model
of the lectin domain of SNA-1 (constructed based on SNA-II) would contain the putative
glycan binding sites. Indeed, site-directed mutagenesis studies with SNA-1 have indicated
the presence of a high affinity binding site in the 2y and a relatively lower affinity
binding site in the la sheet [1891.
6.2.3 Characterizing the glycan binding properties of native SNA-l
As mentioned earlier, SNA-1 has specificity to a2-6 sialylated glycans. Not much is
known about its specificity beyond its linkage specificity. Hence even before we
designed engineered constructs based on SNA-1, it was imperative to understand its
glycan binding specificity beyond its linkage specificity. Hence SNA-1 was analyzed on the
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glycan array platform to quantitatively and qualitatively characterize its binding affinity
and binding specificity. Further, SNA-l (labeled with fluorescein isothiocyanate
designated as SNA-FITC) was used to stain human tracheal tissue sections to understand
its glycan binding specificity in the context of N- and 0- linked glycans.
A dose-dependent glycan array analysis was performed with SNA-FITC. The
analysis showed a highly specific binding of SNA-1 to a2-6 glycans (6'SLN and 6'SLNLN).
No binding to a2-3 glycans was noticed (Figure 6.2). The binding affinity to the a2-6
glycans was calculated by fitting in the Hill's equation and was found to be in the sub-
picomolar range. Staining of human tracheal tissue section revealed that SNA-1 stained
a2-6 glycans in the context of both N- and 0- linked glycans (Figure 6.3A). SNA-1 stained
the apical surface or the glycocalyx (that has a predominant expression of N-linked
glycans) and stained the non-ciliated goblet cells (which have a predominant expression
of mucin-like 0-linked glycans). Staining of 0-linked glycans was further validated by co-
staining SNA-1 with Jacalin (a lectin that binds to Tn antigen predominantly found in 0-
linked glycans) (Figure 6.3A). Sialidase A pre-treatment of human tracheal tissues prior
to SNA I staining caused loss of binding to the apical surface of the ciliated epithelial
cells (predominantly express N-linked glycans) but not to the goblet cells (Figure 6.3B).
This pattern is consistent with the ability of SNA I to bind to the additional disaccharide
.Neu5Aca2->6GalNAca1-+ motif in 0-linked glycans.
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* 6'SLN
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Figure 6.2 Glycan binding specificity of SNA-l. Glycan binding specificity of SNA-1 was characterized by
performing dose-dependent glycan array analysis. SNA-1 has highly specific binding to at2-6 glycan.
Binding affinity of SNA-l to 6'SLN was calculated by linearized Hill's plot. The binding affinity was in the
sub-picomolar range for both 6'SLN and 6'SLNLN.
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Figure 6.3 Cellular tropism of SNA-l. FITC labeled SNA-1 (green) was used to stain paraffinized human
tracheal tissue sections. SNA-1 showed specific binding to the apical surface of the tracheal epithelium.
Both the glycocalyx and the non-ciliated goblet cells were stained by SNA-1 (A). Goblet cell staining by
SNA-1 was confirmed by co-staining tissue sections with both SNA-1 and Jacalin (a lectin that binds to
mucin 0-linked glycans in goblet cells). Co-staining is seen as yellow staining of the goblet cells (A).
Sialidase A (from Arthrobacter ureafaciens) treatment of human tracheal tissue prior to staining with SNA
leads to loss of apical surface staining but some goblet cell staining is retained. Nuclei was counterstained
with propidium iodide (red). The images were captured at 25X magnification. The goblet cell staining is
marked with a star (*). The apical surface is marked with a white arrow.
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6.2.4 Engineering SNA-I to target glycan receptors
The effect of the observed spatial distribution of the two glycan binding sites across
two p-trefoil scaffolds on the glycan binding affinity of SNA-1 is unclear. Therefore
multiple constructs with different spatial arrangements of the glycan binding sites were
constructed (Figure 6.4) and evaluated for their glycan binding properties to determine
the best candidates for targeting the HA-glycan interactions (Figure 6.5). The basis for
generation of these constructs was to generate the smallest possible protein scaffold
that can retain the glycan binding properties viz., specificity and affinity as that of the
native SNA-l.
1. The 2a-26-2y C-terminal single p-trefoil scaffold that comprises of the
putative high affinity glycan-binding site (~121 amino acids)
11. Construct that has only the 2y antiparallel p-sheet (42 amino acids) - it is
anticipated that this single antiparallel s sheet would likely self-associate into
a dimer or trimer given that it is derived from the p-trefoil scaffold
comprising of a hydrophobic core.
Strategy 1: 121aa sequence of SNA- B-chain
2aB loop 2aC 2aD 20A 20B 20C 2SD
TFIV GYKQM CLREN GENN FVWLE DCVLNRVQQ EWAL YGDG TIRV NSNRSL CVTS EDHEP DLI VILK
2yA 2yB 2 C 2 D 2aA
CEGSGNQ RWVF NTNG TISN PNAKL 4VMRDVSLMK I11 RPBGMPMQ QWITT
Strategy 2: 42aa sequence of SNA-I B chain
2yA . . . 2yB 2 C 2 D
RWVF NTNG TISN PNAKL 4 ERDVSLMK I RP PMQ
Figure 6.4 Strategies adopted for engineering SNA-l B chain. In strategy 1 (top), the entire P-trefoil
scaffold comprising the high affinity glycan binding site was retained. In strategy 2 (bottom), only the 2y
sheet of P-trefoil scaffold (high-affinity glycan binding site) was chosen. ey: X - residue within p-strand;
X - side-chain facing inside of P-trefoil core; C - cysteine involved in di-sulfide linkage; i - residue
involved in contacts with Neu5Aca2-6Gal-
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Figure 6.5 Strategies to engineer SNA-I to target host glycan receptors for human influenza A viruses. In
the first strategy the high affinity glycan-binding site present in the 2a-2p-2y C-terminal single pl-trefoil
scaffold (121aa) was cloned and expressed in E.coli. In the second strategy, 2y antiparallel p-sheet, which
has the high affinity glycan binding site (42aa), was cloned and expressed in E.coli. Functionality of both
these protein constructs were tested using the glycan array analysis and by staining of human tracheal
sections. This was compared to that of native SNA-l to check the functional similarity between the native
and engineered SNA-l constructs.
6.2.5 Functional characterization of the receptor binding properties of the
engineered constructs of SNA-!
Both the constructs were cloned into pET15b vector and expressed in E.coli as a
N-terminal his-tagged protein. With both the constructs, expression was challenging as
they were found in the insoluble fraction as inclusion bodies. Both the 42aa and 2l aa
inclusion bodies were solubilized using 6M guanidium hydrochloride to denature the
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protein. Finally the protein was purified and re-folded using reducing concentrations of
6M urea in FPLC purification. It was challenging to purify the 121aa construct this way
but the 42aa peptide was finally purified using the denaturing and renaturing protocol
(Figure 6.7). The 42aa peptide was tested for its functionality using the glycan array
platform (Chapter 1) and by staining of the relevant respiratory tract tissue sections. The
formation of inclusion bodies was attributed to misfolding of the protein due to
bacterial expression. Both 121aa and 42aa proteins were found to have 2 and 1 key
glycosylation sites respectively around the glycan binding site ((Figure 6.6). Lack of these
glycosylations (due to bacterial expression) could have caused misfolding and hence
inclusion body formation.
42 peptide sequence
METGSSHHHHHHSSGLVPRGSHMETRWVFNTNGTISNPNAKLLMDVAQRDVSL
RKIILYRPTGNPNQ
SNA I - B chain (121 aa)
MGSSHHHHHHSSGLVPRGSHMTFIVGYKQMCLRENGENNFVWLEDCVLNRVQ
QEWALYGDGTIRVNSNRSLCVTSEDHEPSDLIVILKCEGSGNQRWVFNTNGTISN
PNAKLLMDVAQRDVSLRKIILYRPTGNPNQQWITT
Figure 6.6 N-glycosylation sites on 42aa and 121aa protein constructs. The Asn residue that is
glycosylated is marked in red. The Asn-Xaa-Thr glycosylation sequon is marked in blue. The lectin domain
of both the protein constructs is marked in green.
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Figure 6.7 Purification of 42aa SNA-l construct. 42aa protein was expressed as an N-terminal his-tagged
protein in E.coli and purified using Fast Performance Liquid Chromatography (FPLC) using Ni2+ column
using a combination of denaturation and renaturation procedure (refer to Materials and Methods
section). The protein was concentrated using a 3K MWCO centrifugation filter and buffer exchanged with
1X PBS (pH 7.4). The concentrated protein was run on SDS-PAGE and stained by coomassie blue as shown
in the left above. The protein was also validated by western blotting, using anti-His antibody (shown in the
right above). The protein was seen as a 7.7kDa protein. Note: in the coomassie blue staining a non-
specific protein (as it did not light-up in western blotting as seen in the image on the right) was also seen
which was purified along with the 42aa protein (seen on top of the 42aa protein in the image on the left).
Key: For the image on the left: Lane 1 - See blue plus 2 protein marker; Lane 2 - concentrated 42aa
protein
For the image on the right: Lane 1 - magic marker; Lane 2 & 3: 42aa protein from two different batches.
A quantitative dose-dependent glycan array analysis was performed using
various concentrations (in pmoles) of the peptide (Figure 6.8A). The peptide showed
binding to all the glycans (a2-3 and a2-6). Negative control (without glycans but with
the peptide) also showed binding to the well (Figure 6.8A). This was attributed to the
hydrophobicity of the peptide Hence though the peptide was being purified it was not
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folded properly and all the hydrophobic sites were exposed leading to the non-specific
binding or "stickiness" of the peptide. Lack of glycosylation can contribute to the
misfolding of the protein. Since the peptide was expressed in E.coli there it was
hypothesized that lack of glycosylation could contribute to misfolding of the peptide.
Putative numbers of N-glycan sequons in the peptide were analyzed using NetNGlyc
program in www.expasy.org. The analysis revealed the presence of several putative N-
glycosylation sites in the peptide. Hence the lack of the N-glycosylation sites in the
peptide (due to its expression in E.coli) could have contributed to the misfolding of the
peptide (Figure 6.6). This hydrophobicity leading to non-specific binding of the 42aa
peptide was further observed when human tracheal tissue sections were stained with
the peptide (Figure 6.8B). Since the 42aa protein is expected the self-associate, 42aa
peptide by itself may exhibit multivalency. Hence dose-dependent tissue staining
experiments were done without pre-complexing the protein with primary and
secondary antibodies. Highly non-specific binding of the human tracheal tissue section
was seen (Figure 6.8B). There was non-specific staining of the apical surface and the
underlying connective tissue with the peptide. This further validated the misfolding and
the ensuing non-specific binding seen with the peptide on the glycan array platform.
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Figure 6.8 Functional characterization of 42aa peptide. A dose-dependent glycan array analysis (A) and
staining of the human tracheal tissue sections (B) with the 42aa peptide was performed to characterize
the glycan binding properties of the peptide. The peptide showed a highly non-specific binding to the
glycans on the glycan array (A) and on the human trachea (B). The glycan array data (A) is representative
of data sets obtained from n=3 experiments. The images were captured at 25X magnification. The apical
surface is marked with a white arrow.
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6.3 Lectin from the mushroom Polyporus squamosus (PSL) to target host glycan
receptor
Lectin from the fruiting body (carpophores) of the mushroom Polyporus squamosus
(termed hereafter as PSL) was purified by affinity chromatography on p-D-galactosyl-
Synsorb and ion exchange chromatography on DEAE Sephacel [191]. PSL agglutinated
human A, B, and 0 and rabbit RBCs but precipitated only with human a2-macroglobulin
[191]. Carbohydrate binding properties were characterized using four different
approaches: precipitation inhibition assay, fluorescence quenching studies, glycolipid
binding by lectin staining on high-performance thin layer chromatography. Based on the
results obtained by these assays, it was concluded that although PSL binds p-D-
galactosides, it has an extended carbohydrate-binding site that exhibits highest
specificity and affinity towards non-reducing terminal Neu5Aca2-6GalP1-4Glc/GlcNAc
(2000-fold stronger than towards galactose) [191].
6.3.1 Molecular structure of PSL
Upon gel filtration chromatography, the purified lectin was eluted as a single,
symmetric peak at an elution volume corresponding to an apparent molecular mass of
52-kDa. Upon SDS-polyacrylamide gel electrophoresis, with or without p-
mercaptoethanol, PSL gave a single band with an apparent mass of 28kDa [191]. This
indicated that the native PSL lectin, is composed of two identical 28-kDa subunits (as a
homodimer) associated by non-covalent bonds.
6.3.2 Homology modeling of PSL
Since there is no X-ray crystal structure of PSL, a homology based structural
model of PSL was generated (Figure 6.9B). PSL shares the highest protein sequence
identity to mushroom lectin, Marasmius oreades agglutinin [MOA] [1921, whose crystal
structure has been solved. Homology-based structural model of PSL using the crystal
structure of MOA showed that PSL comprises of C-terminal and N-terminal domain
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(Figure 6.9B). The C-terminal domain has been implicated in facilitating oligomerization
and providing structural stability [192]. The N-terminus of PSL on the other hand
appears to adopt the anti-parallel 0-trefoil scaffold with three tandemly repeated
homologous p-sheet subdomains (a, p and y) all of which have the conserved (QN)/XW
motif, which is a common feature of the ricin B-chain lectin domains (Figure 6.9A).
Studies have indicated that P and y subdomains comprise the glycan binding sites [191,
192]. The functional role of the C-terminal domain in both PSL and MOA apart from
oligomerization remains unknown due to the unique structural fold adopted by this
domain, which has not been observed thus far in any other protein. Our approach was
remove the C-terminal oligomerization domain and retaining the N-terminal lectin
domain and it was hypothesized that the N-terminal by itself should retain the glycan
binding properties of the full length PSL. Previously, Goldstein et al had cloned and
expressed PSL and its forms in E.coli. Hence PSL's glycan binding domain was cloned
(designated as rPSL-N) and expressed in E.coli as a N-terminal his-tagged protein (Figure
6.10A). Unlike SNA, there were no challenges in the expression and purification of rPSL-
N. The protein was confirmed by western blot analysis with anti-His antibody (Figure
6.10B). This functionality of the protein was then assessed by performing a quantitative
dose-dependent glycan array analysis and by staining human tracheal tissue sections
with rPSL-N.
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Figure 6.9 Molecular structure of PSL and homology modeling of PSL. PSL has a N-terminal glycan
binding domain and a C-terminal oligomerization domain (A & B). The N-terminal lectin domain adopts an
antiparallel $-trefoil fold a common feature of ricin B-chain lectin domain. The exact function of the C-
terminal domain beyond oligomerization and stabilization of the protein structure is not clearly known.
Structure of PSL lectin, which was generated by homology modeling using MOA lectin as template. Based
on the MOA crystal structure (co-crystallized with glycan motif), each of the 0- and y- subdomains
comprises of distinct binding sites for the a2->6 trisaccharide motif.
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Figure 6.10 Purification of rPSL-N. The protein was expressed as a N-terminal his-tagged protein and
purified by Nickel column affinity chromatography (A). The protein was purified as a 17.7kDa protein,
which was validated by western blot analysis (B).
6.3.3 rPSL-N binds to the glycan receptors targeted by human-adapted influenza A
viruses
In order to characterize the glycan binding specificity of rPSL-N, a quantitative
dose-dependent glycan array analysis [110] was performed with the purified rPSL-N
protein. The glycan array platform was composed of both a2-3 and C2-6 sialylated
glycans (Chapter 1). rPSL-N showed a dose-dependent binding to representative aX2-+6
sialylated glycan receptors (6'SLN and 6'SLNLN) of human-adapted influenza A viruses
(Figure 6.11A). This binding to a2-+6 glycans was comparable to that of the full length
PSL (Figure 6.11B) indicating that the rPSL-N is able to retain the glycan-receptor binding
properties of PSL even in the absence of the oligomerization C-terminal domain. In all
the glycan array analysis in order to capture the multivalent rPSL-N-glycan receptor
interaction, rPSL-N was pre-complexed with primary and secondary antibodies before
adding to the glycans. An apparent binding constant (Kd') of rPSL-N for the 6'SLN-LN and
6'SLN glycans was calculated using Hill's equation. The Kd' value (sub picomolar range)
for rPSL-N was in the same range as that calculated for binding of HA from human-
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adapted pandemic H1N1 (A/South Carolina/1/1918) and H2N2 (A/Albany/2/58)
influenza viruses [95, 110] indicating that rPSL-N binds with high-affinity to the glycan
receptors of human-adapted influenza virus HA.
The human upper respiratory tract predominantly expresses a2-+6 sialylated
glycan receptors on their epithelial surface and is the main target for infection by
human-adapted influenza A viruses [40, 41, 43, 48, 49]. rPSL-N showed extensive
staining of the apical surface of the human tracheal epithelium (Figure 6.12A). rPSL-N
also showed staining of the non-ciliated goblet cells as indicated by its co-staining with
Jacalin, a marker for goblet cells (Figure 6.13A) similar to other human adapted HA
(Figure 6.13B, shown is that of a representative H3N2 HA). The apparent binding affinity
(Kd') of rPSL-N to human receptor was also comparable to that of the pandemic HAs
(Figure 6.13C). rPSL-N did not show any staining of the human deep lung and alveolus
(Figure 6.12D) which are known to express c2-3 sialylated glycan receptors [48]. The
binding pattern of rPSL-N to the human respiratory tissues is consistent with the
observed specificity on the glycan array. This binding pattern of rPSL-N to human
tracheal epithelium was comparable to that of the full length PSL lectin which also
showed sialic-acid specific binding to the apical surface and the non-ciliated goblet cells
of the human tracheal epithelium (Figure 6.12B).
The binding of rPSL-N to both ciliated and goblet cells in the tracheal epithelium
points to the expression of the a2-+6 trisaccharide
(Neu5Aca2-+6Galp1-+4GlcNAc$1-+) as a terminal motif on both N-linked (ciliated) and
0-linked (goblet cells) glycoconjugates. The specific binding of rPSL-N to this
trisaccharide motif in the human upper respiratory tissues was confirmed by
pretreatment of the tissue sections with Sialidase A. This enzyme cleaves terminal sialic
acid that is either c2-+6 or a2-+3 linked to a penultimate lactosamine
(Gal$1->4GlcNAc). There was a complete loss of rPSL-N staining of the human tracheal
epithelium upon Sialidase A pre-treatment of the trachea (Figure 6.12C) in contrast to
the SNA-1 staining pattern after Sialidase A treatment (Figure 6.3C) Also the tracheal-
tissue binding of rPSL-N was compared with that of SNA-1 (which shows predominantly
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staining of the apical surface of human tracheal epithelium; Section 6.2). This
highlighted the broader specificity of SNA-1 in that it binds to both the a2->6
trisaccharide motif recognized by PSL as well as disaccharide motifs such as Neu5Ac
a2->6 linked to core GaINAc structure of 0-linked glycoconjugates
(Neu5Aca2->6GalNAca1->).
Human respiratory tissue binding pattern of rPSL-N was further compared with
that of hemagglutinin from human-adapted influenza A viruses analyzed in previous
studies [48, 95]. The binding pattern was very similar wherein the HAs also show specific
binding to ciliated and non-ciliated cells of the human tracheal epithelium and no
binding to the alveolus. Moreover Sialidase A pre-treatment of the tracheal section
completely abolishes binding of HA similar to what is observed for rPSL-N. Together,
these results indicate that rPSL-N specifically binds to the glycan receptors targeted by
human-adapted influenza A viruses.
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Figure 6.11 Glycan binding specificity of rPSL-N and native PSL. A quantitative dose-dependent glycan
array analysis was performed with rPSL-N by pre-complexing it with primary and secondary antibodies
(top). For comparison, the assay was also performed with the native PSL (bottom, EY labs) without pre-
complexation. Similar to native PSL, rPSL-N showed highly specific binding to a2-6 sialylated glycans
(6'SLN and 6'SLNLN). The affinity of rPSL-N was higher than the native PSL.
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Figure 6.12 Cellular tropism of rPSL-N. Confocal image (25X) of paraffinized human tracheal tissue with
20pg/ml of rPSL-N (green) pre-complexed with primary and secondary antibody (labeled with 488
fluorophore). rPSL-N stained the apical surface of the tracheal epithelium and the non-ciliated goblet cells
(marked with an arrowhead) (A). This staining pattern was very similar to that of the native PSL (B).
Sialidase A treatment of human tracheal tissue section prior to staining with rPSL-N led a complete loss of
tracheal epithelium staining indicating sialic acid specific binding of rPSL-N to glycan receptors (C). rPSL-N
did not stain human lung alveolus (D). The apical surface is marked with a solid arrow. The nuclei are
counterstained by propidium Iodide (red). The nucleus was counterstained by propidium iodide (red). The
apical surface is marked with solid white arrow.
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Figure 6.13 rPSL-N binds to the glycan receptors targeted by human influenza A viruses. Similar to the
HAs from human adapted influenza A viruses (B), rPSL-N shows co-staining of the goblet cells with Jacalin
(A) and a complete loss of staining upon Sialidase A treatment (Figure 6.12). This is in contrast to SNA
wherein the goblet cell staining is seen even after Sialidase A treatment (Figure 6.3) indicating that rPSL-N
more specifically targets glycan motifs recognized by human-adapted influenza A HAs. Shown in B is the
confocal image of staining of human tracheal sections with Jacalin and recombinant HA from a
representative H3N2 pandemic influenza A virus Moscow 99. The co-staining is indicated by a yellow
staining pattern of the goblet cells. The images were captured at 63X magnification. The apical surface of
the tracheal epithelium is indicated by a bold white arrow. The co-staining of the goblet cells is indicated
by a broken white arrow. Shown in (C) is the binding affinity of rPSL-N to human receptors and it is
comparable to that of pandemic virus HAs (SC18 and Alb58).
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6.3.4 Inhibition of influenza A virus infection by rPSL-N
To determine the anti-viral effect of rPSL-N against influenza A infection, MDCK
cells (which are known to express both a2-3 and a2-6 sialylated glycans [193] were
incubated with different concentrations of rPSL-N for 2h prior to infection with
representative influenza A viruses. The presence of a2-6 glycan receptors in MDCK cells
were further confirmed by staining with SNA-1 lectin (Figure 6.14B). Two specific viral
strains were chosen for this analysis. The first strain, A/Victoria/3/75 or Vic75, belongs
to the H3N2 subtype and binds specifically to a2->6 sialylated glycans on the glycan
array (data obtained from functionalglycomics.org [194]). The second strain, A/Puerto
Rico/8/34 or PR8, belongs to the HiN1 subtype and shows a mixed binding to both
a2-*3 and a2->6 sialylated glycans on the glycan array [171]. Therefore these
representative strains span different human-adapted influenza A virus subtypes as well
as have varying specificities to c2->6 sialylated glycans. The assay is schematically
represented in (Figure 6.14A).
After 48h of incubation, viral RNA was extracted and the change in viral titer was
quantified by real time PCR analysis of the conserved viral matrix gene (M) [195]. The
reduction in viral RNA was estimated by comparing the viral RNA titer quantified from
untreated MDCK cells (Figure 6.15). A 10-fold dilution of vRNA was made to generate
standard curve for absolute quantification (Figure 6.16). IC50 was calculated as the
concentration of rPSL-N at which there is a 50% reduction in the viral RNA as compared
to the control untreated cells. The results showed that there was a dose-dependent
reduction in viral RNA as compared to the untreated cells (Figure 6.15A). The IC50 of
rPSL-N for inhibiting Vic75 infection was found to be ~2.5 ltg/ml which corresponds to
140nM to 280nM of rPSL-N (Figure 6.15B). On the other hand, IC50 of rPSL-N for
inhibiting PR8 infection was 4-fold higher (~10 Rg/ml) (Figure 6.15B). This observation
further demonstrates that rPSL-N specifically competes with the binding of viral
hemagglutinin to a2-->6 sialylated glycan receptors on the MDCK cells. Further, the
specificity of rPSL-N was validated against avian H5N1 virus. There was no inhibition of
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H5N1 infection. These results also highlight the ability of rPSL-N to inhibit infection of
human adapted influenza A viruses across different subtypes.
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Figure 6.14 Experimental design for rPSL-N inhibition of influenza A infection. Madin-Darby Canine
Kidney Cells (MDCK) were used to test the ability of rPSL-N to inhibit influenza A infection. Two different
human influenza A virus strains (PR8 and Vic75) were used for the assay (A) due to their differential glycan
receptor binding properties. Viral inhibition was assessed by quantification of viral M-gene using
quantitative real time PCR analysis. The presence of ax2-6 receptors on MDCK cells was validated by
staining them with SNA-1 (green) (B). The nuclei were stained with propidium iodide.
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Figure 6.15 rPSL-N inhibits infection of MDCK cells by influenza A viruses. MDCK cells were treated with
a range of concentrations of rPSL-N prior to infecting the cells with influenza A virus. Quantification of
viral M-gene (A) showed a dose-dependent reduction in both PR8 and Vic75 expression. IC50 was
calculated using Graphpad Prism 5 (B). There was a shift in the IC50 values for PR8 as compared to Vic75.
This can be explained by their differential glycan binding properties (see text for details). Data is
representative of n=3 experiments. The data shown here is normalized to the viral RNA quantified from
the virus infected untreated MDCK cells.
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Figure 6.17 Native PSL but not rPSL-N is highly cytotoxic to MDCK cells. (A) Scanned image of cytotoxicity
assay plate showing lectin treated MDCK cells stained with crystal violet. The image on the left shows the
wells treated with rPSL-N and that on the right shows the wells treated with PSL. The concentrations of
lectin used are shown in the left of the image. Note the loss of MDCK cell monolayer in PSL treated wells
on the right as compared to the rPSL-N treated wells on the left. Also shown are the non-treated MDCK
cells stained with crystal violet. (B) shows comparison of cytotoxicity between PSL and rPSL-N.
Densitometric scanning to quantify the crystal violet staining (indicative of intact MDCK monolayer) was
performed using Adobe Photoshop. Relative intensity was calculated after normalizing the crystal violet
staining intensity of the drug treated cells with that of the MDCK cells not treated with the drug. There
were significant cytopathic effects and loss of cell monolayer in MDCK cells treated with full length PSL at
concentrations higher than 9 Vg/ml (A). There were no significant CPEs and loss of cell monolayer in rPSL-
N treated wells. The data is representative of n=4.
6.3.5 PSL and not rPSL-N is cytotoxic to MDCK cells
Since most of the plant lectins possess inherent cytotoxicity [196, 197]
cytotoxicity of PSL and rPSL-N were evaluated. For native PSL, MDCK cells, plated on a
96 well plate, were incubated with various lectin concentrations (from 1.17 g/ml to
300ig/mi) for 2h followed by overlaying the cells with 1X MEM media and incubation
for 48h. Cytopathic effects (CPE) were monitored 24h post-incubation and at 48h post
infection. Visible CPEs (several dead and non-adherent cells) were noticed in drug
treated wells from ~9 Rg/ml. After 48h of incubation, there was complete loss of MDCK
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monolayer in PSL treated cells from ~9 pg/ml as compared to the untreated cells (Figure
6.17).
Cytotoxicity assay with rPSL was performed similar to that for native PSL. After
24h and 48h of incubation, there were no visible CPEs in the rPSL-N treated wells. The
MDCK monolayer was intact after 48h in the drug treated wells. The cells were fixed and
stained with crystal violet (Figure 6.17A). A densitometric scanning (for both native PSL
and rPSL-N treated wells) was done in order to assess the intensity of staining (indicative
of intact monolayer) and normalized to the intensity of untreated cells (Figure 6.17B).
Hence the cytotoxicity analysis showed that removal of the C-terminal oligomerization
domain from native PSL (which is rPSL-N) does significantly reduce its cytotoxicity.
6.3.6 In vivo studies with rPSL-N
In order to test the in vivo efficacy of rPSL-N, 8 weeks old female BALB/c mice
were treated with 1mg/kg of rPSL-N prior to infection with mouse-adapted
A/California/04/09 or maCA04/09. Mice were treated with 1mg/kg of rPSL-N
(intranasally) for 0-5 days. Control mice were treated with 1XPBS prior to infection with
mouse-adapted CA04/09. Daily weight, lung titers and survival were monitored for all
the 6 days. There was no significant reduction in lung viral titers (7.68 logioEIDso/ml and
7.45 7.68 logioEIDso/ml for rPSL-N treated and PBS treated mice respectively). There was
a marginal improvement in the survival of the rPSL-N treated mice (Figure 6.18) though
the mice succumbed to the infection after Day 6.
Previously mouse-adaptation is shown to alter receptor binding specificity of the
virus given the predominant a2-3 glycan expression in the mouse respiratory tract.
Hence a dose-dependent glycan array analysis was performed with the maCA04/09 and
compared with the binding data of the wild-type virus. Interestingly, there was a
reduction in the a2-6 glycan binding affinity (Figure 6.19) as compared to the wild-type
virus (Figure 4.7). Also the maCA04/09 virus showed an increased binding to C2-3
glycans. Given the high specificity of rPSL-N to a2-6 glycans, the a2-3 binding of the ma-
CA04/09 would have negated the inhibitory effects of rPSL-N. Hence ferrets would be a
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more appropriate model system for testing the in vivo effects of rPSL-N, as they
predominantly express a2-6 glycans in their respiratory tract.
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Figure 6.18 Survival curve of BALB/c mice treated with rPSL-N.
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Figure 6.19 Glycan array analysis with mouse-adapted CA04/09 (ma-CA04/09) virus. Mouse adaptation
of a representative 2009 H1N1 influenza A virus A/California/04/09 led to a change in the receptor
binding specificity of the virus. The virus acquired a2-3 binding preference upon mouse adaptation when
compared to the wild-type virus (Figure 4.7).
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6.4 Discussion and Significance of this study
One of the major challenges with current antiviral strategies for influenza A virus
is the emergence of new viral strains which are resistant to these antivirals. Hence there
is a need to look for alternate antiviral strategies to combat influenza A virus infection.
One such strategy that has emerged recently is to generate antibodies that target the
highly conserved stem region of HA that are involved in fusion of viral envelope to the
host nuclear membrane [198, 199]. However, even this strategy has not resulted in an
antiviral agent that broadly targets all subtypes known to have adapted to the human
host such as HINI and H3N2.
Plant lectins have recently been shown to have antiviral properties [151, 200,
201]. For instance, cyanovirin N (CV-N) is a lectin isolated from the cyanobacterium
Nostoc ellipsosporum that to the high-mannose residues on the viral hemagglutinin 1
(HA1) and neutralizes influenza A viral infection [151]. Though CV-N was found to be
effective against several influenza A virus strains, its effectiveness was limited by the
emergence of influenza A virus resistant to CV-N lectin. The CV-N resistant strains lacked
the key glycosylation site specifically targeted by the lectin. Hence one of the main
challenges with the anti-viral drugs targeting the virus itself is the potential emergence
of drug resistant viral strains.
Influenza A virus hemagglutinin binds to specific glycans receptors on the surface
of the host cell. These glycan receptors mediate viral attachment and entry process
during the initial stages of the viral life cycle. Given the importance of these glycan
receptors in the viral life cycle, they offer a promising alternative target for countering
influenza A virus infection. Recently DAS 181, a sialidase fusion protein was found to be
effective against several influenza A viral strains [180, 202, 203]. DAS 181 functions by
removing terminal sialic acid from the glycan receptors for influenza A virus and thus
renders the host cells ineffective from being infected by the virus. Unlike DAS 181,
which cleaves all the sialic acid on the surface of the host cell, recombinant N-terminal
glycan-binding domain of Polyporus squamosus lectin (designated rPSL-N) binds
specifically to the glycan receptors for influenza A virus and inhibits its infection of
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MDCK cells. Although the high affinity glycan binding site of PSL resides in just one of
the antiparallel P-sheets (y subdomain, a 42-mer peptide), this subdomain by itself was
found to be unstable and found to have completely lost its glycan binding specificity (as
mentioned in Section 6.2). On the other hand, rPSL-N, the minimum N-terminal domain
that forms a complete p-trefoil lectin scaffold, is stable and exhibits glycan-binding
properties similar to the native PSL. There is scope for additional improvement in its
stability and efficacy of rPSL-N by various protein engineering strategies. For instance,
addition of cysteine residues in the N- and C- terminus of rPSL-N with an intention of
introducing disulfide linkage could potentially stabilize the p-trefoil fold of rPSL-N.
Given the unique mode of action of rPSL-N as compared to other anti-viral
therapeutics, rPSL-N may offer a potential therapeutic option against influenza A
infection. Targeting the host cells rather than the virus can slow down the emergence of
drug-resistant viral strains. Furthermore rPSL-N also shows a broad-spectrum inhibitory
property across HI and H3 subtypes of influenza A viruses.
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Chapter 7. Summary and Significance of this Thesis
Influenza A virus hemagglutinin (HA) binds to the cell surface sialylated glycan
receptors and mediates viral entry into the host cells. The binding property of the viral
HA to the host cell surface glycan receptor impinges on various aspects of the viral
pathogenesis such as host adaptation and transmissibility. Hence there is a need to
understand the critical HA-glycan interaction to truly correlate it with its functional
significance in viral pathogenicity. Much of influenza A research has been oversimplified
by studying HA only in the context of its sialic acid linkage specificity. This undermines
the complexity associated with the glycan receptor. Moreover the multivalency
associated with the HA-glycan interaction is also not taken into account. In this thesis, in
order to address these aforementioned challenges we undertook a multifaceted
approach going from understanding the two molecular components: HA and glycan
receptors respectively, to converging on their biological relevance in ferret and mouse
models. By interfacing complementary set of tools we were able to deduce a novel
mechanism by which influenza A virus escapes host immune response by modulating
the HA binding avidity to host glycan receptors. We were also able to gain insights into
subtle modifications of HA such as site-specific glycosylation, and its role in determining
the receptor binding property of HA. Further by using recombinant HA from a
representative 2009 H1N1 influenza A virus we were able to correlate the receptor
binding affinity of HA to its transmissibility in ferret model. This highlights the
importance of quantifying HA binding avidity, taking into account the multivalency
associated with HA-glycan interaction. Finally, by multiplexing lectin staining with
enzymes we were able to understand influenza A viral tropism in ferret respiratory tract.
This combined with data mining enabled us to map the gross glycan motif distribution in
ferret upper and lower respiratory tract. Finally based on the understanding of viral
tropism and their glycan receptor distribution, we were able to device a novel
therapeutic strategy to combat influenza A infection. We used a combination of tools
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ranging form data mining analysis, glycan array analysis and human tracheal tissue
staining to identify a derivative of the mushroom lectin rPSL-N, which targets the glycan
receptors of human-adapted influenza A virus and inhibits infection by H1 and H3
viruses in vitro.
It is challenging to decode the functional significance of a protein-glycan
interaction due to the enormous complexity associated with this interaction. The non-
template driven synthesis of glycans combined with its complexity makes it challenging
to analyze the active glycan motif from relevant cells or tissue sections. Lectin staining
combined with mass spectrophotometry analysis enables characterization of the active
glycan motifs at various molecular levels. As highlighted by this thesis, multiplexing
lectin staining with glycosidases can also enable further characterization of glycan
motifs. Further, since any protein-glycan interaction typically exhibits multivalency, it is
important to capture this valency issue in any ELISA based assay system aimed at
characterizing protein-glycan interaction. Further a dose-dependent analysis of the
protein on the glycan array not only enables identifying the glycan binding specificity of
the protein, but also enables characterization of binding avidities (provided multivalency
is captured in the assay).
Overall the approach used in this thesis enabled us to get greater insights into
the role of HA-glycan interaction in various aspects (such as antigenic drift,
transmissibility and host adaptation) of influenza A virus infection (Figure 7.1). Such a
study enabled us to identify a novel therapeutic strategy against influenza A infection.
We have also provided a strategy for effective surveillance of emergence of influenza A
virus into a more pathogenic strain. This thesis has hence contributed to answering the
big question to possibly predict the emergence of any future pandemic outbreaks. Such
an approach can be extended to understanding various protein-glycan interactions that
impinge on other disease models.
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Figure 7.1 Overall summary of this thesis. This thesis has investigated the role of HA-glycan interaction in
influenza A virus antigenic drift, transmissibility and host adaptation. Based this understanding, this thesis
proposes a novel therapeutic strategy of targeting the host glycan receptor instead of the viral
components against influenza A virus infection.
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Appendix 1: Materials and Methods
A1.1 Materials and Methods for Chapter 2
Mice.
Swiss mice were purchased from Charles River and C57BL/6 and Balb/c mice
were purchased from Taconic. Mice were maintained under specific pathogen-free
conditions and all procedures involving mice were approved by the Animal Care and Use
Committee of the National Institute of Allergy and Infectious Diseases.
Viruses.
To study antigenic drift in an animal model, it is essential to start the experiment
with a virus that is completely adapted to its host. Therefore, in these experiments PR8,
a mouse adapted virus was used. Several stocks of viruses were used in these
experiments. 3 independent stocks of PR8 were isolated after transfecting plasmids
containing the 8 PR8 gene segments into MDCK cells. These viruses were expanded only
once on MDCK cells to prevent cell line adaptations. Serial passaging of these viruses
began by directly infecting mice i.n. with MDCK supernatant. In other experiments, virus
that has been continuously grown in 10-day old embryonated chicken eggs (CBT Farms)
was passaged in the laboratory (this virus has never been grown on MDCK cells).
Vaccination.
For all vaccine stocks, allantoic fluid was treated with paraformaldehyde (1:864
dilution) for 2 days at 40C. Mice were injected intraperitoneally with ~100-500
hemagglutination units of inactivated influenza A viruses. 10 days after vaccination,
mice were retro-orbitally bled, and the erythrocytes were removed using serum-gel
tubes (Sarstedt). Serum was inactivated by incubating at 560C for 30 min and tested for
anti-influenza A virus antibodies by HAI. This vaccination scheme induces primarily IgG
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and IgM antibodies. To generate a large diverse pool of antibodies, serum isolated from
45 vaccinated Swiss mice was pooled.
HAl assay.
HAI titrations were performed in 96-well round plates (Corning). Sera were
serially diluted 2-fold and added to 4 agglutinating doses of influenza A virus in a total
volume of 200 p.l. Next, 25 pl of a 2% (vol/vol) erythrocyte solution was added. The sera,
virus, and erythrocytes were gently mixed and the assay was read out after incubating
for 60 min at room temperature. Titers were recorded as the inverse of the highest
antibody dilution that inhibited 4 agglutinating doses of virus.
Polyclonal antibody binding assays.
L929 cells were infected with virus for 3h, the time with maximal ratio of HA to
NA expression. Serial dilutions of polyclonal antibodies were added to the cells for 30
min at 40C. Duplicate samples were incubated with a Ca monoclonal antibody mixture
or an NA antibody to normalize the amount of HA/NA expressed on the cell surface.
Flow cytometry was performed, and data are expressed as normalized mean fluorescent
intensity.
Serial passaging of influenza A virus.
For all in vivo experiments, individual mice were used for each passage. To begin
the passaging experiments, mice were anesthetized with isoflurane and infected i.n.
with stock virus diluted in 50 [tl PBS. Lungs were isolated 2 days after infection and
homogenized. Passaging was continued by infecting a second group of mice with 50 [d
of the lung homogenate from passage #1. Lungs were again isolated 2 days after this
infection and homogenized. This process continued between 6-9 passages for each
experiment. For co-infection experiments using P186S and PR8 and other experiments
using E246G and E246G/A227T, starting virus amounts were normalized based on
infectivity on MDCK cells. The presence of virus was monitored by TCID 50 (lung titers of
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vaccinated mice were typically between 104 and 106 TCID50/mL). When infections were
unsuccessful, the infection using the same lung homogenate from the previous
successful infection was repeated. For vaccination experiments, mice were used 10-21
days following vaccination. Mice with lower HAI titers were used during early passages.
Monoclonal antibody binding analysis.
Influenza A viruses were diluted in PBS and added in triplicate to 96 well flat
bottom microtiter plates (Thermo Electron Corp). After incubation for >15 hr at 40C,
wells were blocked with PBS-FBS. A non-saturating concentration of monoclonal
antibody in the linear portion of the antibody titration curve (determined by prior
titration of each monoclonal antibody stock) was added to each well and allowed to
incubate for 1 hr at room temperature. After washing, anti-mouse HRP antibody (MP
Biomedicals) was then added and allowed to incubate for 1 hr at room temperature.
After washing, TMB substrate (KPL Biomedical) was then added and the reaction was
stopped by adding HCL and the amount of HRP product was determined using a plate
reader. Data (O.D.s) were graphed using matrix2png software (Pavlidis, P. and Noble
W.S. (2003) Matrix2png: A Utility for Visualizing Matrix Data. Bioinformatics 19: 295-
296).
Sequencing.
RNA was extracted from lung homogenate, MDCK supernatant (endpoint titrated
viruses and stocks), or allantoic fluid using QiAmp viral RNA mini kit (Qiagen). cDNA was
made (using a kit from Marligen), HA and NA were amplified by PCR, and sequencing
was performed on an AppliedBiosystem DNA analyzer.
Dose-dependent quantitative glycan array analysis with whole viruses.
Streptavidin-coated high binding capacity 384-well plates (Pierce) were
incubated overnight at 4*C with 50[i of 2.4pM biotinylated 3' SLN, 3' SLN-LN, 6' SLN or
6' SLN-LN (LN corresponds to lactosamine (Gal01-4GIcNAc) and 3' SLN and 6' SLN
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correspond respectively to Neu5Aca2-3 and Neu5Aca2-6 linked to LN). Glycans were
provided by the Consortium of Functional Glycomics (www.functionalglycomics.org).
50[tl virus diluted in PBS 1% (w/v) BSA (PBS-BSA) added to glycan-coated wells were
incubated overnight at 4"C, and washed 3 times with PBST (PBS, 0.1% Tween-20) and
three times with PBS. Wells were then blocked with PBS-BSA for 2 h at 4'C, before
incubating with NA2-1C1 anti-NA mAb diluted in PBSBSA for 5 h at 40 C. After washing as
above, wells were incubated with goat anti-mouse IgG HRP conjugated antibody in PBS-
BSA. Wells were washed as above, and binding of secondary antibody was detected
using the Amplex Red Peroxidase Assay (Invitrogen) according to the manufacturer's
instructions. Appropriate negative controls were included. Assays were performed in
duplicate.
In vitro neutralization assays.
Quadruplicate samples of serial dilutions of polyclonal antibody serum mixed
with viruses were incubated at room temperature for 30 min, and then incubated with
MDCK cells for 1 hr at 370C. Cells were washed twice with serum-free media, and then
serum-free media containing trypsin was added. Virus growth was scored 3 days later by
cytopathic effect. Data are expressed as the inverse dilution of serum that caused
neutralization.
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A1.2 Materials and Methods for Chapter 3
Site-directed mutagenesis of HA.
Site-directed mutagenesis was carried out with the QuikChange multi site-
directed mutagenesis kit (Stratagene). The primer used for mutagenesis was designed
by using the web-based program, Primer3 (http://frodo.wi.mit.edu/primer3/) and
synthesized by IDT DNA Technologies. The primer sequence used for generating T93A
mutants is 5'GAA ACA TCG AAC TCA GAG AAT GGA GCA TGT TAC CCA GGA GAT TTC ATC
G 3'. The primer sequence used for generating N91D mutant in NY18 HA is 5' GTA GAA
ACA TCG AAC TCA GAG GAT GGA ACA TGT TAC CCA GGA GAT TTC 3'.
Cloning, baculovirus synthesis, expression and purification of HA.
Briefly, recombinant baculoviruses with wild-type or mutant HA gene
respectively, were used to infect (MOI=1) suspension cultures of Sf9 cells (Invitrogen,
Carlsbad, CA) cultured in BD Baculogold Max-XP SFM (BD Biosciences, San Jose, CA). The
infection was monitored and the conditioned media was harvested 3-4 days post-
infection. The soluble HA from the harvested conditioned media was purified (using a
gradient of imidazole HCI concentration ranging from 20mM to 250mM) using Nickel
affinity chromatography (HisTrap HP columns, GE Healthcare, Piscataway, NJ). Eluting
fractions containing HA were pooled, concentrated and buffer exchanged into 1X PBS
pH 8.0 (Gibco) using 100K MWCO spin columns (Millipore, Billerica, MA). The purified
protein was quantified using BCA method (Pierce). Shown below is the purification
profile for a representative HA (SC18T93A). HA in lanes 6 and 7 is marked below.
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1 2 3 4 5 6 7 8
Lane 1: See blue plus marker
Lane 2: Crude
Lane 3: Flow through
Lane 4: Wash with 20mM Imidazole HCI
Lane 5: 20% fraction
Lane 6: 40% fraction
Lane 7: 80% fraction
Lane 8: 100% fraction
Figure A1.2 SDS-PAGE profile of recombinant HA purified by affinity chromatography
Circular dichroism analysis of mutant HAs.
Circular dichroism analysis was performed using the Aviv Model 202 Circular
Dichroism spectrometer. The spectra was generated between 190 and 280nm. Identical
concentration of the mutant and wild type proteins was used to avoid any differences in
the spectra due to the differences in their concentration.
Dose dependent direct binding of wild-type and mutant HAs.
To investigate the multivalent HA-glycan interactions a streptavidin plate array
comprising of representative biotinylated a2-.3 and a2--6 sialylated glycans was used
as described previously [110], (Table A1.2). 3'SLN, 3'SLN-LN, 3'SLN-LN-LN are
representative avian receptors. 6'SLN and 6'SLN-LN are representative human
receptors. The biotinylated glycans were obtained from the Consortium of Functional
Glycomics through their resource request program. Streptavidin-coated High Binding
Capacity 384-well plates (Pierce) were loaded to the full capacity of each well by
incubating the well with 50 [i of 2.4 [tM of biotinylated glycans overnight at 4 *C. Excess
glycans were removed through extensive washing with PBS. The trimeric HA unit
comprises of three HA monomers (and hence three RBS, one for each monomer). The
spatial arrangement of the biotinylated glycans in the wells of the streptavidin plate
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array favors binding to only one of the three HA monomers in the trimeric HA unit.
Therefore in order to specifically enhance the multivalency in the HA-glycan
interactions, the recombinant HA proteins were pre-complexed with the primary and
secondary antibodies in the molar ratio of 4:2:1 (HA:primary:secondary). The identical
arrangement of 4 trimeric HA units in the precomplex for all the HAs permit comparison
between their glycan binding affinities.
A stock solution containing appropriate amounts of Histidine tagged HA protein,
primary antibody (Mouse anti 6X His tag IgG, Abcam) and secondary antibody (HRP
conjugated goat anti Mouse IgG Santacruz Biotechnology) in the ratio 4:2:1 and
incubated on ice for 20 min. Appropriate amounts of precomplexed stock HA were
diluted to 250 [d with 1% BSA in PBS. 50 d of this precomplexed HA was added to each
of the glycan-coated wells and incubated at room temperature for 2 hrs followed by the
above wash steps. The binding signal was determined based on HRP activity using
Amplex Red Peroxidase Assay (Invitrogen, CA) according to the manufacturer's
instructions. The experiments were done in triplicate. Minimal binding signals were
observed in the negative controls including binding of precomplexed unit to wells
without glycans and binding of the antibodies alone to the wells with glycans. The
binding parameters, cooperativity (n) and apparent binding constant (Kd'), for HA-glycan
binding were calculated by fitting the average binding signal value (from the triplicate
analysis) and the HA concentration to the linearized form of the Hill equation:
log = n * logfHA]- log(Kd')
where y is the fractional saturation (average binding signal/maximum observed binding
signal). The theoretical y values calculated using the Hill equation:
= [HAT
[HAT +Kd
(for the set of n and Kd' parameters) were plotted against the varying concentration of
HA to obtain the binding curves for the representative human receptor (6'SLN-LN).
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Kd' can also be calculated based on concentration of HA at half saturation.
Kd =[HA 0 5]n
Table A1.2 Expanded nomenclature of glycans used in the glycan array
Glycan Expanded nomenclature
3'SLN Neu5Aca2-3Galp1-4GlcNAcp1-
6'SLN Neu5Aca2-6Gal@1-4GlcNAcp1-
3'SLN-LN Neu5Acax2-3Gal1-4GcNAc$1-3GaIs1-4GlcNAc@l-
6'SLN-LN Neu5Aca2-6Gal1-4GcNAc 1-3Gal1-4GcNAc31-
3'SLN-LN-LN Neu5Aca2-3Gal 1-4GIcNAc1-3Gal 1-4GIcNAc$1-3GalIl-
4GlcNAc$1-
Key: Neu5Ac: N-acetyl D-neuraminic acid; Gal: D-galactose; GlcNAc: N-acetyl D-
glucosamine. a / 1: anomeric configuration of the pyranose sugars. All the sugars are
linked via a spacer to biotin (-Sp-LC-LC-Biotin as described in
http://www.f u nctionalglycomics.org/static/consortiu m/resources/resou rcecored5.shtm
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A1.3 Materials and Methods for Chapter 4
Homology based structural modeling of CA04/09, CA04/09mutl CA04/09mut2.
Using the SWISS-MODEL web-based automated homology-modeling platform
(http://swissmodel.expasy.org/) the homology structural models of CA04/09 (Figure
4.15A), and CA04/09mutl (Figure 4.15B) were constructed. The template structure
chosen by SWISS-MODEL was that of a recently solved crystal structure of 2009 H1N1
HA (PDB ID: 3LZG). The starting pose of the HA-human receptor complex was obtained
by superimposing the modeled HA structure with the co-crystal structure of 1918 H1N1
HA with human receptor (PDB ID: 2WRG). The starting structural complex was subject to
energy minimization (500 steps of steepest descent followed by 500 steps of conjugate
gradient). The AMBER force-field was used to assign potentials and charges. The default
version of AMBER was provided with the Discover module of Insightll molecular
modeling suite (Accelrys, San Diego, CA).
CA04/09mut2 HA (Figure 4.15C) mutant was designed to make the interaction
network involving residues 186, 219 and 227 hydrophobic. Three mutations Ser186Pro,
Ala189Thr and Glu227AIa in CA04/09mut2 HA make the inter-amino acid interaction
network identical to that observed in SC18 HA (Figure 4.15D). The mutated residues are
highlighted in red.
Cloning, baculovirus synthesis, expression and purification of HA.
Site-directed mutagenesis was carried out on CA04/09 wild-type HA backbone to
generate CA04/09mutl, CA04/09mut2, CA04M3, CA04M4, and CA04M5 mutant HAs.
The expression and purification of these mutant HAs were carried out as explained in
Appendix A1.2. The proteins were validated by running them on SDS-PAGE (shown
below, HAs are marked with a black box) and by performing Western blotting using anti-
His antibody.
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1 2 3 4 5
Lane 1: CA04/09Mutl (1[tg)
Lane 2: CA04/09Mut2 (1ltg)
Lane 3: CA04M3 (1[tg)
Lane 4: CA04M4 (1[tg)
Lane 5: CA04M5 (1[tg)
Figure A1.3 SDS-PAGE profile of mutant and wild-type recombinant HA (2009 H1N1) purified by affinity
chromatography
Binding of recombinant CA04/09, CA04/09mutl and CA04/09mut2 HAs to human
tracheal tissue sections.
Paraffinized human tracheal (US Biological) tissue sections were deparaffinized,
rehydrated and incubated with 1% BSA in PBS for 30 minutes to prevent non-specific
binding. HA was pre-complexed with primary antibody (mouse anti 6X His tag, Abcam)
and secondary antibody (Alexa fluor 488 goat anti mouse, Invitrogen) in a molar ratio of
4:2:1, respectively, for 20 minutes on ice. The tissue binding was performed over
different HA concentrations by diluting the pre-complexed HA in 1% BSA-PBS. Tissue
sections were then incubated with the HA-antibody complexes for 3 hours at RT. The
tissue sections were counterstained by propidium iodide (Invitrogen; 1:100 in TBST). The
tissue sections were mounted and then viewed under a confocal microscope (Zeiss
LSM510 laser scanning confocal microscopy). In the case of sialidase pretreatment,
tissue sections were incubated with 0.2 units of Sialidase A (recombinant from
Arthrobacter ureafaciens, Prozyme) for 3 hours at 370 C prior to incubation with the
proteins. This enzyme has been demonstrated to cleave the terminal Neu5Ac from both
Neu5Aca2->3Gal and Neu5Acc2-+6Gal motifs.
204
Dose dependent direct binding of CA04/09, CA04/09mutl, CA04/09mut2, CA04M3,
CA04M4 and CA04M5 HAs.
The protocol described in Appendix A1.2 was used to characterize the binding
affinity and specificity of the mutant and wild-type recombinant HAs.
Construction of plasmids.
The eight reverse-genetics plasmids used for the rescue of recombinant influenza
A/California/04/2009 (Cal/09) virus-pDZ-Ca04-PB2, pDZ-Cal04-PB1, pDZ-Cal04-PA,
pDZ-Cal04-NP, pDZ-Cal04-HA, pDZ-Cal04-NA, pDZ-Cal04-M, and pDZ-Cal04-NS - were
constructed by methods described previously [204, 205]. The HA plasmid pDZ-Cal04-
lle219->Lys was a derivative of the wild-type (WT) HA segment. The mutation lle219-
>Lys was created by altering the position 219 codons from ATA to AAA using Stratagene
QuickChange site-directed mutagenesis kit and pDZ-Cal04-HA as template.
Rescue of recombinant influenza A viruses.
The influenza A CA04/09 viruses were rescued as described previously [206].
Briefly, 293T cells were transfected with the eight pDZ-Cal04 vectors encoding each of
the viral genomic RNA segments. At 12 h post transfection, the 293T cells were co-
cultured with MDCK cells. The rescued viruses were further isolated by plaque
purification on MDCK cells. The coding sequences of each PDZ construct and viruses
generated by reverse genetics were confirmed by automated sequencing performed at
the Centers for Disease Control and Prevention sequencing core facility.
Inoculation of ferrets.
The 2009 H1N1 virus animal experiments were conducted under biosafety level
3 enhanced (BSL3+) laboratory conditions. Male Fitch ferrets (Triple F Farms), 6 to 12
months of age that were serologically negative by hemagglutination inhibition (HI) assay
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for currently circulating influenza viruses were used in this study. At the start of each
experiment, all ferrets had body weights greater than 1.0 kg, with a range of 1.01-1.57
kg. Ferrets were housed throughout each experiment in cages within a Duo-Flo Bioclean
mobile clean room (Lab Products, Inc. Seaford, DE). Baseline serum, temperature and
weight measurements were obtained prior to infection. Temperatures were measured
using a subcutaneous implantable temperature transponder (BioMedic Data Systems,
Inc.). Ferrets were inoculated intranasally with 106 PFU (plaque forming units) in a 1ml
volume, a dose reported to consistently infect ferrets with human or avian influenza
viruses [2071. Ferrets were monitored for changes in body temperature and weight, and
the presence of the following clinical signs: sneezing, lethargy, anorexia, nasal or ocular
discharge, dyspnea, diarrhea, neurological dysfunction [1581. Nasal washes were
collected every other day for at least 9 days post inoculation (p.i.) or contact (p.c.),
analyzed [208] and titrated by standard plaque assay.
Ethics Statement.
All animal research described in this study was specifically approved by CDC's
Institutional Animal care and Use Committee (IACUC). The animal research was
conducted under the guidance of CDC's IACUC and in an Association for Assessment and
Accreditation of Laboratory Animal Care International-accredited facility.
Transmission experiments.
For the respiratory droplet transmission experiments, ferrets were housed in
adjacent transmission cages, each modified so that a side wall was replaced with a
stainless-steel, perforated wall with holes 1-5 mm in diameter and spaced 3 mm apart
to facilitate the transfer of respiratory droplets through the air while preventing direct
contact between ferrets and indirect contact with the bedding and food of neighbouring
ferrets. A total of six ferrets were used for each respiratory droplet transmission
experiment [158]. Twenty-four hours after inoculation (day 1 p.i. for the inoculated
ferrets and day 0 p.c. for the contact ferrets), three naive ferrets were each placed in a
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cage adjacent to an inoculated ferret. To prevent inadvertent physical transmission of
virus by the investigators, the contact ferrets were always handled first, and all items
that came into contact with the ferrets or their bedding were decontaminated between
each ferret. The use of the term "respiratory droplet transmission" throughout this
report refers to transmission in the absence of direct or indirect contact and does not
imply an understanding of the droplet size involved in virus spread between ferrets. The
ability of each virus to undergo respiratory droplet transmission among ferrets was
assessed by measuring virus titres in nasal washes from contact animals every other day
for at least 11 days. HI analysis was also performed on post-exposure ferret sera
collected 18-21 days p.c. using 0.5% turkey erythrocytes against homologous virus [208].
Dose dependent direct binding of rqCA04/09 Ile219Lys HA mutant virus on glycan array.
The protocol described in Appendix A1.1 was used for the glycan array analysis
with the virus. The primary antibody used was ferret anti - CA04/09 antisera; 1:500
diluted in 1X PBS + 1% BSA. The secondary antibody used was goat anti - ferret HRP
conjugated antibody from Abcam; 1:500 diluted in IX PBS + 1% BSA). The assays were
done in duplicates.
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A1.4 Materials and Methods for Chapter 5
Cloning, baculovirus synthesis. expression and purification of HA.
Recombinant SC18 and Alb58 HAs were expressed and purified as mentioned in
Appendix A1.2.
Binding of hemagglutinin to ferret respiratory tissues.
Formalin fixed and paraffin embedded (5u thickness) ferret cranial and caudal
tracheal tissue sections were obtained from Lovelace Respiratory Research Institute
(LRRI). Formalin fixed and paraffin embedded ferret lung hilar tissue sections (5u thick)
were obtained from Professor James G Fox's laboratory (Division of Comparative
Medicine, Massachusetts Institute of Technology). Protocol followed for human tracheal
tissue staining with HAs (Appendix A1.3) was followed for ferret respiratory tract
tissues.
Lectin staining of ferret and human respiratory tract.
Formalin fixed and paraffin embedded ferret tracheal and lung hilar tissue
sections were obtained from Lovelace Respiratory Research Institute and Division of
Comparative Medicine (Massachusetts Institute of Technology) respectively. Tissue
sections were deparaffinized and rehydrated. The tissue sections were incubated with
10[tg/ml of lectins (SNA-1, Jacalin and MAL-Il) respectively for 3 hours in dark at RT.
Lectins were obtained from Vector Labs. To visualize the cell nuclei, sections were
counterstained with propidium iodide (Invitrogen; 1:100 in TBST) for 20 minutes at RT.
Sections were then washed, mounted and viewed under a Zeiss LSM510 laser scanning
confocal microscope. For MAL-ll, since the lectin was biotinylated, prior to adding the
lectin, the tissue sections were incubated with streptavidin/biotin kit (Vector Labs) to
block endogenous biotin for preventing non-specific staining of the tissues. For lectin co-
staining experiments, Jacalin and SNA-1 (10pg/ml each) was added simultaneously to the
tissue sections.
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A1.5 Material and Methods for Chapter 6
Structural analysis of SNA-l to identify its glycan-binding domain
The homology based structural model of SNA-1 lectin domain was constructed
using the co-crystal structure of SNA-Il with lactose (PDB ID: 3CA4) as a template given
that this template was selected by the SWISS-MODEL program. The use of this co-crystal
structure as a template facilitated the identification of the glycan-binding sites (high-
affinity and low-affinity) in the B chain enabling us to engineer the SNA-1 B chain.
Cloninq, Expression and Purification of 2ypeptide of SNA-l
The 2y peptide (42aa, ~7.7kDa) gene sequence was cloned in a pET15b (in Nde I
and BamH I sites). BL21star(DE3) cells (from Invitrogen, Carlsbad) was transformed with
the recombinant plasmid for expression. For expression, an overnight culture (5ml) of
BL21star(DE3) harboring the 2y peptide (in LB ampicillin) was used to inoculate a IL LB
media (containing 100[ig/ml ampicillin). The cells were grown at 37*C till OD6oonm
reached 0.6 to 1. The protein induction was carried out by adding 1mM IPTG (isopropyl
thio p-D galactoside). The cells were grown for 16h at 250C post-induction to avoid
formation of inclusion bodies. The cells were pelleted by centrifugation at 4500rpm at
4"C for 15mins. The supernatant was discarded and the pellets were stored at -80"C.
Purification of the peptide was carried out using a denaturation/renaturation
protocol. Briefly, the protein was unfolded to facilitate binding to the NI column and and
later refolded. The buffers used for the purification are:
e Binding/lysis buffer: 50mM NaH 2PO4, 300mM NaCl, 5mM Imidazole HCI, 6M
Guanidium hydrochloride, pH 8.0
* Wash buffer: 50mM NaH 2PO4, 300mM NaCl, 10mM Imidazole HCI, 6M Urea, pH
8.0
* Refolding buffer: Same as Wash buffer but without 6M urea
e Elution buffer: 50mM NaH 2PO4, 300mM NaCl, 250mM Imidazole HCI, pH 8.0
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Lysate Preparation: The cells (stored in -80"C) were thawed on ice. The cells were
suspended in the lysis buffer and incubated on a magnetic stirrer for 50mins at room
temperature (250C). This process should lyse the cells and unfold the protein. The lysate
was then centrifuged at 4800rpm for 30mins. The supernatant was harvested and used
for purification on a nickel column using FPLC (AKTA purifier from GE). For the
purification, the lysate was loaded onto the nickel column followed by a wash with the
binding buffer. Following this the column was washed with the wash buffer (containing
6M urea). To re-fold the protein, the column was washed with a gradient of urea
concentration from 6M urea to no urea (in the re-folding buffer). Following this the
protein was eluted from the column using a gradient method, which involves a gradual
increase in imidazole concentration ranging from 10mM to 250mM. Fractions were
collected when peaks (at OD280nm) were seen during the process of elution. The
samples were analyzed on SDS PAGE and fractions containing the peptide were
identified by western blotting using anti-his antibody (Abcam). The fractions containing
the peptide were pooled, concentrated and buffer exchanged to 1X PBS in Vivaspin filter
spin column with 50ODa MWCO. Protein concentration was estimated by Bradford's
method.
Structural analysis of PSL to identify its glycan-binding domain
Although the crystal structure of PSL has not been solved, based on sequence
identity, it has been implicated to adopt the same fold observed in the crystal structure
of Marasmius oreades agglutinin (MOA). In this structural fold, PSL has a single ricin-B
like p-trefoil domain at the N-terminus that is composed of three homologous
subdomains (a, P, and y). Mutant constructs that have single amino acid mutations in
the putative sugar-binding sites, based on the sequence alignment with the ricin B-
chain, indicate that P and y subdomains are the probable sugar binding sites [192]. The
homology based structural model of PSL was constructed using the co-crystal structure
of MOA with Galal-3Galpl-4GcNAc (PDB ID: 21HO) as a template given that this
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template was selected by the SWISS-MODEL program. The use of this co-crystal
structure as a template facilitated the identification of the glycan-binding sites on PSL
and docking of an a2-6 oligosaccharide motif (Neu5Aca2-6Gal 1-4GlcNAc) into the
glycan binding site of the modeled PSL structure. These docking studies facilitated the
identification of the p-trefoil lectin domain in PSL and also provided insights into the
molecular interactions of this lectin domain with the glycan motif.
Cloning, Expression and Purification of glycan binding domain of PSL
The glycan binding domain of PSL (6-149aa) was synthesized (DNA2.0) and
subcloned into Nde I and BamH / sites of pET15b vector and transformed into
BL21star(DE3) E.coli (Invitrogen) cells. The expression of rPSL-N was carried out as
described previously. Briefly, a 5ml overnight culture of BL21star(DE3) E.coli cells
harboring the recombinant rPSL-N expression vector was grown at 370C in Luria-Bertani
(LB) medium containing 100[tg/ml of ampicillin. The 5ml culture was added to a 11 LB
medium containing 100[tg/ml of ampicillin and incubated at 370C shaker. The culture
was induced with 1mM (final concentration) of isopropyl f-D-thiogalactoside (IPTG)
after the absorbance at 600 nm reached ~0.6-1 and the cells were further cultured at
25'C overnight. The induced cells were harvested by centrifugation. The cells were lysed
by sonication and the insoluble fraction was removed by centrifugation. The soluble
rPSL-N from the lysate was purified using Nickel affinity chromatography (HisTrap HP
columns, GE Healthcare, Piscataway, NJ). Eluting fractions containing rPSL-N were
pooled, concentrated and buffer exchanged into 1X PBS pH 8.0 (Gibco) using 3K MWCO
spin columns (Millipore, Billerica, MA). The purified protein was quantified using BCA
method (Pierce).
Cytotoxicity Analysis of PSL vs. rPSL-N
MDCK cells were seeded in a 96-well plate and incubated with various lectin
concentrations for 2h in 37'C, 5% CO2 incubator. The cells were then overlayed with 1X
MEM + 0.1% BSA and incubated for 48h in 37*C, 5% CO2 incubator. Cytopathic effects
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were analyzed in light microscope after 24h and 48h of incubation and compared with
that of the non-treated cells. To quantitatively estimate the cytotoxicity, the cells were
stained with crystal violet and densitometric scanning was performed using Adobe
Photoshop. Briefly, after 48h of incubation with the drug, the media was aspirated and
the cells were washed twice with 1X PBS. The cells were fixed for 15mins with 10%
buffered formalin followed by washes with water. The cells were finally stained with
10% crystal violet (in 20% methanol) for 15 mins. The cells were washed with tap water
and allowed the plate to dry completely before performing the densitometric scanning
analysis with Photoshop. For each lectin concentration, 4 microwells were used.
Binding of recombinant rPSL-N to human tracheal and alveolar tissue sections
The protocol followed for HA staining (Appendix A1.3) was followed for rPSL-N
staining of human tracheal tissue section. rPSL-N was precomplexed with primary
(mouse anti-his monoclonal antibody) and secondary (goat anti-mouse IgG HRP)
antibodies in a molar ratio of 4:2:1 before adding to the tissue sections.
Dose dependent direct binding of rPSL-N protein
The protocol followed for glycan array analysis of HA (Appendix A1.2) was
followed. The binding parameters, cooperativity (n) and apparent binding constant (Kd')
were calculated by fitting the average signal value (from the triplicate analysis) and the
rPSL-N concentration to the linearized form of the Hill equation:
lo( I) = n * log([rPSL]) - log(K)
where y is the fractional saturation (average binding signal/maximum observed binding
signal). The theoretical y values calculated using the Hill equation:
[rPSL]"
[rPSL" + Kd
(for the set of n and Kd' parameters) were plotted against the varying concentration of
rPSL-N to obtain the binding curves for the representative human receptor (6'SLN-LN).
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Inhibition of influenza A virus infection by rPSL-N: detection of viral RNA by quantitative
real time PCR
For measuring inhibition of influenza A virus infection by rPSL-N, viral M-gene
copy number was quantified from the rPSL-N treated Madin Darby Canine Kidney Cells
(MDCK) cells by real time PCR analysis. Briefly, MDCK cells were seeded in a 96-well
plate at a density of 2.4 X 104 cells per well and incubated overnight at 37'C in 5% CO2.
After the cells were grown to a confluent monolayer, the cells were pretreated with
various rPSL-N dilutions for 2h in 370C, 5% CO2 incubator. After 2h, the pretreated cells
were infected with influenza A virus (diluted in 1X MEM + 2 tg/ml of TPCK trypsin) at a
multiplicity of infection (MOI) of 0.001 for 1h in 35*C, 5% CO2 incubator. The influenza A
viruses used for the assay are A/Victoria/3/75 (H3N2) [ATCC] and A/PR/8/34 (H1N1).
The cells were overlayed with 1X MEM + 0.1% BSA + 2 [tg/ml of TPCK trypsin and
incubated in 350C, 5% CO2 incubator. After 48h of incubation, the media was harvested
and 50 [d of the conditioned media was used for viral RNA extraction using QlAamp viral
RNA mini kit (Qiagen). Quantitative real time PCR (qRT-PCR) reaction was set up as
described [195] using Qiagen one-step RT-PCR kit (Qiagen). The conditions used for the
PCR were: reverse transcription at 500C for 30 mins, heat inactivation of polymerase at
940C for 15 mins followed by two-step cycle (45 cycles) involving denaturation at 940 C
for Is and annealing/extension at 600C for 20s. The quantitative PCR was carried out
with 8 l of viral RNA (for both standards and the samples) or water for the no template
control. The standards for the qRT-PCR analysis were generated by doing serial dilution
(4 times) of viral RNA extracted from influenza A virus with a known titer (from 4 X 106
to 975). Ct threshold was determined manually and the Ct values for the standards were
plotted. The standards gave a good linearity (R2 ~ 0.99). The assay was repeated twice
and for each rPSL-N concentration, 8 microwells for were used. Viral RNA extracted
from each of the technical replicate was then used in triplicate for the qRT-PCR analysis.
Curve - fitting and IC50 calculation was done using Graphpad Prism 5 software.
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In vivo studies with rPSL-N
On the morning of day 0, ketamine anesthetized 8 week-old female BALB/c mice
(weighing 25g) received the first intranasal treatment of rPSL-N (or PBS for control
animals) at a concentration of 1mg/kg. 6 hours later, the mice were inoculated
intranasally with 5 LD50 of mouse-adapted CA04/09 virus. Following this mice were daily
treated intranasally with 1mg/kg of rPSL-N for 5 days p.i. Totally 10 mice were treated
with rPSL-N or with 1X PBS alone. Survival and weights were monitored for 6 mice and
virus tissue titers were estimated for the rest of the 4 mice 4 days post-infection (p.i.).
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Abbreviations Used
A60o Absorbance at 600nm
BSA Bovine Serum Albumin
CBD Carbohydrate Binding Domain
CDC Centers for Disease Control
CPE Cytopathic Effect
FDA Food and Drug Administration
FITC Fluorescein Isothiocyanate
FPLC Fast Protein Liquid Chromatography
HA Hemagglutinin
HAl Hemagglutinin Inhibition
H & E Hematoxylin and Eosin
HPAI Highly Pathogenic Avian Influenza A virus
IC50  Concentration of a drug at which there is 50% reduction
Kd Apparent Dissociation constant
LB Luria Bertani media
LPAI Low Pathogenic Avian Influenza A virus
MAL-1I Maackia amurensis Lecti n II
MDCK Madin-Darby Canine Kidney Cells
MOA Marasmium oreades Agglutinin
mRNA messenger Ribonucleic Acid
MWCO Molecular Weight Cut-Off
NA Neuraminidase
NEP Nuclear Export Protein
Neu5Ac N-Acetyl Neuraminic acid
pAb Polyclonal Antibody
PBS Phosphate Buffer Saline
PFU Plaque Forming Units
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PI Propidium Iodide
PSL Polyporus squamosus Lectin
rPSL-N N-terminal of PSL lectin
RBCs Red Blood Cells
RBS Receptor Binding Site
rg Reverse Genetics
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
SNA Sambucus nigra Agglutinin
vRNA Viral Ribonucleic Acid
vRNP Viral Ribonucleoprotein
y Fractional Saturation
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